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Abstract 
Voltage-gated ion channels are physiologically important transmembrane proteins involved 
in several pathologies including cardiac, muscular and neuronal disorders. Efforts are 
underway to develop potent and selective modulators of voltage-gated ion channels for the 
purposes of probing the pharmacology of these channels, and for the development of safe, 
efficacious therapeutics.  
Gating modifier toxins (GMTs) are a class of peptide toxins (30–40 amino acid residues in 
length) that modulate the gating mechanism of voltage-gated ion channels and are being 
pursued as probes and drug leads for these transmembrane proteins. GMTs can be isolated 
from the venom of various animals including cone snails, scorpions and spiders.  
GMTs that contain a conserved inhibitor cystine knot (ICK) motif in which disulfide bridges 
are arranged in a Cys I–IV, Cys II–V, Cys III–VI pattern, typically display a surface profile 
including a hydrophobic patch and a charged ring. This amphipathic structure putatively 
facilitates interactions between GMTs and lipid membranes giving rise to a tri-molecular 
complex formed when GMTs interact with the lipid bilayer during modulation of voltage-
gated ion channels. 
The first aim of this thesis is to examine GMT–lipid bilayer interactions and to investigate 
how these interactions influence potency and selectivity for voltage-gated sodium channels. 
Secondly, the objective is to determine whether GMT–lipid bilayer interactions can be 
included in the design of potent and selective GMT modulators of NaV1.7. The third aim is 
to explore the pharmacological relevance of GMTs in terms of their stability, and as tools 
that can be used to derive novel insight about voltage-gated sodium channel pharmacology. 
Given that voltage-gated sodium channel pharmacology is currently a widely pursued field, 
bivalent GMTs, known as double-knottins, were designed and produced semi-enzymatically, 
in order to examine the possibility of bimodal modulation of NaV1.7. 
Disulfide-rich GMTs were obtained using optimized conditions for thermodynamic and 
regioselective oxidative folding. Double-knottins were produced via chemoenzymatic 
ligation using sortase A, a bacterial enzyme. Solution state NMR was used to examine 
structural integrity of the peptides and previously unsolved three-dimensional NMR 
structures were also completed. Cell-based biological FLIPRTETRA assays were conducted 
to analyze the activity of GMTs in the study and these assays were complemented by 
electrophysiological studies conducted by collaborators. Membrane binding affinity of 
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peptides was studied with model lipid bilayers using surface plasmon resonance and the in-
depth location of tryptophan residues into model lipid bilayers was examined using 
fluorescence spectroscopy methodologies. 
Through these studies, it was determined that not all native GMTs have affinity for lipid 
bilayers, but those with affinity bind preferentially to model membranes with anionic charge, 
primarily via electrostatic interactions. HwTx-IV, a GMT with weak affinity for lipid bilayers 
was re-engineered to form gHwTx-IV, an analogue with a higher electropositive potential 
and this peptide showed higher affinity for model membranes combined with a higher 
potency at NaV1.7 compared to HwTx-IV. Unconventionally, selectivity of gHwTx-IV was 
improved by modifications to important pharmacophore residues with the rationale that 
affinity for the lipid bilayer would compensate for potency whereas pharmacophore 
modifications would improve selectivity. [R26A]gHwTx-IV, [K27A]gHwTx-IV and 
[R29A]gHwTx-IV had lower affinity for the lipid bilayer compared to gHwTx-IV but higher 
affinity compared to HwTx-IV. The three analogues were more selective for NaV1.7 
compared to off target NaVs, and the lipid bilayer had thus been included in the design of 
potent, selective modulators of NaV1.7. Stability of GMTs in physiologically relevant 
conditions was established using stability assays, and the versatility of these peptides as 
pharmacological tools was shown in their chemoenzymatic conversion to double-knottins 
that revealed cooperative modulation of NaV1.7, a feature that provides a novel bivalent 
approach to the modulation of NaVs for the design of therapeutics. 
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Chapter 1  
An overview of the thesis 
 
  
 2 
Scope of the thesis 
The broad aim of this thesis is to examine the pharmacology of spider gating modifier toxins 
(GMTs) at voltage-gated sodium channels (NaVs), while considering the role that the lipid 
bilayer may play in influencing GMT potency and selectivity for the pain-relevant NaV1.7. To 
achieve this aim, the thesis consists of seven chapters and an appendix. Chapter 1 is a 
brief overview of each chapter. 
Chapter 2 introduces the tripartite GMT–lipid bilayer–voltage-gated ion channel relationship 
in the form a review that uses key GMTs to study the history of the tri-molecular complex 
and to critically evaluate the choice of model membranes and techniques used in the study 
of the tri-molecular complex thus far.  
Chapter 3 is a strategic study of a panel of nine native GMTs, and the binding of these 
peptides to model membranes chosen to represent lipids relevant to the environment in 
which NaV1.7 is likely to be found. This chapter examines the potency and selectivity of 
these peptides at NaV1.7 to determine whether there is a link between GMT–lipid membrane 
binding and interaction with this transmembrane protein. 
Chapter 4 consists of two parts; in Chapter 4A, HwTx-IV, a potent GMT known to have 
minimal interaction with the cell membrane is successfully engineered to form gHwTx-IV, an 
analogue with increased affinity for model lipid bilayers and increased potency at NaV1.7. In 
Chapter 4B, the selectivity of gHwTx-IV for NaV1.7 is improved using an alanine scan to the 
pharmacophore that facilitates the achievement of a balance between affinity for lipid 
bilayers, potency and selectivity at NaV1.7.  
The purpose of Chapter 5 is to establish the stability of GMTs in physiologically relevant 
and extreme thermal, pH, proteolytic and chemical settings. Prior to this there was no 
focused attempt to determine whether the ICK motif of GMTs confers them with 
physiologically relevant stability for their subsequent use as drug leads. 
In Chapter 6, sortase A, an enzyme obtained from Staphylococcus aureus, is used in the 
biochemical conjugation of bivalent GMTs to form double-knottins. The double-knottins, 
together with monovalent GMTs are then used to examine the potential to influence NaV1.7 
activity via cooperative modulation. 
Finally, Chapter 7 summaries the thesis with comments on the future of GMTs as drug leads 
and the tri-molecular complex as a viable novel approach to drug design. 
 3 
Appendix 1 is an applicable tool, in the form of a protocol that details the use of sortase A 
in the chemoenzymatic ligation of disulfide rich peptides. 
Taken together, this work shows that each native GMT behaves differently with respect to 
lipid bilayers and to NaV1.7 and therefore broad generalizations must be avoided. However, 
it is possible to include the lipid bilayer in the design of potent and selective modulators of 
NaV1.7. GMTs are thus useful drug leads, with exceptional stability in physiological 
environments. The double-knottin study provides a novel approach in which GMTs can be 
used as pharmacological tools by revealing the possibility for cooperative binding at NaV1.7. 
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Chapter 2 
 
An introduction to the tri-molecular complex 
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Overview 
Initial observations that some GMTs show affinity for model membranes (1-5), led to the 
conception of the term ‘tri-molecular complex’ (5,6), or ‘tripartite complex’ (7).The tri-
molecular complex is an intriguing concept because it provides a third-dimension to the 
traditional lock-and-key approach to drug design, where the membrane is considered in 
addition to specific interactions between a ligand and a transmembrane protein.  
Whereas previous and recent reviews have discussed GMTs as potential drugs (6,8,9), and 
their use as voltage-gated ion channel probes (10-12), the motivation behind this review 
was to gather evidence pertaining to the tri-molecular complex, questioning whether this 
complex is worth pursing as a novel approach to drug design. The chapter covers key GMTs 
including VsTx-I, SgTx-I, ProTx-II, ProTx-I, HwTx-IV and Hd1a, and the main insights that 
these GMTs have provided with respect to interactions with lipid bilayers. The chapter also 
critically examines the various techniques and model membranes used to study the tri-
molecular complex. 
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Gating modifier toxin interactions with ion channels and lipid bilayers: is the tri-
molecular complex real? 
Akello J. Agwa1, Sónia Troeira Henriques1,*, Christina I. Schroeder1,* 
1Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia 
* Corresponding authors 
Abstract 
Spider peptide toxins have attracted attention because of their ability to target voltage-gated 
ion channels, which are involved in several pathologies including chronic pain and some 
cardiovascular conditions. A class of these peptides acts by modulating the gating 
mechanism of voltage-gated ion channels and are thus called gating modifier toxins (GMTs). 
In addition to their interactions with voltage-gated ion channels, some GMTs have affinity 
for lipid bilayers. This review discusses the potential importance of the cell membrane on 
the mode of action of GMTs. We propose that peptide–membrane interactions can anchor 
GMTs at the cell surface, thereby increasing GMT concentration in the vicinity of the channel 
binding site. We also propose that modulating peptide–membrane interactions may be 
useful for increasing the therapeutic potential of spider toxins. Furthermore, we explore the 
advantages and limitations of the methodologies currently used to examine peptide-
membrane interactions. Although GMT–lipid membrane binding does not appear to be a 
requirement for the activity of all GMTs, it is an important feature, and future studies with 
GMTs should consider the tri-molecular peptide–lipid membrane–channel complex. 
 
Highlights 
• Spider toxins are excellent tools to study voltage-gated ion channel pharmacology 
• Some gating modifier toxins have shown affinity for lipid membranes  
• The role of the membrane in spider toxin activity can guide drug design  
• The cell membrane, ion channel and spider toxins should be studied as a complex 
 
Keywords: Disulfide-rich peptides, model membranes, pain, drug design, surface plasmon 
resonance, sodium channel 
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Abbreviations: Cryo-EM, cryo-electron microscopy; DOPG, 1,2-dioleoyl-sn-glycero-3-
phosphoglycerol; DHPC, 1,2-diheptanoyl-sn-glycero-3-phosphocholine; GMT, gating 
modifier toxin; GUV, giant unilamellar vesicle; ICK, inhibitor cystine knot; KV, voltage-gated 
potassium channel; LUV, large unilamellar vesicle; MSP, membrane scaffold protein; NaV, 
voltage-gated sodium channel; NMR, nuclear magnetic resonance; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, 
phosphatidylinositol; PS, phosphatidylserine; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPG, 
1-palmitoyl-2-oleoyl-sn-glycero-3-glycerol; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-L-serine; SAR, structure activity relationship; SMA, stearic maleic acid; SPR, 
surface plasmon resonance; SUV, small unilamellar vesicle; VSD, voltage sensor domain 
 
Introduction 
Voltage-gated ion channels are transmembrane proteins that are involved in almost all 
aspects of human physiology and many of these channels have been validated as 
therapeutic targets for conditions such as neuropathic and chronic pain, irritable bowel 
syndrome, cardiovascular disease and epilepsy (13-17). The development of 
pharmaceutical modulators for voltage-gated ion channels is therefore an area of great 
interest (18-22). Peptide toxins extracted from animal venoms are a particularly important 
class of ion channel inhibitors because they have shown a naturally high potency and 
relative selectivity for a range of therapeutically relevant voltage-gated ion channels (13-15).  
Gating modifier toxins (GMTs) are a class of venom peptides that derive their name from 
the mechanism by which the toxins modify the kinetics and gating behavior of voltage-gated 
ion channels (12). GMTs can be extracted from the venoms of various animals including 
spiders, cone snails, scorpions and snakes (12); however, this review will focus on spider-
derived GMTs. Some GMTs have been shown to bind to lipid membranes (Table 1) (5,23-
25), and a correlation has been drawn between GMT lipid binding and the affinity and 
inhibitory potency of some of these toxins to voltage-gated ion channels (3,23,25-28). GMTs 
are therefore excellent tools to study the emerging tri-molecular complex involving peptide 
ligands, voltage-gated ion channels, and the lipid membranes surrounding these channels. 
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This review examines the interplay between GMT structure, interactions with voltage-gated 
ion channels and interactions with lipid membranes. 
 
Gating modifier toxin structure 
GMTs typically contain an inhibitor cystine knot (ICK) motif characterized by two–three anti-
parallel -strands stabilized by three disulfide bridges with Cys1–Cys4, Cys2–Cys5 and 
Cys3–Cys6 connectivity (29,30), as illustrated in Figure 1A by ProTx-II, SgTx-I, VsTx-I and 
HwTx-IV. Notably, anti-parallel -sheets are not always present in the secondary structures 
of the GMTs (e.g. ProTx-II and HwTx-IV, Figure 1A) due to variation in the size of the 
interconnecting loops (25,26,31); however the conserved cystine knot connectivity renders 
stability to these types of peptides (29,32). An additional conserved structural feature is the 
folding of these peptides to form an amphipathic surface profile consisting of a hydrophobic 
patch surrounded by a charged ring of amino acid residues (Figure 1B) (30,33-35). The 
amino acid residues forming the hydrophobic patch and charged ring include Trp, Tyr and 
Lys, which are often involved in peptide–lipid bilayer binding (36) (for sequences, see Figure 
1C), therefore the conserved hydrophobic patch and charged ring may confer GMTs with 
affinity for lipid membranes in addition to interactions with the voltage-gated ion channels. 
 
  
 10 
Table 1. Studies on the binding of gating modifier toxins to lipid membranes  
Peptide Experiment Resultse,f Reference 
VsTx-I NMR chemical shift 
mapping 
Hydrophobic residues bind to 
DHPC  
(23) 
Centrifuge spin-down  Binds preferentially to POPG (23) 
Trp fluorescence 
emissiona,b 
Shallow position in POPC/POPG 
(1:1)  
(37) 
Centrifuge spin-down Binds to POPG  (35) 
Trp fluorescence 
emissiona,b 
Does not bind strongly to POPC 
lipid vesicles  
(35) 
Trp fluorescence 
emissiona,b 
Binds to POPE/POPG (3:1) (2) 
SgTx-I NMR transferred 
cross-saturation 
Hydrophobic patch interacts with 
lipid core and charged ring with 
head groups of POPC 
(24) 
Trp fluorescence 
emissiona,b 
Positioned at a shallow position in 
POPC/POPG (1:1) 
(5) 
Centrifuge spin-down Binds to membrane of oocytes  (5) 
Trp fluorescence 
emissionb 
Binds to POPC/POPG (1:3)  (38) 
ProTx-I SPR Binds to POPC/POPS (4:1) (39) 
Trp fluorescence 
emissiona,b and 
membrane dipolar 
potentialc 
Adopts a shallow position in 
POPC/POPS (4:1) 
(39) 
ProTx-II SPR Binds preferentially to 
POPC/POPS (4:1), POPC/POPG 
(1:1) and POPC/Cer-P (3:2) over 
POPC, POPC/POPE (4:1) and 
POPC/SM/CHOL (2.7:4:3.3) lipid 
vesicles  
(25) 
Trp fluorescence 
emissiona,b and 
membrane dipolar 
potentialc 
Adopts a shallow position in 
POPC/POPS (4:1) 
(25) 
FRET membrane 
depolarizationd 
Binds to membrane of 
neuroblastoma cells  
(25) 
Trp fluorescence 
emissiona  
No significant interaction with 
POPC lipid vesicles; adopts a 
shallow position in POPC/POPG 
(1:1) 
(27) 
Centrifuge spin-down No interaction with POPC lipid 
vesicles; binds to POPE/POPG 
(3:1) 
(33) 
Centrifuge spin-down Binds to POPC/POPS (3:1) (4) 
HwTx-IV Centrifuge spin-down No binding to POPC or 
POPE/POPG (3:1)  
(33) 
 SPR Minimal binding to POPC, 
POPC/POPS (4:1), 
POPC/SM/CHOL (2.7:4:3.3) and 
POPC/C1P/CHOL (2.7:4:3.3)  
(28) 
 Trp fluorescence 
emissiona,b 
Minimal binding to POPC/POPS 
(4:1) 
(28) 
Hd1a SPR Minimal binding to POPC and 
POPC/POPS (4:1) 
(39) 
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Trp fluorescence 
emissiona and 
membrane dipolar 
potentialb 
Adopts a shallow position in 
POPC/POPS (4:1) 
(39) 
HaTx-I Trp fluorescence 
emissiona 
Positioned at a shallow position in 
POPC/POPG (1:1) 
(5) 
Centrifuge spin-down Binds to membrane of oocytes  (5) 
Trp fluorescence 
emissiona,b 
Positioned at a shallow position in 
POPC/POPG (1:1) 
(3) 
GsMTx-IV Trp fluorescence 
emissiona 
Binds to anionic and zwitterionic 
lipid vesicles (1:3) 
(38) 
Trp fluorescence 
emissiona 
Binds to lipid vesicles of egg 
lecithin  
(1) 
Hm-3 1D 1H NMR Binds preferentially to 
POPC/DOPG (3:1)  
(40) 
PaTx-I Trp fluorescence 
emissiona 
Preferential binding to 
POPC/POPG (1:1) over POPC  
(27) 
GsAF-I Trp fluorescence 
emissiona 
Preferential binding to 
POPC/POPG (1:1) over POPC 
lipid vesicles  
(27) 
GsAF-II Trp fluorescence 
emissiona 
No binding to POPC/POPG (1:1) 
or POPC  
(27) 
aTrp fluorescence emission of peptides is followed in the presence or absence of lipids, 
an increase in quantum yield and leftward (blue) shift in the emission spectrum indicates 
that Trp residues are partitioning into more hydrophobic environments 
bTrp fluorescence emission of peptide/lipid suspension is followed in the presence or 
absence of a quencher, to monitor the depth to which the Trp residues insert into the 
lipid vesicles  
cChanges to the membrane dipolar potential in the presence of a peptide are followed 
by monitoring the excitation spectrum of di-8-ANEPPS dye 
dMembrane depolarization of cell membranes in the presence of peptides is monitored 
using fluorescence resonance energy transfer between nitrobenzoxadiazol-labelled 
membranes and DisBaC2 dye 
eLipid mixtures are in molar ratios 
fC1P, Ceramide-1-phosphate; Cer-P, ceramide-phosphate; CHOL, cholesterol; DHPC, 
1,2-diheptanoyl-sn-glycero-3-phosphocholine; DOPG, 1,2-dioleoyl-sn-glycero-3-
phosphoglycerol; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPE, 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine; POPG, 1-palmityl-2-oleoyl-
phosphoglycerol; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine; SM, 
sphingomyelin. 
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Figure 1. Conserved structural features of GMTs. 
 ProTx-II (PDB ID: 2N9T), SgTx-I (PDB ID: 1LA4), VsTx-I (PDB ID: 2N1N) and HwTx-IV (PDB ID: 2M4X). 
(A) Ribbon representations oriented to show the conserved ICK motif characterized by three disulfide 
bridges (yellow) and two–three anti-parallel -strands in SgTx-I and VsTx-I, respectively. ProTx-II and 
HwTx-IV are examples of GMTs that have the ICK motif but do not have anti-parallel -sheets. NT and 
CT are the N-terminal and C-terminal, respectively. (B) Surface representations of the GMTs showing 
the conserved hydrophobic patch and charged ring colored by residue type (hydrophobic, green; 
positively charged, blue; negatively charged, red; polar uncharged, white) (C) Sequence alignment of 
GMTs mentioned in the review. Sequences are aligned along cysteine residues. Trp, Tyr and Lys 
residues have been identified as important for lipid membrane interactions and are colored green (Trp 
and Tyr) and blue (Lys). Residue sequence numbers according to HwTx-IV, HnTx-IV and Hd1a are 
shown as well as species names of the spiders from which the peptides were extracted. 
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Voltage-gated ion channel structures: a basis for understanding the mechanism of action of 
gating modifier toxins 
Voltage-gated ion channels share similar structural features thus the structures of voltage-
gated potassium (KV) and voltage-gated sodium (NaV) channels will be reviewed as 
representatives of this diverse family of transmembrane proteins. KVs and NaVs comprise 
four domains (domain I–domain IV) (41-43) with each domain comprising six 
transmembrane helical segments (S1–S6) (Figure 2A). Whereas each KV  channel can exist 
as a homo- or heterotetramers, NaVs possess intracellular loops of various lengths and post-
translational modifications that connect the four domains to form a heterotetramer (Figure 
2A–C) (41,44-48). In each domain, segments S1–S4 are classified as the voltage sensor 
domain (VSD) whereas segments S5 and S6 form the pore domain (Figure 2B,C) (41,44-
48).  
During channel activation, a change in the extacellular voltage is detected by a portion of 
the VSD known as the paddle motif (S3b–S4) (Figure 2D) (41,49). The VSDs of domain I–
domain III control the movement of the paddle motif such that the paddle moves to open an 
activation gate and allow the inward conduction of ions through the pore (S5–S6 of domain 
I–domain IV). Following channel activation some of the voltage-gated ion channels can self-
inactivate when the VSD of domain IV closes an inactivation gate to prevent further entry of 
ions (50-53). GMTs alter the kinetics, gating mechanisms and relative stability of the closed, 
open and inactivated states of the channels by modulating the motion of the paddle motif as 
it translocates through the membrane (6,54-57). 
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Figure 2. The architecture of voltage-gated ion channels.  
(A) A schematic of the four domains and six transmembrane segments (S1–S6) of a voltage-gated ion 
channel colored to differentiate the voltage sensor domains (white) and the pore domain (red). Schematic 
is based on available NaV structures (Including PDB ID: 4EKW and PDB ID: 5X0M). (B,C) Top and side 
views of a voltage-gated ion channel identifying the pore domain (red) and the four voltage sensor 
domains (VSD I–VSD IV) (white). (D) Side view of VSD II is shown highlighting segments S1–S4. S3–S4 
(gold) form the paddle motif that facilitates gating of the voltage-gated ion channels. 
 
Specific interactions between gating modifier toxins and voltage-gated ion channels 
The pharmacological effect of GMTs on voltage-gated ion channels has been studied using 
structure activity relationship (SAR) studies using peptide analogues and novel techniques 
like multiple attribute positional scanning (19,21,23,31,58-62).  
The pharmacology of GMTs has also been examined using voltage-gated ion channel 
chimeras where components of one channel are introduced onto a second channel 
(50,63,64). Bosmans et al. (2008), designed a chimera channel consisting of the rat 
potassium channel, KV2.1, and each of the paddle motifs from domain I–domain IV of the 
rat sodium channel, NaV1.2 (50). This study demonstrated that the mechanism of action of 
GMTs is dictated by the site on the voltage-gated ion channels to which the peptides bind. 
The authors found that GMTs able to bind to both domain II and domain IV (e.g. ProTx-II 
and ProTx-I), impaired channel activation, whereas GMTs (e.g. SgTx-I) that had affinity only 
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for domain IV, impaired channel inactivation (50). GMT mechanism of action may however 
be more complex and peptide specific as was evident when ProTx-II inhibited both activation 
and inactivation of NaV1.7 even though the peptide is not selective to domain IV (65).  
 
 
 
Figure 3. The tri-molecular complex.  
(A) Sequences of the S3–S4 regions of KV2.1 and NaV1.7; the residues that are targeted by GMTs are 
highlighted in green (hydrophobic) and red (anionic). (B) Two possible GMT–lipid membrane–ion channel 
binding modes with SgTx-I (PDB ID: 1LA4) used to represent a binding mode where the GMT is nestled 
between the S1–S2 and S3–S4 loop (23,31,66); and ProTx-II (PDB ID: 2N9T) used to represent a binding 
mode where the GMT interacts with the channel and the membrane whilst interacting mainly with the S3–
S4 loop (3,25,28,39). (C) The proposed overlapping channel binding and membrane binding region of 
SgTx-I (PDB ID: 1LA4) (purple) is shown (5,24). (D) The residues that have been proposed to be relevant 
for the membrane binding of ProTx-II (PDB ID: 2N9T) form a membrane binding region (green), which is 
distinct from the residues that are involved in binding to the channel (gold) (25).  
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In addition to intra-channel promiscuity, mutagenesis studies on voltage-gated ion channels 
show that GMTs bind to similar restricted residue positions on different channels 
(3,23,57,65,67). These restricted positions comprise conserved hydrophobic and acidic 
residues on the different voltage-gated ion channels, which aligns well with the overall 
positive charge and hydrophobic patch on the structures of the GMTs (Figure 3A) 
(57,65,67,68). For instance, HaTx-1 is a KV2.1 inhibitor that forms interactions with the 
hydrophobic Ile273 and Phe274 and the anionic Glu277 located on transmembrane portion 
of S3b on domain II of the channel (57). Likewise, ProTx-II forms key interactions with 
Phe813 on the distal transmembrane portion of S3b, and with Glu818 on the extracellular 
S3–S4 loop on domain II of NaV1.7 (65,68), whereas HwTx-IV, another NaV1.7 inhibitor, 
interacts with Glu811 on the distal transmembrane portion of S3b, and with Leu814, Asp816 
and Glu818 on the extracellular S3–S4 loop on domain II (65,69,70). 
In silico docking studies on HwTx-IV and HnTx-IV, two NaV1.7 inhibitors, led to the 
proposition that the GMTs recognize the 3D-conformation on their targets rather than 
specific residues. This hypothesis resulted from the observation that both toxins inserted in 
the groove between the loops of S1–S2 and S3–S4 on NaV1.7 domain II (31,66). This 
binding mode places the peptides in a cleft between S2–S3 and S1–S4 allowing GMTs to 
bind to both the voltage-gated ion channels and the lipid membrane (Figure 3B) (23,31,66).  
 
Gating modifier toxins and lipid membrane interactions 
VsTx-I: the lipid membrane can act as an anchor for gating modifier toxins in their 
interactions with voltage-gated ion channels 
Studies on VsTx-I contributed to the initial evidence that some GMTs interact with lipid 
bilayers (2). The authors noted that VsTx-I had weaker affinity for KVAP, a bacterial 
potassium channel, when KVAP had been extracted from the membrane using detergent, 
compared to when the channel was embedded in the membrane (2). When VsTx-I was 
incubated with model lipid membranes and centrifuged in a spin-down assay, the GMT was 
observed to co-precipitate with the model membranes comprising 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE)/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-
rac-glycerol) (POPG) (3:1 molar ratio) (see Table 1). The spectral properties of Trp residues 
in peptides is dependent on the local environment (aqueous or surrounded by lipid) of the 
peptide, therefore if the Trp residues are inserted into model membranes, the fluorescence 
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emission spectrum of the peptide is expected to show a change in the quantum yield as well 
as a shift towards shorter wavelengths (blue shift) (71,72). Studies following the VsTx-I Trp 
fluorescence emission upon titration with POPE/POPG model membranes showed both an 
increase in the fluorescence quantum yield and a blue shift of the fluorescence emission 
spectra, suggesting that the Trp residues of VsTx-I insert into the lipid membranes. Similar 
results were obtained when the GMT was studied in model membranes composed of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/POPG (1:1 molar ratio) (2,37). 
Together, these results suggested that the discrepancy in GMT–KVAP binding with and 
without membranes was because the lipid membranes provide an excess of free energy of 
partitioning. The study further proposed a step-wise mechanism of GMT action where the 
toxin binds first to the membrane then, being concentrated there, is enabled to increase the 
frequency and apparent affinity of interaction with the paddle motif. A recent study also 
suggested that the ability of VsTx-I to interact with the lipid membranes further improves its 
affinity for the KVAP VSD (23).  
NMR chemical shift mapping is a technique used to monitor the local environment of a 
peptide ligand upon its interaction with its target (23,73), and was used to examine the 
interaction of VsTx-I with the KVAP VSD (23). The KVAP VSD was stabilized in a 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (DHPC) micelle and chemical shift changes 
observed in the 2D 1H-15N HSQC and 3D HNCO spectra of the KVAP VSD were studied in 
the presence and absence of VsTx-I to identify residues to which the GMT interacts with. 
Residues on the extracellular loops of S1–S2 and S3–S4 of the KVAP VSD showed the 
largest chemical shift perturbations and were identified as the VsTx-I binding site (23). The 
importance of the hydrophobic patch of VsTx-I in interactions with lipid membranes was 
confirmed using NMR chemical shift mapping in DHPC model membranes which showed 
that the VsTx-I residues with the largest chemical shift changes belonged to the conserved 
amphipathic GMT motif. Furthermore, analogues of VsTx-I containing mutations to the 
hydrophobic patch and charged ring were compared using centrifuge spin-down assays in 
POPG model membranes and showed that both the hydrophobic patch and the charged 
ring of VsTx-I were involved in interactions with lipid membranes (23). Complementary in 
silico docking studies of VsTx-I to the VSD of KVAP, outlined that when the GMT binds 
between loops S1–S2 and S3–S4 of the VSD, VsTx-I is oriented to form interactions with 
the VSD in a way similar to that proposed earlier for HwTx-IV and HnTx-IV (31,66). In this 
spatial orientation, the hydrophobic patch of VsTx-I is proposed to be placed in a lipid filled 
cavity formed between S2–S3 and S1–S4 (Figure 3B) (23). This model suggests that the 
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membrane anchors the peptide in the interaction between VsTx-I and KVAP, and that the 
specific arrangement of the residues of the GMTs is important for both channel and lipid 
membrane interactions. 
 
SgTx-I: the amphipathic structure of gating modifier toxins promotes electrostatic 
interactions with the lipid membrane 
SgTx-I is a GMT initially identified as an inhibitor of the rat potassium channel, KV2.1 
(58,74). There is an overlap between the SgTx-I amino acid residues that bind to the channel 
and those that interact with lipid membranes (5,58). Specifically, residues Arg3, Tyr4, Leu5, 
Phe6, Arg22 and Trp30 were initially identified as important for interactions with KV2.1 (58), 
and later as important for interactions with model membranes (Figure 3C) (5). These findings 
support a binding mode where overlapping residues on SgTx-I interact with the membrane 
and the channel at the same time (Figure 3B, C). An alternative hypothesis is that some 
GMTs bind to the membrane with a membrane interaction face and to the channel with a 
distinct channel binding face (Figure 3B, D) (25,28,39). Molecular dynamic studies on ProTx-
I and ProTx-II suggest that these peptides bind to lipid membranes with a region of the GMT 
distinct from the channel interaction region on the peptides (25,39). These findings place 
ProTx-I and ProTx-II in a more surface exposed location of the channel when compared to 
the binding mode suggested for HwTx-IV, HnTx-IV and VsTx-I (23,31,66), whilst still allowing 
for key interactions with channel residues on the extracellular S1–S2 and S3–S4 loops 
(Figure 3B) (25,39). This binding mode was also proposed in earlier studies on HaTx-I (3), 
and more recently for gHwTx-IV, a mutant of HwTx-IV (28). Both binding modes suggest 
that GMTs adopt a shallow location in lipid membranes.  
Quenchers of peptide Trp fluorescence such as, acrylamide, bromine and 5- and 16-doxy 
stearic acid adopt different locations within the lipid bilayer and can be used to determine 
the depth to which peptides insert into model membranes. Quenchers can also be covalently 
linked to varying positions on the acyl chains of the phospholipid forming lipid bilayers to 
determine the depth of peptide insertion (3,71,72,75). To determine the depth to which the 
Trp30 residue of SgTx-I interacts with the membrane, phospholipids containing bromine at 
different lengths along the acyl chains of the lipids were used in the preparation of model 
membranes composed of POPC/POPG (1:1 molar ratio) (see Table 1). Bromine was used 
as a quencher of the Trp fluorescence and the study determined that the fluorescence 
emission from Trp30 on SgTx-I was quenched when the bromine was localized at a depth 
 19 
of about 9 Å from the center of the model membranes (24). This shallow location in the 
membrane has also been seen for VsTx-I and HaTx-1 in anionic lipid membranes (3,37). 
The orientation of specific residues on SgTx-I during interactions between the GMT and 
model membranes was further studied using NMR transferred cross-saturation (NMR-TCS) 
experiments. In these experiments irradiation was applied to POPC model membranes 
causing a saturation of the resonances from the phospholipids due to spin diffusion. The 
saturation was then transferred to the residues on uniformly labelled 2H- 15N SgTx-I that 
form the peptide–lipid vesicle interface (24,76,77). The experiments showed that SgTx-I 
residues forming the hydrophobic patch interacted with hydrophobic core of the lipid bilayer 
and that this orientation placed the GMT such that residues forming the charged ring would 
interact with the phospholipid head-groups of the lipid bilayer (24). 
Binding of SgTx-I to the surface of lipid bilayers suggests that GMT–lipid interactions are 
governed by electrostatic interactions between the peptides and the phospholipid head-
groups. The importance of electrostatic interactions is supported by an improved interaction 
with anionic compared to zwitterionic model membranes as well as through stronger 
interactions with lipid bilayers prepared using buffers of low ionic strength compared to 
buffers of higher ionic strength (5). If GMTs are to be used as pharmacological tools, it is 
therefore relevant to determine whether the electrostatic interactions between these toxins 
and the lipid membrane can be exploited to optimize the inhibitory potency of the peptides 
at the voltage-gated ion channels. 
 
ProTx-I and ProTx-II: exploiting electrostatic interactions to increase potency of gating 
modifier toxins 
ProTx-I and ProTx-II have also been shown to interact preferentially with anionic lipid 
bilayers via electrostatic interactions (25,39). Both studies used surface plasmon resonance 
(SPR) to examine peptide–membrane binding experiments, where lipid bilayers were 
immobilized onto a chip, and a range of concentrations of the peptide of interest was injected 
onto the lipid bilayers such that affinity was calculated from the amount of peptide bound to 
the model membrane at the end of the association phase (71,78,79). SPR was used for 
analysis of the binding kinetics of both ProTx-I and ProTx-II on lipid bilayers with varying 
properties including fluid zwitterionic POPC and anionic POPC/1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (POPS) (4:1 molar ratio) (see Table 1). ProTx-II was also 
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studied in several lipid systems including rigid, raft-like lipid bilayers comprising the 
zwitterionic POPC/sphingomyelin (SM)/Cholesterol (2.4:3.3:4 molar ratio) and anionic 
POPC/ceramide-1-phosphate (C1P) (3:2 molar ratio) (25). Both studies determined that the 
peptides had slower dissociation rates when interacting with anionic compared to 
zwitterionic lipid bilayers regardless of the fluidity of the model membranes tested (25,39). 
The preferential interaction between ProTx-II and anionic lipid bilayers has been shown in 
additional studies, supporting the hypothesis that electrostatic interactions are important for 
the interaction of this GMT with lipid bilayers (4,33).  
To show that ProTx-I and ProTx-II adopt shallow positions on the lipid bilayers, the ability of 
the peptides to cause changes in the membrane dipole potential was studied (25,39). The 
membrane dipole potential arises from the sum of the polar head-groups and ester carbonyl 
regions of the phospholipids and is dependent on the arrangement of the dipoles at the 
water/lipid interface (78,80). If a peptide perturbs the lipid bilayer, the arrangement of the 
phospholipid bilayer is disturbed and this can be detected by following changes in the 
fluorescence excitation properties of di-8-ANNEPS, a membrane dipole potential probe. An 
increase in membrane dipole potential typically results in a blue shift in the fluorescence 
excitation maximum of di-8-ANNEPS, whereas if a peptide causes a decrease in the 
membrane dipole potential, this will be evidenced as a red shift in the fluorescence excitation 
maximum of di-8-ANNEPS (78,80). Neither ProTx-I nor ProTx-II caused considerable 
changes in the membrane dipole potential of POPC/POPS (4:1 molar ratio) lipid bilayers 
(see Table 1), providing further evidence for a shallow positioning of the peptide toxins in 
the lipid membrane (25,39).  
Despite the shallow positioning of ProTx-II in the lipid membrane, a correlation between 
membrane interactions and potency of ProTx-II at NaV1.7 has been observed (25). Mutants 
of ProTx-II were designed to investigate the role of Trp and Lys amino acid residues in lipid 
membrane interactions and analogues in which Trp residues were replaced with Tyr showed 
both a decrease in lipid affinity and a decrease in the potency of the peptides on inhibition 
of NaV1.7, whereas a [Glu17Lys]ProTx-II mutation showed a comparable potency to the wild 
type sequence of ProTx-II in addition to stronger affinity to lipid membranes (25). A positive 
correlation between membrane interactions and inhibitory potency of ProTx-II has also been 
found for the interaction of this peptide with voltage-gated calcium channels (27), and for 
the inhibition of NaV1.7 by gHwTx-IV (28). These findings raise the interesting possibility that 
increasing membrane binding of GMTs can be used as a strategy to increase the potency 
of these peptides as inhibitors of the voltage-gated ion channels. 
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HwTx-IV and Hd1a: membrane binding is not a prerequisite for potent inhibition of voltage-
gated ion channels 
Despite the findings that several GMTs show affinity for lipid membranes, some GMTs have 
been shown not to have strong interactions with the lipid membrane (28,33,38,39). HwTx-
IV and Hd1a are two examples of GMTs with potent inhibitory activity at NaV1.7 that have 
been shown not to have strong interactions with lipid bilayers (IC50 values of HwTx-IV and 
Hd1a are 26 nM and 115 nM, respectively) (69,81). HwTx-IV failed to co-precipitate with 
anionic POPE/POPG (3:1 molar ratio) and zwitterionic POPC lipid bilayers (33); furthermore 
the peptide showed minimal binding to various lipid bilayers when studied using SPR and 
upon following Trp emission of the peptide toxin using fluorescence spectroscopy (see Table 
1) (28). Similarly, SPR sensorgrams of Hd1a showed a low binding maximum accompanied 
by a fast dissociation rate from anionic POPC/POPS (4:1 molar ratio) and zwitterionic POPC 
lipid bilayers (39). The absence of considerable lipid interactions in both neutrally charged 
and negatively charged lipid bilayers in these three studies indicate GMTs are capable of 
potent inhibition of voltage-gate ion channels in the absence of strong membrane binding 
(28,33,39). Therefore, the shared hydrophobic patch and charged ring of native GMTs do 
not necessarily facilitate membrane binding. 
 
Possible effects on selectivity arising from increasing gating modifier toxin–lipid membrane 
interactions 
A major limitation to the use of GMTs as therapeutic leads is that these toxins show 
promiscuous interactions with various types and subtypes of the voltage-gated ion channels 
(6,82,83). Little has been done to delineate the possibility of modulating ion channel subtype 
selectivity of the GMTs by altering peptide–lipid membrane binding. There are two possible 
scenarios; firstly, engineering peptides to increase overall lipid membrane binding could 
result in peptides with even higher voltage-gated ion channel subtype promiscuity. This 
would occur as a result of peptides accumulating close to and binding to membranes related 
to undesired transmembrane proteins and leading to unwanted downstream effects. 
Secondly, increasing the lipid interactions of the GMTs could act to augment their specificity 
for a voltage-gated ion channel of interest resulting in a more selective as well as a more 
potent modulator of the voltage-gated ion channel. Though several recent efforts have been 
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directed towards the development of selective analogues of GMTs (19-22,61,84), the 
relationship between membrane interactions and selectivity of the GMTs remains to be 
explored and the methodology required to study these interactions in greater detail is still 
being developed. 
 
Choice of model membranes for the study of gating modifier toxins and their 
interactions with the lipid membrane 
The choice of model membranes for the study of the tri-molecular complex is important and 
is dependent on the methodology used. For instance, giant and large unilamellar vesicles 
(GUVs and LUVs) are liposomes that have been used in centrifuge spin-down assays and 
fluorescence spectroscopic experiments because these vesicles have large diameters that 
create a relatively planar surface for the study of the peptides as they interact with lipids 
(Figure 4) (85,86). Small unilamellar vesicles (SUVs) are used in SPR experiments because 
their small diameters create a curvature strain that allows for their fusion and deposition in 
the form of lipid bilayers on the sensor chips (Figure 4) (25,28,39,85,86). 
 
Figure 4. Model membranes.  
Vesicles commonly used in peptide–membrane interaction studies are composed of a single lipid bilayer 
and are named small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs) and giant unilamellar 
vesicles (GUVs), based on their sizes. An example of a transmembrane protein in a micelle (surfactant 
shown in red) and a nanodisc are also shown. 
 
Micelles were used to stabilize the KVAP VSD in the recent NMR study on VsTx-I (Figure 4) 
(23). Disadvantages of micelles are that these spherical aggregates do not provide a planar 
surface with the distinct water/lipid interface and hydrophobic core that is typical of 
physiologically relevant lipid bilayers. Furthermore, micelles are formed using detergent and 
peptide interactions studied using these model membranes may therefore be skewed 
because of the solubility of the peptides in the detergent (87,88).  
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Recent advances in the formation of nanodiscs make these model membranes a stable 
system for the study of the tri-molecular complex (7,87,89). Nanodiscs are portions of bilayer 
phospholipids stabilized by a belt-like membrane scaffold protein (MSP) or copolymers like 
stearic maleic acid (SMA) (Figure 4) (87,88). Transmembrane proteins can be embedded in 
nanodiscs allowing for the study of these proteins and their ligands in more physiologically 
relevant oligomeric protein states in the absence of detergent (87,88,90-92). Furthermore, 
the size of the nanodiscs can be adjusted by modifying the size of the stabilizing membrane 
scaffold peptide or copolymer (87,88). Additionally, nanodiscs allow for accessibility of the 
extracellular and intracellular domains of the transmembrane proteins which allows their 
immobilization of the nanodisc onto SPR sensor chips and other surfaces (93).  
 
Choice of physiologically relevant lipids for the formation of model membranes 
The specific compositions and distributions of the lipids surrounding voltage-gated ion 
channels has not yet been delineated. However, KVs, NaVs and additional ion channels 
targeted by GMTs are embedded in axons, which transmit electrical signals (94,95); thus, 
the lipids forming the plasma membrane of the axon are relevant to the study of GMT–lipid 
membrane interactions. Table 2 shows the relative proportions of the lipids of the plasma 
membrane of a human axon as well as the lipids from the oocytes of Xenopus laevis which 
are model cells often used for electrophysiological measurements on voltage-gated ion 
channels (96-98). 
Phospholipids containing phosphatidylcholine (PC) head-groups are zwitterionic and are the 
most abundant type of phospholipid in the plasma membranes of most eukaryotic cells 
(Table 2) (98,99). Therefore, model membranes containing PC-phospholipids have been 
used to study interactions of GMTs with lipid bilayers. Phospholipids containing 
phosphatidylethanolamine (PE) head-groups are also zwitterionic and though PE-
phospholipids are more abundant than PC-phospholipids in the overall membrane 
composition of human axonal cells (Table 2) (96), PE-phospholipids are primarily distributed 
to the inner leaflet of plasma membranes where they are involved in the formation of vesicles 
for the processes of endocytosis (99,100). Therefore, the use of lower concentrations of PE-
phospholipids with respect to PC-phospholipids would represent more physiologically 
relevant model membranes when studying peptides like GMTs, which appear to adopt a 
shallow positioning in the outer leaflet of the lipid membrane.  
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Table 2. Lipid composition of cell membranes relevant to GMTs  
Cell  Lipida Proportionb (%) 
Human 
axonc  
Phosphatidylethanolamine 19.8 
Phosphatidylcholine  18.7 
Sphingomyelin 3.0 
Phosphatidylserine 3.0 
Phosphatidylinositol 4.4 
Cholesterol 25.3 
 Galactolipid (cerebroside and 
sulfatide) 
25.8 
Xenopus 
laevis 
oocyted 
Phosphatidylcholine 65 
Phosphatidylethanolamine 19 
Sphingomyelin 5 
Phosphatidylinositol 10 
 Phosphatidylserine 2 
 Cholesterol Cholesterol/phospholipid 
(mol/mol (0.6–0.7) 
aPhospholipids are identified in the table by their head groups 
bProportions are a percentage of dry weight unless otherwise specified 
c(96) 
d(98) 
 
Phospholipids containing a phosphatidylglycerol (PG) head group are anionic, and found in 
bacterial cell membranes and therefore studies relating to GMTs that inhibit KVAP, a 
bacterial potassium channel, can justify the use of this anionic phospholipid in their studies 
(2,23,35,37). However eukaryotic cells only have PG-phospholipids in the mitochondria 
(100) and PG-phospholipids are therefore less physiologically relevant to studies involving 
GMTs that inhibit eukaryotic NaVs and KVs. Phospholipids containing a phosphatidylserine 
(PS) head-group form anionic signaling phospholipids and are mostly found in the inner 
leaflet of the membrane bilayer of eukaryotic cells. The presence of PS-phospholipids in the 
outer leaflet of a cell membrane is a signal to trigger cell apoptosis (99). Studies that have 
used PS- and PG-phospholipids have conferred an artificial ability of the positively charged 
GMTs to have a higher affinity for the anionic model membranes compared to neutral model 
membranes made from PC-phospholipids and many of these studies have used this as 
evidence for electrostatic interactions between the peptide toxins and the lipid membrane 
(4,5,25,27,28,33,38-40,101). This raises the question of whether or not the tri-molecular 
complex involving GMTs, the voltage-gated ion channels and the lipid membrane is real. 
The next sub-section examines compelling reasons to continue to investigate the tri-
molecular complex. 
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Why study the tri-molecular complex? 
Despite criticism of the use of PS- and PG-phospholipids to show interactions between the 
GMTs and the lipid bilayer in the studies thus far, the outer leaflet of eukaryotic cell 
membranes is not entirely zwitterionic, there are several anionic charged moieties including 
the sugar moieties of glycosphingolipids (100,102). Therefore, the use of phospholipids 
containing PS and PG head-groups can be used to represent an artificial anionic contribution 
to the overall charge of the outer leaflet of the cell membrane. Secondly, the in silico docking 
studies of HwTx-IV and HnTx-IV and the recent NMR analysis of VsTx-I suggest that these 
GMTs are located in a portion of the VSD that allows for interactions between the peptide 
toxins and the lipid membrane and therefore studies should examine the three components 
of the tri-molecular complex concomitantly before a definitive conclusion can be made 
(23,31,66). 
Additional evidence to support the need for studies on the three components of the tri-
molecular complex comes from work by Milescu et al. (2009). Milescu and colleagues 
studied an enzyme, sphingomyelinase D (SMase D), which hydrolyses SM, a zwitterionic 
lipid, to anionic C1P (103,104). The VSDs of various voltage-gated ion channels were 
studied as chimeras of KV2.1, and it was observed that SMase D modified the behavior of 
each VSD differently (103). To examine the pharmacology of this phenomenon, the ability 
of a ProTx-I, VsTx-I and GxTx-1E to detect changes in the lipid from SM to C1P was studied. 
The study showed that each GMT studied had an apparent increase in affinity to its VSD in 
the presence of SMase D. Furthermore, they determined that when two different domains 
of NaV channels (domain II and domain IV) were compared to each other by studying the 
same toxin inhibitor, ProTx-I, there was a considerable difference in increase in affinity. This 
indicated that ProTx-I was capable of detecting different interactions of the lipids to the VSD 
and highlights the importance of studying the three molecules of the tri-molecular complex 
together (103). 
 
Methods used in the study of the tri-molecular complex and outlook for future 
directions 
Many of the methods currently used to study the relationship between GMTs and the lipid 
membrane lack the sensitivity required to fully delineate intimate binding events between 
the peptides and the lipid membranes to provide us with an overall picture of the potential 
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molecular interactions taking place. As increasingly sensitive methodologies are being 
developed including 3D and 4D NMR and cryo-electron microscopy (cryo-EM), we expect a 
more detailed picture to emerge over the next few years including the complete tri-molecular 
complex and not just the peptide–lipid membrane or peptide–channel interactions. A brief 
summary of current methodologies, their advantages and disadvantages follow. 
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Figure 5. Techniques used to examine GMT–lipid bilayer interactions.  
(A) Centrifuge spin-down assay with representative RP-HPLC analytical traces of the peptide in aqueous 
solution (black) compared to the peptide after incubation with liposomes and spin-down (orange) (B) 
Surface plasmon resonance sensorgram showing deposition of the lipid bilayer followed by injection of 
the peptide onto the bilayer (association) and dissociation over time. A representation of a peptide binding 
to the lipid at different concentrations is shown in the inset. (C) Trp fluorescence emission spectra 
showing partitioning of peptides into lipid bilayers. The Trp emission spectra shown represent the peptide 
in aqueous solution (black) and upon insertion in the lipid bilayer when in the presence of liposomes 
(orange). (D) Stern-Volmer representation of Trp fluorescence emission of a peptide in the presence 
(orange) or absence (black) of liposomes upon titration with an aqueous soluble quencher. (E) 1D 1H 
NMR lipid titration experiment showing the amide region of the spectrum of a peptide in aqueous solution 
(black) compared to the peptide in lipid suspension (orange). (F) NMR transferred cross-saturation 
experiment showing the 2D 15N HSQC spectrum of a peptide in the absence of lipid (black) and in the 
presence of lipid (orange) following irradiation of the lipid and transferred cross-saturation to the peptide. 
(G) NMR chemical shift mapping experiment showing the 2D 15N HSQC spectrum of a peptide in the 
absence of lipid (black) and on lipid titration (orange and red). The arrows show the direction of change 
in the chemical shifts of the residues. (H) Illustration of a Cryo-EM experiment depicting freezing the 
sample on a grid prior to the collection of images using transmission emission microscopy. The images 
are then processed prior to the construction of a 3D-model. 
 
Centrifuge spin-down assays 
Centrifuge spin-down assays involve the incubation of peptides with model membranes, 
spinning down the suspension and using analytical reversed-phase high performance liquid 
chromatography to quantify the amount of peptide left in the supernatant as a measure of 
the extent to which the peptide has bound to the lipid membrane (Figure 5A). Spin-down 
assays have been used in several studies between GMTs and lipid membranes 
(1,2,4,5,23,33). The advantage of centrifuge spin-down assays is that they provide a quick 
screening method to determine whether or not the GMTs are combined with the model 
membranes in the pellet of the suspension. However, this method assumes that the absence 
of the peptides in the supernatant following centrifugation is evidence that the peptide is 
bound to the lipid bilayers. In reality, artificial co-precipitation of peptide molecules with the 
lipids following centrifugation may occur as a result of liposome disruption and/or 
aggregation, and not necessarily through interactions of the peptide molecules with stable 
lipid membranes. Thus, using techniques such as fluorescence spectroscopy or SPR to 
study peptide–lipid interactions would be preferable to avoid artefacts. 
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Surface plasmon resonance 
More recently, SPR has been used to screen for the presence or absence of interactions 
between GMTs and model membranes (25,28,39). SPR experiments involve deposition of 
lipid bilayers onto the surface of an L1 sensor chip, peptides are then injected onto the lipid 
bilayer surface and the time-dependent binding of the peptides to the lipid bilayers is 
measured by an increase in the refractive index on the surface of the sensor chip. Once 
injection of the peptide is stopped, the dissociation of the peptide from the lipid bilayer can 
be followed by monitoring the decrease in the refractive index on the surface of the L1 
sensor chip (Figure 5B) (71,78,79,105). The advantages of SPR are that the experiments 
allow for sensitive, automated, semi high-throughput screening of peptides binding to lipid 
bilayers. Additionally, the peptides do not require prior labelling, and SPR allows for the 
quantification affinity and kinetic rates in peptide–lipid bilayer binding. Some disadvantages 
of this method however include firstly, that SPR does not give information on the orientation 
of the peptide toxins in relation to the lipid bilayers. Secondly, the kinetic experiments are 
lengthy, and available instruments only allow the study of a few peptides at a time during 
affinity assays making the process semi high-throughput. Furthermore, the cost of sensor 
chips, coupled with experience in our lab showing that some GMTs bind so strongly to the 
sensor chip that it is impossible to wash them off rendering the sensor chip non-reusable, 
limits the cost-effectiveness of the SPR technique. 
 
Fluoro-spectrophotometric techniques 
So far, all GMTs whose interactions with the lipid membrane have been studied contain one 
or more conserved Trp residues in their sequence (Figure 1C). As mentioned in section 2.1 
and 2.2, the fluorescence emission properties of GMT Trp residues can be followed upon 
titration of the GMTs with LUVs (Figure 5C), or using quenchers of fluorescence emission 
to quantify the depth to which Trp residues on GMTs insert into lipid bilayers (Figure 5D) 
(71,72,86,106). The advantages of the fluorescence techniques mentioned is that these 
methods provide for sensitive analysis of the peptide interactions with the model membranes 
allowing for the use of low concentrations of the samples. Furthermore, because of the 
intrinsic fluorescent properties of the Trp residues, there is no need to label the peptide 
toxins for these experiments (80). Some disadvantages are that GMTs typically contain 
more than one Trp residue and it is not possible to distinguish which Trp residue/s is/are 
responsible for the observed spectral behavior without mutagenesis studies. Furthermore, 
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the exact positioning of non-fluorescent amino acid residues in relation to model membranes 
cannot be monitored using these techniques. 
 
Molecular dynamics 
Molecular dynamics (MD), including atomistic and coarse-grained simulations, have been 
used to model the binding of GMTs to lipid bilayers (25,39,107-113). MD studies have 
recently been used alongside experimental studies and have supported the findings that 
GMTs, which bind to model membranes are likely to have a shallow location at the 
membrane surface (25,39). A limitation of MD studies is that unlike nanodiscs and liposomes 
that can be made from complex mixtures of lipids, simulation time constraints have so far, 
limited MD experiments to model membranes made from only one or two different 
phospholipids (25,39,107-113). Furthermore, to date, no MD studies have examined all 
three components of the tri-molecular complex simultaneously. 
 
Nuclear magnetic resonance 
NMR allows for the identification of specific amino acid residues that are involved in the 
interactions between peptides and model membranes by identifying changes in chemical 
shifts and in the intensities of resonances of the residues (23,24,73,76). 
1D 1H NMR spectra have been used to study Hm-3, a NaV inhibitor, in its interaction with 
POPC and POPC/1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) (3:1 molar ratio) 
model membranes (Figure 5E) (40). The intensities of the peaks in the amide region of Hm-
3 decreased upon titration with model membranes and the authors correlated this to an 
increase in binding between the peptide and the model membranes (40). A disadvantage of 
this method however is that there was also a broadening of the peaks in the amide region 
of the 1D 1H NMR spectrum of Hm-3 upon lipid titration, and this presents the possibility that 
rather than interacting with the membrane, the GMT could have been forming aggregates 
(40,114). 
NMR transferred cross-saturation experiments on SgTx-I involved the transfer of saturation 
of the resonances from irradiated POPC SUVs to uniformly labelled 2H-15N SgTx-I by cross 
relaxation at the interaction interface such that the resonances of amino acids interacting 
with the membrane were identified by loss in intensities on 2D 1H-15N HSQC spectra (Figure 
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5F) (24,76,77). The use of transferred cross-saturation enabled the examination of weak 
interactions between the peptide toxin and the model membrane, a feature which is 
beneficial to study the superficial relationship evident between GMTs and lipid membranes. 
However, this method cannot be used for lipid systems that would show stronger interactions 
with the peptide toxins because the validity of effective transferred cross-saturation from the 
lipids to the free peptide is dependent on the kinetics of the interaction and requires a fast 
dissociation rate (24,76,115). 
NMR chemical shift mapping was recently used to study VsTx-I and its relationship with 
model membranes as well as interactions between the peptide toxin and the KVAP VSD 
stabilized by micelles (23). Chemical shift mapping experiments allow for the identification 
of peptide toxin amino acid residues interacting with the target (e.g. model membrane or 
VSD) because the resonances from these residues are expected to show changes to their 
chemical shifts and intensities (Figure 5G) (73). The experiments use 15N labelled ligands 
and unlabeled targets such that the target remains invisible on 15N HSQC spectra, but the 
effect of ligand–target interaction is visible as changes to the spectrum of the labelled ligand. 
The advantage of chemical shift mapping over transferred cross-saturation experiments is 
that NMR chemical shift mapping considers the relative strength of interaction between the 
peptide toxin and the target (model membrane or VSD). Disadvantages of NMR chemical 
shift mapping are that the technique requires isotopic labelled 15N ligand for the assignment 
of the spectra in the free state and in the case of strong interactions, additional assignment 
of the spectra in the bound state (73). 
 
Cryo-electron microscopy 
Cryo-EM involves the use of cryogenic temperatures to obtain images of biological 
structures using transmission emission microscopy (Figure 5H) (116). Several images of the 
structures in different orientations are obtained, and computational image processing and 
particle picking is applied to build a 3D model based on an average of the processed images 
(116). A recent study has used cryo-EM to delineate the binding of DkTx to TRPV1, its target 
ion channel, embedded in a nanodisc (7). DkTx is a bivalent GMT containing two ICK motifs 
joined with a seven amino acid long chain linker (117). The cryo-EM model obtained from 
the study of DkTx showed the GMT interacting with phospholipids involved in the 
stabilization of the TRPV1 ion channel (7). The use of cryo-EM has some disadvantages, 
including the requirement for highly specialized skills, expensive equipment, and an inability 
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of this technique to follow the kinetics of peptide–lipid interactions using a single sample. 
However, the study by Gao et al. (2016), which was the first high-resolution depiction of the 
tri-molecular complex including a GMT, a transmembrane protein and a model membrane 
in concert, highlights the potential benefits of using cryo-EM in the study of GMT–lipid bilayer 
interactions in the future.  
 
Conclusion 
This review has examined the concept of a tri-molecular relationship between GMTs 
extracted from spider venoms, voltage-gated ion channels, and the lipid membrane. The 
studies thus far suggest that the lipid membrane acts to anchor and orient some GMTs for 
optimal interactions with voltage-gated ion channels and that the interactions between 
GMTs and the lipid membrane appear to be superficial and primarily electrostatic in nature 
(2,3,23-25,28,38,39). Furthermore, initial evidence suggests that increasing the interactions 
between these peptide toxins with the membrane can be exploited to optimize the inhibitory 
potency of the GMTs (21,25,28).  
A major drawback to the available information we have on the tri-molecular complex is that 
most of the studies have studied GMTs and model membranes without the voltage-gated 
ion channels. However, evidence from recent studies showing VsTx-I interacting with KVAP 
VSD stabilized in micelles, and the atomistic details of DkTx interacting with phospholipids 
that stabilize the TRPV1 ion channel embedded in nanodiscs represent evidence that we 
have the technology that will enable the study of each of the three components within the 
tri-molecular complex at the concurrently in more physiologically valid model membranes 
(7,23). 
The tri-molecular complex is an intriguing concept, which if proven to be existent and 
relevant, will contribute to a shift from the typical lock-and-key approach to drug design and 
allow for the consideration of the role of the lipid membrane in drug design.  
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A survey of the lipid interactions, potency and selectivity of 
native gating modifier toxins 
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Overview 
This chapter is a study on the interplay between the conserved amphipathicity of GMTs with 
lipid binding and inhibition of voltage-gated sodium channels. A panel of nine GMTs 
including GpTx-I, HwTx-IV, HnTx-IV, ProTx-I, SgTx-I, GsMTx-IV, CcoTx-I, CcoTx-II and 
PaurTx-III were used to answer the following six questions: (i) to what extent do native GMTs 
bind to model membranes? (ii) What is the depth to which GMTs insert into the lipid bilayer? 
(iii) What forces govern GMT–lipid bilayer interactions? (iv) Can GMT 
structural/physicochemical properties be used to predict their ability to bind to the lipid 
bilayer? (v) Is there a relationship between membrane binding and inhibition of NaV1.7 by 
GMTs? (vi) Is there a relationship between membrane binding and selectivity of GMTs 
against other NaVs? These questions were crafted with the vision that the information 
gathered from this section of the project would provide information on the applicability of the 
tri-molecular complex, particularly the GMT–lipid interactions, in drug design. 
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A conserved amphipathic surface of spider-derived gating modifier toxins promotes 
simultaneous modulation of multiple voltage-gated sodium channels. 
Akello J. Agwa1, Steve Peigneur2, Chun Yuen Chow1, Nicole Lawrence1, David J. Craik1, Jan Tytgat2, 
Glenn F. King1, Sónia Troeira Henriques1, Christina I. Schroeder1,* 
1Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia 
2Toxicology and Pharmacology, University of Leuven (KU Leuven), 3000 Leuven, Belgium 
* Corresponding author 
Abstract 
Gating modifier toxins are peptides isolated from spider venom and modulate activity of 
disease-relevant voltage-gated ion channels and are therefore being pursued as therapeutic 
leads. The amphipathic surface profile of GMTs has prompted the proposal that some GMTs 
simultaneously bind to the cell membrane and voltage-gated ion channels in a tri-molecular 
complex. Here we examine whether there is a relationship between GMT amphipathicity, 
membrane binding and potency or selectivity for voltage-gated sodium (NaV) channels. We 
used NMR spectroscopy and in silico calculations to examine the structures and 
physicochemical properties of a panel of nine GMTs and deployed surface plasmon 
resonance to measure GMT affinity for lipids putatively found in proximity to NaV channels. 
Electrophysiology was used to quantify GMT activity on NaV1.7, an ion channel linked to 
chronic pain. Selectivity of the peptides was further examined against a panel of NaV channel 
subtypes. We show that GMTs adsorb to the outer leaflet of anionic lipid bilayers through 
electrostatic interactions. We did not observe a direct correlation between GMT 
amphipathicity and affinity for lipid bilayers. Furthermore, GMT–lipid bilayer interactions did 
not correlate to potency or selectivity for NaVs. We therefore propose that increased 
membrane binding is unlikely to improve subtype selectivity and that the conserved 
amphipathic GMT surface profile is an adaptation that facilitates simultaneous modulation 
of multiple NaVs. 
 
Keywords: Amphipathic surface, disulfide-rich peptides, gating modifier toxin, oxidative 
folding, pain, drug design, sodium channel, tarantula venom, voltage sensor domain 
 
Abbreviations: CHOL, cholesterol; C1P, ceramide-1-phosphate; ACN, acetonitrile; GMT, 
gating modifier toxin; HEK, human embryonic kidney; ICK, inhibitor cystine knot; LUV, large 
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unilamellar vesicle; PI, L--phosphatidylinositol; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; POPS, 1-palmitoyl-2-oleoylsn-glycero-3-phospho-L-serine; SM, 
sphingomyelin; SMase D, sphingomyelinase D; SUV, small unilamellar vesicle. 
 
Introduction 
Gating modifier toxins (GMTs) extracted from spider venom are a class of peptides that are 
valuable probes for studying the physiology and pharmacology of voltage-gated ion 
channels (1-4). GMTs alter the gating kinetics of voltage-gated ion channels (4), which are 
transmembrane proteins integral to a range of physiological processes in humans (1,5,6). 
GMTs contain six Cys residues arranged to form an inhibitor cystine knot (ICK) motif (7). In 
addition, these peptides share a conserved amphipathic surface profile characterized by a 
high proportion of hydrophobic amino acid residues such as Trp, Tyr and Phe, surrounded 
by a ring of cationic residues including Arg and Lys that typically promote peptide–
membrane interactions (Figure 1A, B) (8).  
Several GMTs, including GsMTx-IV, HaTx-I, VsTx-I, ProTx-I, ProTx-II and SgTx-I, have 
been shown to bind to model membranes (8-12). The concept of a tri-molecular lipid–
peptide–channel complex has subsequently been proposed to exist in interactions between 
GMTs, voltage-gated ion channels and the lipid membrane (10,13,14). A tri-molecular 
complex presents the possibility for a novel approach to drug design whereby the cell 
membrane is considered as a third component in addition to the traditional approach which 
only takes into account the transmembrane protein and the modulatory ligand (10,14,15). 
The objective of the current study was to determine if there is an overall relationship between 
the amphipathic surface profile of GMTs, and their ability to bind lipid membranes and 
modulate voltage-gated ion channels. Electrophysiology was used to examine potency of 
the peptides at voltage-gated sodium channel 1.7 (NaV1.7), a transmembrane protein, that 
is currently being pursued as a target for development of therapeutics for chronic pain (5,16). 
GMTs are likely to show toxicity in mammals if they show activity at off-target NaVs, therefore 
NaV1.2, NaV1.4, NaV1.5 and NaV1.6 were included to study whether there is a relationship 
between GMT amphipathicity, affinity for lipid bilayers and off-target selectivity. Previous 
reports have examined lipid binding properties of small GMT cohorts (10,11,17,18), but the 
current study represents the first concerted effort to study the membrane binding of a cohort 
of native GMTs in model membranes chosen to mimic physiological properties (15).  
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CcoTx-I, CcoTx-II, PaurTx-III and ProTx-I were chosen because these GMTs are known 
promiscuous modulators of NaVs (19,20), and would therefore provide information on the 
relationship between GMT amphipathicity, promiscuity for NaVs and affinity for lipid bilayers. 
HnTx-IV, HwTx-IV and GpTx-I were chosen for their known potency at NaV1.7 (21-23), and 
though we have recently examined the lipid affinity of HwTx-IV (24), we have not done so in 
the context of a comparative analysis with native GMTs. GsMTx-IV is a known modulator of 
stretch activated mechano-sensitive channels with a mechanism of action that is primarily 
related to interactions with the lipid bilayer (12,25), and was included in the present study 
as a positive control for the lipid affinity studies and as a negative control for the studies on 
NaVs. SgTx-I is a known modulator of KV channels, and as an inhibitor of the voltage of 
inactivation of NaV1.2 (26-28), and like GsMTx-IV was included as a negative control for the 
studies on NaVs. Our results suggest that the conserved amphipathic surface profile of 
spider-derived GMTs is most probably an adaptation that allows the concomitant modulation 
of several voltage-gated ion channels, and that GMTs have preferential affinity for anionic 
model membranes. 
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Figure 1. Surface profiles and sequences of the panel of nine GMTs used in this study.  
CcoTx-I (PDB 6BR0), CcoTx-II (PDB 6BTV), GpTx-I (23), HnTx-IV (PDB 1NIY) (21), HwTx-IV (PDB 
2M4X) (29), PaurTx-III (PDB 5WE3) (30), ProTx-I (PDB 2M9L) (31), and SgTx-I (PDB 1LA4) (32). (A) 
Surface representations of the GMTs colored by residue type with hydrophobic (green); positively 
charged (blue), negatively charged (red) and uncharged (white). All the peptides are in the same 
orientation. (B) Alignment of GMT sequences relative to HnTx-IV and HwTx-IV. Cysteine residues are 
highlighted in grey. Residues that contribute to the hydrophobic patch (green) and positively charged ring 
(blue), as well as negatively charged residues (red) are labelled. NT and CT show N- and C-termini of 
the peptides. * represents C-terminal amidation (The numbers below the table refer to the residue 
number). 
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Results 
Oxidative folding of GMTs 
To optimize the yield of GMTs with correct disulfide connectivity, each peptide was subjected 
to 3–5 oxidative folding trials in which the effects of temperature and folding buffer were 
examined (pH was always 7.7–8.0) (Supporting Information, Table S1). Peptide folding was 
monitored using analytical reverse phase HPLC (RP-HPLC) and LC/MS (Supporting 
Information, Figure S2). Most GMTs were successfully folded at 25 ºC in buffer containing 
7.5% (v/v) acetonitrile (ACN) (method A). GsMTx-IV was folded using both method A and 
B; but formed aggregates using method B, probably because of the lack of organic solvent 
(Supporting Information, Table S1). Furthermore, correct folding using method B took 24 h 
for GsMTx-IV compared to 16 h for method A. Correct folding of both HnTx-IV and HwTx-IV 
proceeded in the absence of organic solvent at room temperature in 16 h (methods C and 
D), whereas SgTx-I and ProTx-I required a slow reaction in 0.1 M ammonium acetate buffer, 
using 2 M urea at 4 ºC for 72 h (Method E). 
 
NMR analysis of the GMTs 
One-dimensional 1H spectra (Supporting Information, Figure S3) of all GMTs revealed good 
dispersion of amide-proton resonances (7–10 ppm), suggesting that the peptides were 
folded and structured. H chemical shifts derived from two-dimensional TOCSY and 
NOESY spectra were used for sequential assignment of the peptides (Figure 2), and H 
shifts for GpTx-I (23), HnTx-IV (PDB 1NIY) (21), HwTx-IV (PDB 2M4X) (29), and ProTx-I 
(PDB 2M9L) (31), were in good agreement with literature values, with small differences 
attributable to differences in chemical shift referencing or pH (Figure 2). Structures of 
GsMTx-IV and SgTx-I are available (32,33), but H shifts have not been reported (Figure 
2). The solution structures and chemical shift assignments for CcoTx-I (PDB 6BR0; BMRB 
30376) and CcoTx-II (PDB 6BTV; BMRB 30377) are reported here for the first time and have 
been submitted to the Protein Data Bank and to the BioMagnetic Resonance Bank, 
respectively (Figure 4A; Supporting Information, Table S4). The disulfide bridges in these 
GMTs form a classical ICK motif in which the cystine knot stabilizes a structure comprised 
of loops, turns and two antiparallel  strands (Tyr20–Cys22 and Cys29–Tyr31). The 
hydrophobic residues form a cluster with the side chains showing  – stacking and 
attractive hydrophobic interactions (Figure 3B). The structure for PaurTx-III, which we 
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recently solved and submitted to the PDB (PDB 5WE3; BMRB 30317) is also shown (Figure 
3) (30). 
  
 
Figure 2. NMR analysis of GMTs included in this study.  
Secondary H chemical shifts of synthetic GMTs were obtained using 2D TOCSY and NOESY spectra. 
Secondary H chemical shifts were in agreement with literature shifts for HnTx-IV (PDB 1NIY) (21), 
HwTx-IV (PDB 2M4X) (29), ProTx-I (PDB 2M9L) (31) and GpTx-I, (1), H shifts from (23). 
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Figure 3. Solution NMR structure calculations. 
CcoTx-I (PDB 6BR0), CcoTx-II (PDB 6BTV) and PaurTx-III (PDB 5WE3).Overlay of the ensemble of 20 
conformers selected on the basis of lowest energy of minimization and best MolProbity scores. (A) 
Schematic of CcoTx-I, CcoTx-II and PaurTx-III with disulfide bridges shown in gold and cysteines 
labelled. NT and CT are the N- and C-termini respectively. (B) The three GMTs are oriented the same 
way as in A with side chains of aromatic residues forming the hydrophobic patch shown in white.  
 
GMT–lipid bilayer interactions 
Surface plasmon resonance (SPR) was used to compare GMT affinity for different model 
membranes. Comparisons are made relative to GsMTx-IV, which had the highest affinity for 
all the model membranes (Figure 4, Supporting Information, Table S5). Within the context 
of the current study, affinity refers to amount of peptide bound to lipid (peptide/lipid (P/L) 
(mol/mol)), and the rate of dissociation of the peptide from the lipid bilayer (Figure 4; 
supporting information, Table S5). Here, ‘weak affinity’, refers to GMTs that either dissociate 
from the lipid bilayers rapidly, or that do not reach a P/L (mol/mol) that is as high as GsMTx-
IV. In some instances, we compare the affinity of specific GMTs to different model 
membranes, in which case ‘weak affinity’, ‘high affinity’ or ‘preferential affinity’ compare a 
specific peptide’s affinity for one model membrane to another model membrane.  
Our examination of GMT interactions with model membranes began with lipid bilayers 
composed of zwitterionic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) as 
phospholipids containing phosphatidylcholine headgroups are the most abundant 
phospholipids in the outer leaflet of healthy mammalian cells (34). Sensorgrams and 
concentration–response curves revealed that GsMTx-IV had the highest affinity (highest 
amount of maximum peptide bound to lipid i.e. 0.071 P/L (mol/mol), with the slowest 
dissociation from the POPC model membranes) (Figure 4; Supporting Information, Table 
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S5). The remaining peptides had weak affinity (0.002–0.031 P/L (mol/mol)) for POPC lipid 
bilayers (Figure 4; Supporting Information, Table S5). 
There is evidence that voltage-gated ion channels are embedded within lipid rafts that form 
domains around these transmembrane proteins for functional and structural integrity 
(35,36). A mixture of POPC/sphingomyelin (SM)/cholesterol (CHOL) (2.7:4:3.3 molar ratio) 
was therefore used to mimic the environment formed by lipid rafts (37,38). GsMTx-IV and 
CcoTx-II showed the highest amount of peptide bound to lipid (0.045 and 0.041 P/L 
(mol/mol) respectively) although CcoTx-II dissociated faster than GsMTx-IV. All other 
peptides bound weakly to POPC/SM/CHOL model membranes (0.012–0.028 P/L (mol/mol)) 
(Figure 4; Supporting Information, Table S5).  
We also examined GMT affinity for anionic POPC/ceramide-1-phosphate (C1P)/CHOL 
(2.7:4:3.3) model membranes, in which C1P possesses a negatively charged headgroup. It 
was previously shown that GMTs have stronger affinity for voltage-gated ion channels when 
sphingomyelinase D (SMase D), an enzyme found in the venom of sicariid spiders, 
hydrolyses SM to C1P (35,36,38). The GMTs had highest affinity for this model membrane 
compared to other model membranes used in this study, except PaurTx-III, which showed 
weak affinity for this lipid type (0.001 P/L (mol/mol)) (Figure 4; Supporting Information, Table 
S5). 
We also examined GMT affinity for POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-
serine (POPS) (4:1) model membranes because phosphatidylserine phospholipids have 
frequently been used to mimic the influence of anionic moieties found on the outer leaflet of 
cell membranes (11,24,38,39). CcoTx-II, HnTx-IV, ProTx-I and HwTx-IV showed preferential 
binding to POPC/POPS (4:1) over POPC lipid bilayers (0.045, 0.023, 0.049 and 0.013 P/L 
(mol/mol) respectively for POPC/POPS compared to 0.023, 0.002, 0.029 and 0.004 P/L 
(mol/mol) respectively for POPC. However, there was no difference between binding to 
POPC and POPC/POPS (4:1) for CcoTx-I, GsMTx-IV, GpTx-I and SgTx-I (Figure 4; 
Supporting Information, Table S5).  
Phosphatidylinositol phospholipids are negatively charged; they form a ring-like shell around 
transmembrane proteins and may have a role in modulating the function of voltage-gated 
ion channels (37,40,41). Thus, we examined the affinity of HnTx-IV, HwTx-IV, ProTx-I and 
SgTx-II for model membranes composed of POPC/L- - phosphatidylinositol (PI) (4:1). 
HnTx-IV had the highest amount of peptide bound to model membrane (0.055 P/L (mol/mol)) 
but dissociated rapidly (Figure 4), whereas HwTx-IV had the lowest affinity (0.015 P/L 
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(mol/mol)). The four peptides bound to POPC/PI higher affinity than their binding to POPC 
lipid bilayers (0.055, 0.015, 0.042 and 0.042 P/L (mol/mol) for HnTx-IV, HwTx-IV, ProTx-I 
and SgTx-I respectively at POPC/PI compared to 0.002, 0.004, 0.029 and 0.020 P/L 
(mol/mol) respectively for POPC) (Figure 4; Supporting Information, Table S5).  
 
Figure 4. Binding of GMTs to model membranes. 
(A) SPR sensorgrams of each peptide at 64 M and (B) corresponding concentration–response curves 
were obtained and used to examine the affinity of GMTs for model membranes composed of POPC, 
POPC/POPS (4:1), POPC/SM/CHOL (2.7:3.3:4), and POPC/C1P/CHOL (2.7:3.3:4). For HnTx-IV, HwTx-
IV, ProTx-I and SgTx-I, POPC/PI (4:1) model membranes were also examined. Peptide association and 
dissociation phase is indicated on the sensorgram for GpTx-I. Response units were converted to ratio of 
Peptide/Lipid (mol/mol) at the end of peptide injection (t = 170 s), and concentration–response curves 
were obtained using peptide concentrations ranging from 0–64 M.  
 
 
 53 
GMT interactions with model membranes upon variation of ionic strength 
To examine the importance of electrostatic interactions in driving GMT binding to model 
membranes, we compared GMT binding to POPC/POPS (4:1) lipid bilayers in buffers of 
varying ionic strength. All GMTs showed increased binding to lipid vesicles formed in lower 
ionic strength buffer (50 mM NaCl) compared to lipid vesicles formed in high ionic strength 
buffer (300 mM NaCl) (Figure 5). PaurTx-III, HnTx-IV and GpTx-I had fast dissociation rates 
from lipid bilayers prepared in low ionic strength buffer suggesting that these three GMTs 
form weaker electrostatic interactions with POPC/POPS (4:1) lipid bilayers than the 
remaining six GMTs (Figure 5). 
 
 
 
 
 
 54 
 
Figure 5. The importance of electrostatic forces in peptide–lipid interactions. 
Interactions of GMTs with POPC/POPS (4:1) bilayers prepared in buffers of different ionic strength 50, 
150 or 300 mM NaCl in 10 mM HEPES, pH 7.4. 
 
Analysis of environment surrounding GMT Trp residues upon lipid titration 
The fluorescence emission spectrum of Trp residues is dependent on their local 
environment. As a Trp residue on a peptide moves from a polar to an apolar environment, 
an increase in quantum yield and a leftward (blue shift) of the fluorescence emission 
spectrum is expected (42,43). These properties were used to examine whether Trp residues 
found on GMTs insert into the hydrophobic acyl chains of model membranes. Large 
unilamellar vesicles (LUVs) were used to mimic a planar bilayer surface (42,44). All nine 
GMTs have a fluorescence emission spectrum with a maximum near 350 nm, which is close 
to the fluorescence emission of L-Trp in buffer (354 nm); suggesting the presence of solvent 
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exposed Trp residues, and that the fluorescence spectra can be used to gauge if the 
peptides move from a polar to an apolar environment. None of the GMTs showed a 
significant change in the fluorescence emission properties of their Trp residues upon titration 
with POPC/POPS LUVs (Figure 6), suggesting that the Trp residues do not deeply insert 
into the acyl core of the lipid bilayers but rather adopt a superficial position on the lipid 
bilayer. The conclusion that the peptides adopt a shallow position is supported by the SPR 
data for the peptide affinity at POPC/POPS model membranes (Figure 4), where none of 
the peptides bound to the lipid at a ratio of greater than 0.1 P/L (mol/mol), the peptides could 
not have inserted deeply into the lipid bilayer with this level of affinity for the model 
membranes. For comparison [E5K, E8K]MfVIA, a peptide that we have recently reported 
on, showed both an increase in quantum yield and a blue shift in the emission spectrum 
(Figure 6), accompanied by a maximum P/L mol/mol ~ 0.5 as calculated using SPR in the 
presence of POPC/POPS model membranes (45). 
 
 
Figure 6. Analysis of the environment around GMT Trp residues upon lipid titration. 
Fluorescence emission spectra of the peptides were followed in the absence (0 mM) and presence (4 
mM) of POPC/POPS (4:1) LUVs. Excitation at  = 280 nm; peptide concentrations were 25  M for all 
GMTs except PaurTx-III (12.5  M) in HEPES buffered saline. Spectra for [E5K,E8K]MfVIA, are included 
as a positive control (45). 
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Inhibitory potency of GMTs at NaV1.7 
GMT inhibition of NaV1.7 current was examined using whole-cell patch clamp 
electrophysiology. All peptides except SgTx-I and GsMTx-IV, inhibited NaV1.7 with mid-
nanomolar potency, as reported for ProTx-I, GpTx-I and HwTx-IV (19,23,46). HnTx-IV was 
the most potent inhibitor of NaV1.7 followed by ProTx-I, HwTx-IV, PaurTx-III, CcoTx-II, 
GpTx-I and CcoTx-I in descending order of potency (Figure 7).  
 
Figure 7. GMT inhibition of NaV1.7.  
Automated whole-cell patch-clamp electrophysiology was used to compare the inhibitory potency of the 
peptides at NaV1.7. Representative concentration–response curves and comparative IC50 values for the 
peptides are shown. Data are mean ± SEM where n = 3 and one cell was considered an independent 
experiment. 
 
NaV subtype selectivity of GMTs 
Two-electrode voltage-clamp electrophysiology was used to examine the effect of GMTs on 
NaV1.2, NaV1.4, NaV1.5 and NaV1.6 expressed in Xenopus oocytes (difficulties with 
expression of NaV1.7 in oocytes precluded TEVC studies). The GMTs showed absence of 
selectivity when studied against the NaV channels. (Figure 8, Table 1). ProTx-I, CcoTx-I, 
PaurTx-III and CcoTx-II inhibited 80–100% of current from all the NaV channels examined 
(Figure 8 A–D; Table 1). HwTx-IV, HnTx-IV and GpTx-I had the best overall selectivity as 
they only showed complete current inhibition of NaV1.2 and NaV1.6, but did not completely 
inhibit current from NaV1.4 and NaV1.5 as seen for CcoTx-I, CcoTx-II, PaurTx-III and ProTx-
I (Figure 8, Table 1). HwTx-IV was equipotent on NaV1.2 and NaV1.6 (Figure 8; Table 1), 
whereas HnTx-IV was slightly more potent at NaV1.2 and had two-fold lower potency for 
NaV1.6 (Figure 8; Table 1). GpTx-I had the best overall selectivity with a six-fold difference 
in potency between NaV1.6 and NaV1.2 (Figure 8; Table 1). GsMTx-IV failed to inhibit 100% 
of current from any NaV channel subtype and SgTx-I caused a delay in channel inactivation 
accompanied by an increase in sodium peak current. Despite these differences between 
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GsMTx-IV and SgTx-I compared to the remaining seven GMTs, both GsMTx-IV and SgTx-
I were not selective (Figure 8; Table 1). 
 
Figure 8. NaV subtype selectivity of GMTs. 
TEVC electrophysiology on oocytes was used to examine the effects of GMTs NaV1.2, NaV1.4, NaV1.5 
and NaV1.6. All GMTs promiscuously modulated the activity of all NaV channels tested, with GpTx-I, 
HwTx-IV and HnTx-IV showing the best overall selectivity. SgTx-I showed an increase in current influx 
for NaV channel subtypes therefore I30ms/IPeak is shown for this peptide. Data for the remaining eight 
peptides were normalized to maximum current inhibition. Error bars represent ± SEM, where n = 3. 
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Examination of the physicochemical properties of the GMTs 
All nine GMTs have similar net positive charge with no observable relationship between net 
charge and affinity for lipid membranes (Table 2; Figure 9A). GMT hydrophobicity was 
compared using their RP-HPLC retention times, and the proportion of apolar solvent 
accessible surface area (SASA) was used to measure the solvent accessible hydrophobic 
area of each peptide. There was no correlation between GMT hydrophobicity or apolar 
SASA and membrane binding (Table 2; Figure 9B,C). For instance, CcoTx-I and PaurTx-III 
have retention times of ~ 27 min and apolar SASAs of 57% and 65% respectively, but these 
peptides show different affinities for the lipid bilayers examined (Table 2; Figure 4; Figure 
9). Likewise, PaurTx-III and GsMTx-IV have the highest % apolar SASAs (65% and 66% 
respectively) but consistently had the weakest and strongest affinities respectively, for the 
model membranes studied (Table 2; Figure 4; Figure 9). 
 
 
 
Table 1. Gating modifier toxin inhibition of voltage-gated sodium channels (EC50, 
nM)a,b 
Peptide  NaV1.2 NaV1.4 NaV1.5 NaV1.6 
ProTx-I 59.7 ± 7.4 108.6 ± 19.3 76.3 ± 9.1 133 ± 10 
CcoTx-I 6.1 ± 0.7 263± 45 188± 20 40.6 ± 5.8 
PaurTx-III 0.70 ± 0.07 92.9 ± 12.7 46.3 ± 8.8 20.0 ± 2.1 
CcoTx-II 3.7 ± 0.6 113 ± 24 1524 ± 58 49.9 ± 7.1 
GsMTx-IV  >3  M >3  M >10  M >3  M 
SgTx-I >3  M >10  M >10  M >3  M 
HwTx-IV  116 ± 16 >10  M >10  M 117 ± 21 
HnTx-IV  22.4 ± 3.0 >10  M >10  M 50.1 ± 7.4 
GpTx-I  128 ± 12 >10  M >10 M 20.1 ± 1.7 
a % Inhibition of sodium currents was measured using TEVC electrophysiology 
and EC50 values are ± SEM n = 3  
b Values for SgTx-I are I30ms/Ipeak since this GMT displayed a delay in channel 
inactivation accompanied by an increase in current  
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Figure 9. Correlation between GMT affinity for model bilayers and physicochemical properties 
No correlation was observed between membrane binding (peptide/lipid mol/mol) and (A) apolar surface 
area (B) net charge (C) hydrophobicity as measured by retention time on analytical RP-HPLC. Each 
symbol represents a lipid system and the quantitative physicochemical value of the peptides in the 
present study. 
Table 2. Physicochemical properties of GMTs 
Peptide Peptide RTa 
(min) 
Polar 
SASAb 
Apolar 
SASA 
% Apolar 
SASA 
Net 
chargec 
CcoTx-I 26.5 1230 1653 57 3 
CcoTx-II 27.0 1083 1736 62 4 
GpTx-I 24.1 1187 1873 61 4 
GsMTx-IV 35.4 1023 2010 66 5 
HnTx-IV 20.7 1245 1604 56 4 
HwTx-IV 26.0 1289 1888 59 4 
PaurTx-III 26.9 1046 1914 65 4 
ProTx-I 32.7 1165 1830 61 2 
SgTx-I 35.7 1001 1823 65 2 
a RT is retention time of peptides obtained by analytical HPLC (1%/min gradient 
of 0–60% solvent B at a flow rate of 0.3 mL/min) 
b Solvent accessible surface area (SASA) calculated using GETAREA: 
http://curie.utmb.edu/getarea.html 
c Net charge was calculated at pH = 7.4 using pKa values from Propka (47) 
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Discussion 
GMTs isolated from spider venom share a conserved hydrophobic patch surrounded by a 
ring of positively charged residues that together have been proposed to promote peptide 
affinity for lipid membranes (Figure 1) (8,48). Here we examined the extent to which nine 
GMTs bound to a series of model membranes, whether there is a relationship between 
membrane binding and inhibition of NaV1.7, and whether GMT amphipathicity is important 
for membrane binding and/or inhibition of NaV channels. 
 
GMT affinity for model lipid bilayers 
Overall, the nine GMTs showed weak affinity for model membranes prepared using POPC 
and mixtures of POPC/SM/CHOL (Figure 4; Supporting Information, Table S5), in 
agreement with previous studies showing that GMTs such as VsTx-I, Hd1a and ProTx-II 
have weak affinity for zwitterionic model membranes (8,13,17,24,38,39,46).  
GMTs showed preferential affinity for negatively charged POPC/C1P/CHOL model 
membranes compared to those made from POPC/SM/CHOL (Figure 4; Supporting 
Information, Table S5), as observed previously for ProTx-II (38). Interestingly, the 
pharmacology of some voltage-gated ion channels has previously shown sensitivity to the 
enzymatic conversion of SM to C1P by SMase D (35,36); it is possible that sicariid spiders 
take advantage of the presence of SMase D, and perhaps additional venom components, 
to increase GMT binding to both cell membranes and the voltage-gated ion channels to 
optimize activity (38). This hypothesis is supported by a study showing that ProTx-I has 
increased affinity for voltage-gated ion channels upon conversion of SM to C1P by SMase 
D (36).  
The preferential affinity of GMTs for anionic compared to zwitterionic model membranes was 
further observed in a higher GMT affinity for POPC/POPS and POPC/PI compared to POPC 
lipid bilayers (Figure 4). This affinity is presumably driven by electrostatic interactions 
between the positively-charged peptides and anionic lipid head groups, and may be 
indicative of GMT affinity for negative moieties on the outer leaflet of cell membranes (Table 
2). The importance of electrostatic interactions is further supported by the observed increase 
in GMT affinity for POPC/POPS with low ionic strength (see results with 50 mM NaCl, Figure 
5). These results agree with previous studies that also emphasized the importance of 
electrostatic interactions in driving GMT binding to lipid bilayers (10,18,38,39). 
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Analysis of the environment surrounding GMT Trp residues in anionic lipids 
The absence of a blue shift or change in quantum yield in the fluorescence spectra of the 
GMTs in the presence of anionic lipids (Figure 6) suggests that they adopt a shallow position 
on anionic lipid bilayers as reported for ProTx-II and ProTx-I (38,39). Although SgTx-I and 
HaTx-I were previously shown to insert into lipid membranes up to a distance of ~9 Å from 
the center of the bilayer, these studies employed model membranes containing 50% anionic 
PG-phospholipids and model membranes were prepared in solutions without NaCl (9,49). 
Some GMTs like VsTx-I modulate the function of bacterial voltage-gated potassium 
channels (3,13,50), and therefore the use of PG-phospholipids can be justified in the studies 
of the tri-molecular complex formed by these peptides. However, PG-phospholipids are 
unlikely to be found on the outer leaflet of mammalian cell membranes (34), and therefore 
were not included in the current study. Taken together, the present work indicates that GMTs 
adsorb to the outer leaflet of anionic lipid bilayers. 
 
Relationship between GMT–membrane binding and NaV channel inhibition 
Potency of the panel of GMTs for NaV1.7 appears not to be correlated to affinity for any 
model membrane. For example, GsMTx-IV and SgTx-I are both known poor inhibitors of 
NaV1.7 but had different affinities for the model membranes. The other GMTs studied were 
mid-nanomolar inhibitors of NaV1.7 (Figure 7), but had varied affinities for the model 
membranes. We previously showed that reducing the membrane affinity of ProTx-II results 
in analogues with weaker potency at NaV1.7 (38). We also demonstrated that the membrane 
binding and potency of HwTx-IV can be increased without changing the pharmacophore of 
this particular GMT (24). Thus, although membrane binding is not essential for inhibition of 
NaV1.7, modulating affinity of individual GMTs for lipid bilayers can be exploited to increase 
or decrease potency. 
We next examined if differences in membrane binding properties may be important in 
dictating NaV subtype selectivity. None of the GMT studied displayed exceptional selectivity 
for any NaV channel subtype (Figure 8; Table 1), affirming previous reports on the 
promiscuity of most of these peptides (14,19,20). There was also no direct correlation 
between selectivity and membrane binding. However, GpTx-I, HwTx-IV and HnTx-IV, three 
peptides with an overall weak affinity for model membranes in the current study (Figure 4), 
had the best overall selectivity as they achieved 100% current inhibition and strong potency 
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only for NaV1.2 and NaV1.6 (Figure 8). Conversely, ProTx-I, CcoTx-I and CcoTx-II, three 
peptides that achieved 100% current inhibition for at least three NaV channel subtypes 
(Figure 8, Table 1), all had overall higher affinity for model membranes compared to HnTx-
IV, HwTx-IV and GpTx-I (Figure 5). Therefore, it appears that increasing membrane binding 
is unlikely to improve the NaV subtype selectivity of spider-venom GMTs.  
 
Deductions on the role of GMT amphipathicity for NaV inhibition 
There was also no apparent correlation between GMT physicochemical properties and 
affinity for the lipid membranes studied (Figure 9), and these results are in agreement with 
our previous work involving a smaller sample of GMTs (39). Since the global 
physicochemical properties of native GMTs are not correlated with their propensity to 
interact with cell membranes, and there is no correlation between membrane binding and 
the modulation of NaV channels, the combination of a hydrophobic patch and positively 
charged ring is a conserved feature more likely to promote simultaneous potency for several 
voltage-gated channels. The current consensus is that GMTs employ certain residues 
incorporated in the hydrophobic patch and positively charged ring to bind to conserved 
sequences consisting of hydrophobic and anionic amino acid residues on voltage-gated ion 
channels (Figure 10) (23,29,46,51-53). This hypothesis is supported by two observations: i) 
the overall potency of most GMTs is comparatively lower for NaV1.4, NaV1.5, or both (Figure 
8), and these channels have fewer anionic residues in the GMT binding region of their 
voltage-sensor domains (Figure 10); ii) SgTx-I and GsMTx-IV, which either have a different 
mechanism of action or do not potently inhibit NaVs respectively (Figure 8), have fewer 
positively charged residues in their C-terminal regions (Figure 1B). The C-terminal region 
contains residues that contribute to the putative pharmacophores of some GMTs that inhibit 
NaV channels, including HnTx-IV, HwTx-IV and GpTx-I for NaV1.7 (23,29,54). 
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Figure 10. GMT amphipathicity and promiscuity 
The hydrophobic patch surrounding cationic ring in spider-venom GMTs promotes NaV channel 
promiscuity. HnTx-IV (PDB 1NIY) is shown as a representative GMT with hydrophobic patch (green), 
positively charged residues (blue), and anionic amino acid residues (red). Cartoon representations of 
NaV1.2, NaV1.4, NaV1.5 and NaV1.6 and NaV1.7 are also shown with the putative GMT target sequence 
shown to highlight the conserved hydrophobic (green) and anionic (red) residues. 
 
Conclusions and summary 
This study revealed that some GMTs adsorb via electrostatic interactions to the outer leaflet 
of anionic lipid membranes and that the amphipathic surface profile of the peptides is most 
probably an adaptive strategy that enables simultaneous inhibition of several voltage-gated 
ion channels (Figure 10), in a multi-pronged approach to immobilize insect prey (55). From 
a pharmacological perspective, application of the tri-molecular complex to drug design 
cannot be based on broad generalizations about GMTs but each GMT will require focused 
studies to explore the possibilities that membrane interactions present. 
Most studies on the tri-molecular complex have thus far been limited by distinct studies of 
GMTs–model membranes and GMTs–ion channel interactions. However, as novel systems 
continue to be developed, including the use of nanodiscs containing the transmembrane 
voltage-gated ion channels in combination with rationally chosen model membranes, 
techniques such as cryo-electron microscopy and NMR may be able to provide better 
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insights into the tripartite interactions occurring between GMTs, lipids and the voltage-gated 
ion channels (13,15,56). 
 
Experimental procedures 
Peptide synthesis and folding 
GMTs were synthesized using Fmoc chemistry and purified as previously described (24,38). 
Briefly, peptides were assembled on a 2-chlorotrityl chloride resin, or on a Rink amide resin 
if C-terminal amidation was required (Figure 1B). All peptides were synthesized at a scale 
of 0.25 mmol on a Symphony peptide synthesizer (Gyros Protein Technologies, Tucson, 
AZ, USA). Peptides were released from resin and side chain protecting groups were 
simultaneously removed by treatment with 96% (v/v) TFA, 2% (v/v) H2O and 2% (v/v) 
triisopropylsilane for 2.5 h. Cleaved, reduced peptides were purified using RP-HPLC on a 
C18 column (Phenomenex Jupiter, 250 mm x 50 mm, 10 m; Phenomenex CA, USA), using 
a 1%/min gradient of 0–50% solvent B (solvent B: 90% (v/v) acetonitrile (ACN) and 0.05% 
(v/v) TFA) in solvent A (0.05% (v/v) TFA), and peptide elution monitored at 215 and 280 nm. 
Electrospray ionization-MS was used to identify relevant fractions which were pooled and 
lyophilized prior to oxidative folding of the peptides.  
Optimal conditions for oxidative folding of GMTs were chosen from one of several buffer 
formulations (Table 1). In each case, peptides were added into the oxidation buffer dropwise 
to achieve a final peptide concentration of 0.1 mg/mL and oxidized at 25 °C unless otherwise 
stated. CcoTx-I, CcoTx-II, GpTx-I, GsMTx-IV, and PaurTx-III, were dissolved in 50% (v/v) 
ACN and added to a buffer containing 7.5% (v/v) ACN and 0.1 M Tris, 0.81 mM GSH, and 
0.81 mM GSSG at pH 7.7. Reactions were quenched by lowering the solution to pH 4 after 
16 h using 2 M acetic acid (Method A) (23). GsMTx-IV was also successfully oxidized by 
dissolving the peptide in 50% (v/v) ACN and adding it to 0.1 M Tris, 10 mM GSH and 1 mM 
GSSG at pH 7.8. The reaction was quenched by lowering the solution to pH 2 after 24 h 
using 100% (v/v) TFA (Method B) (57). HnTx-IV was oxidized using 0.1 M Tris, 0.1 M NaCl, 
5 mM GSH and 0.5 mM GSSG at pH 8. 100% (v/v) HCl was used to quench the reaction to 
pH 4 after 16 h (Method C) (54). HwTx-IV was oxidized using 0.1 M Tris, 5 mM GSH and 
0.5 mM GSSG pH 8. The reaction was quenched after 16 h to pH 4 using 100% (v/v) HCl 
(Method D) (46). ProTx-I and SgTx-I were oxidized at 4 °C in 0.1 M ammonium acetate, 2 
M urea 2.5 mM GSH and 0.25 mM GSSG. pH was adjusted to 7.8 using ammonium solution. 
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The reactions were quenched after 72 h by lowering the buffer solution to pH 3 using 2 M 
acetic acid (Method E) (32). All oxidation reactions were monitored using LC/MS and 
analytical RP-HPLC (1%/min gradient of 0–60% solvent B at a flow rate of 0.3 mL/min) using 
a C18 analytical column (Grace Vydac, 150 mm x 2.1 mm, 5 m; Thermo Fisher Scientific, 
MA, USA), 
Folded peptides were purified via RP-HPLC using a preparatory C18 column (Agilent, 250 
mm x 30 mm, 100Å; Agilent Technologies, CA, USA) with a 1%/min gradient of 10–70% 
solvent B at a flow rate of 8 mL/min, and further using a semi-preparatory C18 column 
(Phenomenex Gemini 250 mm x 10 mm 5 m) at 3 mL/min on a 0.5%/min gradient of 15–
45 % solvent B. Relevant fractions were pooled, lyophilized and stored at –20 °C. Folding 
of the peptides was confirmed using NMR spectroscopy. 
 
NMR spectroscopy 
Peptides were dissolved to a concentration of ~1 mg/mL in 90% (v/v) H2O and 10% (v/v) 
D2O at pH 6. NMR spectra were collected at 25 °C on an Avance 600 MHz NMR 
spectrometer equipped with a cryoprobe (Bruker Biospin, Callerica, MA, USA). NMR 
experiments used to examine the structure of the peptides included 1D 1H, and 2D TOCSY 
(80 ms mixing time) and NOESY (200 ms mixing time). Spectra were processed using 
TopSpin 3.5 (Bruker), and resonances assigned using CCPNMR Analysis 2.4.1 (CCPN, 
University of Cambridge, Cambridge, UK) (58). The assigned H chemical shifts of GpTx-I 
(23), HnTx-IV (PDB 1NIY), HwTx-IV (PDB 2M4X) and ProTx-I (PDB 2M9L) were consistent 
with previously published values (21,29,31).  
Additional NMR spectra acquired to determine the solution structures of CcoTx-I and CcoTx-
II included natural abundance 2D 1H-15N HSQC and 1H-13C HSQC (samples in 90% (v/v) 
H2O and 10% (v/v) D2O) and 1H-1H, TOCSY, NOESY and E.COSY (samples in 100% (v/v) 
D2O). A series of TOCSY spectra were obtained in 5 °C temperature increments (from 5–
25 °C) to obtain amide proton temperature coefficients. The structures of the two peptides 
were calculated from the NMR data using methods described previously (24,30). The 
structure of PaurTx-III (PDB 5WE3) has recently been published (30). 
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Calculations of physicochemical properties 
The SASA of each peptide was calculated with GETAREA (59), using a 1.4 Å water probe 
to compare polar and apolar surface areas of the peptides. Propka (47), was used to assign 
protonation states to the side chains at pH 7.4 for net charge calculations. Hydrophobicity 
was assumed to be directly proportional to retention time of the peptides when eluted using 
a 1%/min gradient of 0–60% solvent B at a flow rate of 0.3 mL/min on analytical RP-HPLC 
using a C18 column (Grace Vydac, 150 mm x 2.1 mm, 5 m). 
 
Peptide quantification 
Peptide concentrations were determined from absorbance at 280 nm theoretical extinction 
coefficients (280) calculated from the sum of contributions from Trp amino acid residues (280 
= 5690 M-1cm-1), Tyr amino acid residues (280 = 1280 M-1cm-1) and disulfide bonds (280 = 
120 M-1cm-1) (60): CcoTx-I 280 = 14300 M-1cm-1; CcoTx-II 280 = 15580 M-1cm-1; GpTx-I 
280 = 7330 M-1cm-1; GsMTx-IV 280 = 11740 M-1cm-1; HnTx-IV 280 = 7330 M-1cm-1; HwTx-
IV 280 = 7365 M-1cm-1; PaurTx-III 280 = 12865 M-1cm-1; ProTx-I 280 = 18365 M-1cm-1; 
SgTx-I 280 = 8610 M-1cm-1. 
 
Preparation of lipid vesicles 
Lipids used included CHOL (Sigma Aldrich), PI (soy extract), POPC, POPS, C1P and SM 
(Avanti Polar Lipids, Alabaster, AL, USA). Molar ratio mixtures of the lipids were prepared 
in chloroform, the solvent was evaporated under a stream of N2, then lipids dried overnight 
in vacuo. Lipid films were hydrated with buffer and lipid suspensions subjected to eight 
freeze-thaw cycles. Liposomes were then sized by extrusion through a polycarbonate filter 
(50 nm to produce small unilamellar vesicles (SUVs) or 100 nm for LUVs).  
 
GMT–membrane interactions  
SPR (Biacore 3000, GE Healthcare Life Sciences, Chicago, IL, USA) was used to examine 
the binding of GMTs to model membranes made from molar ratio mixtures of POPC, 
POPC/POPS (4:1), POPC/PI (4:1), POPC/SM/CHOL (2.7:4:3.3), POPC/C1P/CHOL 
(2.7:4:3.3). Unless otherwise stated, SUVs were prepared in HEPES buffer solution (HBS; 
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10 mM HEPES, 150 mM NaCl, pH 7.4) and deposited on L1 sensor chips (2 L/min, 2,600 
s). Peptides were injected at various concentrations (0–64 M) over the lipid surface at a 
rate of 5 L/min, for 180 s; the dissociation phase was followed for 600 s. The effect of ionic 
strength on GMT affinity for lipid membranes, was examined by comparing peptide binding 
to POPC/POPS (4:1) bilayers in 10 mM HEPES, pH 7.4 at varying concentrations of NaCl 
(50 mM, 150 mM or 300 mM). The same buffer was used to prepare SUVs and peptide 
samples, and as running buffer in SPR. All experiments were conducted at 25 °C. Binding 
affinity was compared by calculating the peptide-to-lipid ratio near the end of peptide 
injection and close to equilibrium (t = 170 s). Data were corrected for buffer contribution and 
normalized using the assumption that 1 response unit = 1 pg/mm2 of lipid deposited (or 
peptide bound) (61). Concentration–response curves were fitted with a standard Hill 
equation using Prism 7 (GraphPad Softwear Inc, San Diego, CA, USA). This is the first time 
we have reported on the current data for peptide–lipid affinity for CcoTx-I, CcoTx-II, GpTx-
I, GsMTx-IV, HnTx-IV, PaurTx-III and SgTx-I (Figure 4), however the data for peptide to lipid 
affinity for HwTx-IV as shown for POPC POPC/POPS, POPC/SM/CHOL and 
POPC/C1P/CHOL is in agreement with our recent study on HwTx-IV (Figure 4, 
Supplementary information, Table S5) (24). 
 
Fluorescence spectroscopy 
Trp fluorescence emission spectra (excitation = 280 nm) of each GMT (25  M, or 12.5  M 
for PaurTx-III because the fluorescence emission spectrum for this GMT was saturated at 
12.5  M) were acquired upon titration with LUV suspensions (0–4 mM) to examine whether 
the environment surrounding the peptide Trp residue changes upon lipid titration (62). Data 
were corrected for dilution and light dispersion upon titration with vesicle suspension. The 
overall area of the emission spectra was used to compare quantum yield, and spectra were 
normalized to maximum fluorescence emission wavelength to check for presence of a blue 
shift. The fluorescence spectroscopy experiments for the eight peptides is represented here 
for the first time (Figure 6), and the data for HwTx-IV is in agreement with our recently 
published work (24). Previously published spectra for [E5K,E8K]MfVIA, are included as a 
positive control (45). 
 
 
 68 
Cell culture 
Human embryonic kidney (HEK) 293 cells expressing human NaV1.7 channels along with 
the β1 auxiliary subunits (SB Drug Discovery, Glasgow, UK) were maintained at 37 °C in a 
humidified 5% CO2 incubator in minimum essential medium supplemented with 10% (v/v) 
heat inactivated fetal bovine serum, 1% (v/v) glutamax, 0.004 mg/mL blasticidin and 0.6 
mg/mL geneticin. Cells were subcultured every 3 days in a 1:5 ratio using 0.1% (v/v) trypLE 
express reagent (Thermo Fisher Scientific, Waltham, MA, USA) in a T75 flask.  
 
Whole-cell patch-clamp electrophysiology on HEK cells 
The inhibitory potency of GMTs on hNaV1.7 stably expressed in HEK293 cells was examined 
using an automated QPatch-16 electrophysiology platform (Sophion Bioscience, Ballerup, 
Denmark) at room temperature (~25 °C). The intracellular solution comprised (in mM): 140 
CsF, 1/5 EGTA/CsOH, 10 HEPES, and 10 NaCl, pH 7.4 with CsOH, 320 mOsm. The 
extracellular solution comprised (in mM): 2 CaCl2, 1 MgCl2, 10 HEPES, 4 KCl, 145 NaCl, pH 
7.4 with NaOH, 305 mOsm. Solutions were filtered using a 0.22 μm membrane filter (Merck 
Millipore; Cork, Ireland). Before recordings, cells were detached from culture flasks with 
Detachin (Genlantis, San Diego, CA, USA). Na+ currents were acquired at 25 kHz and 
filtered at 4 kHz. Cells with less than 1 nA peak current were excluded. To determine IC50 
values, NaV1.7, cells were held at –90 mV in the presence of varying concentration of GMT, 
then stepped to –120 mV for 200 ms, followed by 20 ms test depolarisation to 0 mV. Na+ 
currents were normalised after leak subtraction. Offline analysis was performed using 
Microsoft Excel and GraphPad Prism 7. Data are presented as mean ± SEM of at least three 
independent experiments. 
 
Two-electrode voltage-clamp electrophysiology  
Harvesting of stage V–VI oocytes from ovarian lobes of Xenopus laevis and the subsequent 
expression NaV1.2, NaV1.4, NaV1.5 and NaV1.6 channels was performed as described (63). 
After injection with cRNA (50 nL of 1 ng/nL) using a micro-injector (Drummond Scientific®, 
Broomall, PA, USA), oocytes were incubated in (mM) 96 NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2 
and 5 HEPES, pH 7.4, supplemented with 50 mg/L gentamycin sulfate. Whole-cell currents 
were recorded after 1–4 days incubation periods, at room temperature using two-electrode 
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voltage-clamp electrophysiology recordings using a Geneclamp 500 amplifier (Molecular 
Devices, Downingtown, PA, USA) together with pClamp data acquisition software (Axon 
Instruments®, Union City, CA, USA). The bath solution contained (mM) 96 NaCl, 2 KCl, 1.8 
CaCl2, 2 MgCl2 and 5 HEPES, pH 7.4. Voltage and current electrodes were filled with 3 M 
KCl (resistance 0.8–1.5 M) (63). A four-pole low-pass Bessel filter was used to filter 
currents at 1 kHz with sampling at 20 kHz. A -P/4 protocol was used for leak subtraction. 
Currents for NaV channels were elicited from the oocytes using 30 ms step depolarizations 
from -90 mV to 70 mV in 5 mV increments. Current traces were obtained by 50 ms 
depolarizations to Vmax, the voltage at maximal current in control settings. Modulation of 
current by GMTs was examined by normalizing the data to peak current amplitude 
(I30ms/Imax), and concentration-response curves were used to obtain EC50 values as before 
(63). Data are presented as mean ± SEM of at least three independent experiments. 
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Supporting information 
 
  
Table S1. Theoretical mass, experimental mass, and oxidation method for GMTs 
Peptide Theoretical 
ion massa 
reduced 
(m/z) 
Experimenta
l ion mass 
reduced 
(m/z) 
Theoretical 
ion mass 
oxidized 
(m/z) 
Experimental 
ion mass 
oxidized (m/z) 
Oxidation 
methodb 
CcoTx-I 4050.7 4050.0 4044.6 4044.3 A 
CcoTx-II 4098.7 4098.5 4092.7 4092.4 A 
GpTx-I 4079.9 4079.0 4073.8 4073.5 A 
GsMTx-IV 4101.9 4102.8 4095.9 4095.9 A,B 
HnTx-IV 3993.6 3992.4 3987.6 3987.5 C 
HwTx-IV 4112.9 4112.5 4106.8 4106.6 D 
PaurTx-III 4065.7 4065.6 4059.7 4059.3 A 
ProTx-I 3993.6 3993.1 3987.5 3987.0 E 
SgTx-I 3782.3 3782.3 3776.3 3776.7 E 
a Theoretical ion mass (m/z) was calculated from the sequence of the peptides. Experimental 
ion mass is observed mass. 
b Oxidation methods are A: 7.5 % (v/v) ACN, 0.1 M Tris, 0.81 mM GSH, 0.81 mM GSSG, pH 
7.7, 16 h. B: 0.1 M Tris, 10 mM GSH, 1 mM GSSG, pH 7.8, 24 h. C: 0.1 M NaCl, 0.1 M Tris, 5 
mM GSH, 0.5 mM GSSG, pH 8, 16 h. D: 0.1 M Tris, 5 mM GSH, 0.5 mM GSSG, pH 8, 16 h. E: 
0.1 M Ammonium acetate, 2 M Urea, 2.5 mM GSH, 0.25 mM GSSG, pH 7.8, 4 °C, 72 h. 
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Figure S2.  
Analytical traces of the reduced (dashed grey) and oxidized (solid black) GMTs as monitored using RP-
HPLC. 
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Figure S3.  
Amide regions of the 1D 1H NMR spectra of the oxidized GMTs, demonstrating that the peptides were 
successfully folded. 
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Table S4. Energies and structural statistics a for NMRb structures of CcoTx-I and CcoTx-IIa 
Energies (kcal/mol) CcoTx-I CcoTx-II 
Overall -1134.52 ± 30.71 -1149.81 ± 22.89 
Bonds 24.62 ± 1.85 28.34 ± 1.93 
Angles 70.00 ± 5.30 76.46 ± 4.87 
Improper 22.23 ± 2.84 22.89 ± 3.77 
Dihedral 160.15 ± 2.60 167.62± 2.76 
Van der Waals -143.53 ± 7.02 -152.45 ± 5.89 
Electrostatic -1268.62 ± 28.21 -1293.30 ± 26.81 
NOE 0.40 ± 0.04 0.54 ± 0.06 
Constrained dihedral (cDih) 0.54 ± 0.38 0.09 ± 0.09 
MolProbity statistics   
Clash score (>0.4 Å / 1000 
atoms) 
13.47 ± 2.82 15.36 ± 3.27 
Poor rotamers 0 ± 0 2.19 ± 2.05 
Ramachandran outliers (%) 0.32 ± 0.99 0.65 ± 1.33 
Ramachandran favored (%) 87.61 ± 4.17 88.39 ± 4.84 
MolProbity score 2.21 ± 0.15 2.48 ± 0.33 
MolProbity percentile 64.05 ± 8.19c 49.20 ± 17.45 
Atomic RMSD (Å)   
Mean global backbone (2–31)d 0.64 ± 0.17 0.39 ± 0.10 
Mean global heavy (2–31) 1.55 ± 0.22 1.16 ± 0.19 
Mean global backbone (1–33) 0.86 ± 0.22 0.53 ± 0.11 
Mean global heavy (1–33) 1.74 ± 0.22 1.30 ± 0.18 
Distance restraints   
Intraresidue (i – j = 0) 142 128 
Sequential (|i –j| = 1) 140 137 
Medium range (|i –j| < 5) 36 46 
Long range (|i –j| > 5) 92 98 
Hydrogen bondse 12 6 
Total 422 415 
Dihedral angle restraints   
 10 16 
 11 13 
1 4 7 
Total 25 36 
Violations from experimental 
restraints 
  
Total NOE violations exceeding 
0.2 Å 
3 2 
Total dihedral violations 
exceeding 2.0° 
2 2 
a ± St Dev  
b Based on 20 structures with highest overall MolProbity score (64). 
c 100th percentile is the best among structures of comparable resolution; 0th percentile is the 
worst. 
d RMSD calculated in MOLMOL (65). 
e Two restraints were used per hydrogen bond. 
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Table S5. GMTs binding to various lipid systems (Peptide/Lipid mol/mol)a 
Peptide POPC POPC/POPS 
(4:1) 
POPC/PI 
(4:1) 
POPC/SM/CHOL 
(2.7:4:3.3) 
POPC/C1P/CHOL 
(2.7:4:3.3) 
CcoTx-I 0.031 0.028 N/A 0.028 0.070 
CcoTx-II 0.023 0.045 N/A 0.041 0.095 
GpTx-I 0.011 0.023 N/A 0.020 0.048 
GsMTx-IV 0.071 0.067 N/A 0.045 0.087 
HnTx-IV 0.002 0.023 0.055 0.013 0.045 
HwTx-IV 0.004 0.013 0.015 0.012 0.034 
PaurTx-III 0.012 0.014 N/A 0.013 0.001 
ProTx-I 0.029 0.049 0.042 0.020 0.062 
SgTx-I 0.020 0.013 0.042 0.017 0.046 
a Peptide/Lipid (mol/mol) was calculated at a point of binding equilibrium (t = 170 s) following 
injection of 64 µM peptide onto the lipids using SPR  
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Chapter 4 
 
Applying the concept of the tri-molecular complex to the design 
of potent and selective modulators for NaV1.7 
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Overview 
Each of the nine GMTs studied in chapter 2 displayed a unique set of physicochemical, 
pharmacological and lipid binding properties and no broad generalizations could be drawn 
about the peptides. Therefore, HwTx-IV was chosen as a case-study to further investigate 
whether the lipid component of the tri-molecular complex could be included in the design of 
potent, selective NaV1.7 modulators. Chapter 4 is presented in two parts: part A asks the 
question- how is the potency of HwTx-IV affected when affinity for the lipid bilayer is 
increased? Part B is an attempt to strike the fine balance between affinity for model 
membranes with potency and selectivity for NaV1.7. 
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increased inhibitory potency at human voltage-gated sodium channel hNaV1.7 
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Abstract  
The human voltage-gated sodium channel sub-type 1.7 (hNaV1.7) is emerging as an 
attractive target for the development of potent and sub-type selective novel analgesics with 
increased potency and fewer side effects than existing therapeutics. HwTx-IV, a spider 
derived peptide toxin, inhibits hNaV1.7 with high potency and is therefore of great interest 
as an analgesic lead. In the current study we examined whether engineering a HwTx-IV 
analogue with increased ability to bind to lipid membranes would improve its inhibitory 
potency at hNaV1.7. This hypothesis was explored by comparing HwTx-IV and two 
analogues [E1PyrE]HwTx-IV (mHwTx-IV) and [E1G,E4G,F6W,Y30W]HwTx-IV (gHwTx-IV) 
on their membrane-binding affinity and hNaV1.7 inhibitory potency using a range of 
biophysical techniques, including computational analysis, NMR spectroscopy, surface 
plasmon resonance, and fluorescence spectroscopy. HwTx-IV and mHwTx-IV exhibited 
weak affinity for lipid membranes, whereas gHwTx-IV showed improved affinity for the model 
membranes studied. In addition, activity assays using SH-SY5Y neuroblastoma cells 
expressing hNaV1.7 showed that gHwTx-IV has increased activity at hNaV1.7 compared to 
HwTx-IV. Based on these results we hypothesize that an increase in the affinity of HwTx-IV 
for lipid membranes is accompanied by improved inhibitory potency at hNaV1.7 and that 
increasing the affinity of gating modifier toxins to lipid bilayers is a strategy that may be 
useful for improving their potency at hNaV1.7.  
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Highlights 
• gHwTx-IV, an analogue of HwTx-IV, shows increased membrane binding. 
• Interactions between gHwTx-IV and the membrane appear to be electrostatic. 
• Increased membrane binding is accompanied by increased potency at hNaV1.7. 
Keywords: drug design; peptide-membrane interactions; venom peptide; huwentoxin; pain 
therapeutic; gating modifier toxin 
Abbreviations: BSA, bovine serum albumin; CHOL, cholesterol; C1P, ceramide-1-
phosphate; FLIPRTETRA, fluorescence imaging plate reader; GMT, gating modifier toxin; 
HBS, HEPES buffered saline; ICK, inhibitor cystine knot; LUV, large unilamellar vesicle; 
hNaV, human voltage-gated sodium channel; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; POPS, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; PSS, 
physiological salt solution; SAR, structure-activity relationship; SM, sphingomyelin; SPR, 
surface plasmon resonance; SUV, small unilamellar vesicle; TFA, trifluoroacetic acid; TIPS, 
triisopropylsilane. 
 
Introduction 
There is a compelling need to improve currently available therapies for severe and chronic 
pain (1,2). Voltage-gated ion channels located on sensory neurons are involved in the 
transmission of pain signals to the central nervous system for interpretation and response. 
Some sub-types of the human voltage-gated sodium channels (hNaVs), including the sub-
type 1.7 (hNaV1.7), have been linked to pain (3,4). Loss of function mutations on SCN9A, 
the gene encoding hNaV1.7, result in unresponsiveness to pain, whereas gain of function 
mutations result in increased chronic and acute pain sensations (3,4). Because of this link 
to pain, efforts to identify potent and selective inhibitors of hNaV1.7 are underway (5-8). 
Peptide toxins isolated from spider venoms have shown promising potency for inhibiting 
hNaV1.7 and therefore have potential as therapeutic leads (9). Most of these toxins modify 
the kinetics and gating behavior of voltage-gated ion channels and alter the relative stability 
of the closed, open or inactivated states of the channels. The peptide toxins are thus 
classified as gating modifier toxins (GMTs) (10).  
GMTs typically have a conserved amino acid arrangement resulting in a surface profile 
comprising a hydrophobic patch surrounded by a ring of charged residues (Figure 4A-1B) 
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(9,11). Structure activity relationship studies between the toxins and their target channels 
reveal that this surface motif appears to be involved in the binding of GMTs to target residues 
on the voltage-gated ion channels and that these peptides recognize overlapping target 
residues on the channels (12-14). For example, the channel binding region of ProTx-II has 
been determined to bind to F813, D816 and E818 on hNaV1.7, whereas HwTx-IV has been 
shown to interact with E811, L814, D816, E818 on the same channel (15,16). This raises 
the possibility that the toxins, rather than recognizing specific channel residues, identify a 
local binding site on the voltage sensor domain that is structurally and chemically 
complementary to the surface motif of the GMTs (12,17). 
ProTx-II is an example of a GMT whose inhibitory activity has been suggested to be 
dependent on ability of the peptide to bind to lipid membranes (18). This mechanistic 
suggestion is based on studies showing that ProTx-II analogues with reduced or no binding 
affinity to lipid membranes were shown to be inactive against hNaV1.7 whereas native 
ProTx-II, a potent inhibitor of hNaV1.7 (IC50 = 0.3 nM) showed affinity for lipid membranes 
(18). Interestingly, HwTx-IV, despite showing a high potency at hNaV1.7 (IC50 = 27 nM), 
binds poorly to tested model membranes (19). In the current study we examined whether 
engineering a HwTx-IV analogue with increased ability to bind to lipid membranes would 
improve its inhibitory potency at hNaV1.7 (Figure 4A-1C). Biophysical studies were used to 
characterize peptide–membrane binding on model membranes and inhibitory potency at 
hNaV1.7 was studied using bioassays on SH-SY5Y neuroblastoma cells. The combined 
results showed that increasing the membrane binding affinity of HwTx-IV also increased the 
inhibitory potency of the peptide toxin and these insights have the potential for translation to 
the design of analgesic inhibitors of hNaV1.7. 
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Figure 4A-1. HwTx-IV (PDB ID:2M4X) shown as a representative GMT. 
The peptide is colored by residue type with hydrophobic (green); positively charged (blue); negatively 
charged (red) and polar uncharged (white). (A) Ribbon representation of HwTx-IV with the inhibitor cystine 
knot (ICK) motif formed by three disulfide bridges (yellow) consisting of cysteine amino acid residues with 
the C1-C4, C2-C5, C3-C6 connectivity. (B) Surface representation showing the conserved hydrophobic 
patch and charged ring typically found in GMTs extracted from spider venom. (C) Sequence alignment 
of HwTx-IV, mHwTx-IV and gHwTx-IV. The sequences are aligned along the cysteine residues (bold 
black), amino acid modifications on mHwTx-IV and gHwTx-IV are underlined and * represents C-terminal 
amidation. 
 
Results 
The purpose of this study was to determine whether increasing the membrane binding 
properties of HwTx-IV would increase its inhibitory at hNaV1.7. To achieve this goal, two 
analogues of HwTx-IV, [EPyrE]HwTx-IV (mHwTx-IV) and [E1G,E4G,F6W,Y33W]HwTx-IV 
(gHwTx-IV), were studied (Figure 4A-1C). mHwTx-IV is a naturally occurring derivative of 
HwTx-IV characterized by a post-translational modification conferring a pyroglutamic acid 
(PyrE) residue at position 1. The E1PyrE modification on mHwTx-IV has been determined 
previously to result in a longer duration of inhibition of hNaV1.7 (20). gHwTx-IV is a derivative 
of another HwTx-IV analogue: [E1G,E4G,Y33W]HwTx-IV, shown previously to have 
increased potency at hNaV1.7 (IC50 = 0.4 nM) compared to HwTx-IV (IC50 = 27 nM) (21).  
 
Peptide synthesis and NMR analyses on HwTx-IV, mHwTx-IV and gHwTx-IV 
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All peptides in this study were successfully synthesized and oxidized with final yields 
(reduced to oxidized peptide) of > 90% for HwTx-IV and mHwTx-IV and approximately 10% 
for gHwTx-IV. One-dimensional (1D) 1H and two-dimensional (2D) total correlated 
spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) spectra were 
obtained for HwTx-IV, mHwTx-IV and gHwTx-IV. All peptides were confirmed to be folded 
as was evidenced by well dispersed peaks in the amide region (7–10 ppm) of the 1D 1H 
spectra. TOCSY and NOESY spectra were then used for the successful sequential 
assignment of individual amino acid spin systems (22). H chemical shifts were used to 
compare mHwTx-IV and gHwTx-IV to native HwTx-IV. Overall, there were minimal chemical 
shift differences except at, or near positions on mHwTx-IV and gHwTx-IV where sequence 
modifications were present (Figure 4A-2A). This observation indicated that the three 
synthetic peptides have similar overall structures and the same disulfide connectivity. 
The NMR solution structure of gHwTx-IV was calculated and refined using CYANA and 
CNS. The 20 final structures were based on 400 distance restraints, including 130 
intraresidue, 134 sequential, 36 medium range (|i – j| < 5), 90 long range (|i – j| >5 and 10 
hydrogen bond distance restraints. In addition, 42 dihedral angle restraints composing 18 , 
19  and 5 1 angle restraints were included (Table 1). The final 20 structures were selected 
based on low overall energies, two or fewer violations from experimental restraints, and 
satisfactory MolProbity scores (Figure 4A-2B). The 20 conformers were superimposed and 
gave an overall global backbone RMSD of 0.99 ± 0.34 Å and a global heavy RMSD of 1.72 
± 0.38 Å. Not including the flexible N- and C-termini (residues 1 and 32-35), global backbone 
RMSD was 0.59 ± 0.13 Å and global heavy RMSD was 1.34 ± 0.17 Å (Table 1). The solution 
structure of gHwTx-IV was characterised by an ICK motif typical of spider derived GMTs (9). 
The ICK structure featured loops and turns as well a pair of short antiparallel -strands 
between residues 23–24 and 31–32; features common to ICK peptides (23). 
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Figure 4A-2. NMR analysis of HwTx-IV and its analogues. 
(A) Secondary H shift comparisons of synthetic HwTx-IV, mHwTx-IV and gHwTx-IV. The peptides 
showed good backbone alignment except at or near positions where mutations were present. Residue 
numbers of HwTx-IV and its analogues are shown on the x-axis. (B, C) NMR solution structure of gHwTx-
IV (PDB ID: 5TLR). (B) The 20 best conformers as determined by lowest energy of minimization and 
highest MolProbity scores are superimposed with disulfide bridges shown in yellow. (C) Mutated residues 
(G1, G4, W33 and W6) of gHwTx-IV are shown in white.  
 
Peptide–lipid bilayer kinetic and affinity studies using SPR 
Peptide–lipid bilayer interactions of HwTx-IV and its analogues were studied using surface 
plasmon resonance (SPR) and model membranes of varying charge and fluidity. Choice of 
model membranes in this study was based on features of the eukaryotic cell membrane, 
which exists as a heterogeneous fluid bilayer. Phospholipids containing a 
phosphatidylcholine headgroup are the most abundant lipids in eukaryotic cell membranes, 
thus vesicles composed of (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) POPC, 
which forms zwitterionic fluid model membranes at 25 C, were used as an initial simple 
model membrane (24). Negatively-charged vesicles composed of POPC/1-palmitoyl-2-
 88 
oleoyl-sn-glycero-3-phospho-L-serine (POPS) (4:1) were used to examine the importance 
of electrostatic interactions between the peptide and the membrane and to mimic the effect 
of having negatively-charged molecules at the cell surface. Although the lipids that compose 
the outer leaflet of the cell membrane are primarily neutrally charged, there are anionic 
molecules present in the outer leaflet of physiological membranes (24) (e.g. extracellular 
regions of NaV channels and proteoglycans that possess a serine to which 
glycosaminoglycan chains are attached to (25)). The membrane environments in the vicinity 
of ion channels are proposed to have lipids arranged in domains (rafts) whose compositions 
typically have high proportions of cholesterol (CHOL) and sphingomyelin (SM); furthermore, 
studies have shown that the venoms of some spiders have enzymes that drive the 
conversion of SM to the anionic ceramide-1-phosphate (C1P) (26,27). Therefore, the 
neutrally charged, POPC/SM/CHOL (2.7:4:3.3) and anionic POPC/C1P/CHOL (2.7:4:3.3 
molar ratio) model membranes were also studied (28,29). 
The SPR data showed that gHwTx-IV has higher affinity and binding maxima in the four 
model membranes studied when compared to HwTx-IV and mHwTx-IV (Figure 4A-4A, B). 
Furthermore, gHwTx-IV had preferential interactions (higher binding maxima and slower 
dissociation-rates) with the anionic POPC/POPS (4:1) and POPC/C1P/CHOL (2.7:4:3.3), in 
comparison to neutral POPC and POPC/SM/CHOL (2.7:4:3.3) model membranes (Table 2). 
 
Table 2. Binding affinity and dissociation rates of HwTx-IV and its analogues to model 
membranes as determined from SPR studies 
POPC POPC/POPS  
(4:1) 
POPC/SM/CHOL 
(2.7:4:3.3) 
POPC/C1P/CHOL 
(2.7:4:3.3) 
Peptide P/Lmax a 
(mol/mol)  
Koff b 
(s-1) 
P/Lmax 
(mol/mol) 
Koff  
(s-1) 
P/Lmax 
(mol/mol) 
Koff 
(s-1)  
P/Lmax 
(mol/mol) 
Koffb 
(s-1)  
HwTx-IV 0.01±0.01 N/A negligible N/A 0.03±0.05 N/A 0.05±0.01 N/A 
mHwTx-IV 0.01±0.01 N/A negligible N/A 0.02±0.01 N/A 0.05±0.01 N/A 
gHwTx-IV 0.07±0.02 95±11 0.16±0.03 75±5 0.05±0.01 89±3 0.11±0.01 76±4 
a Peptide–lipid ratio (P/L mol/mol) calculated at the end of the association phase (t = 170 s) was 
plotted as a function of peptide concentration (0 – 64 M) and fitted with Prism 7 using one-
site specific binding analysis; fitted P/Lmax and ± SE are shown; n = 3. 
b Koff was calculated on Prism 7 by fitting the data to an association then dissociation curve 
based on the 1:1 Langmuir binding equation at a fixed peptide concentration of 32 M and 
assuming t0 = 170 s (the point during the experiment when peptide injection was ceased); data 
is ± SE of the fitted parameters n = 3, Koff was not calculated for HwTx-IV or mHwTx-IV because 
the peptides showed minimal binding to the lipid bilayers studied. 
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In-depth location of peptide Trp residues within the lipid membrane 
Fluorescence emission of Trp residues on peptides is sensitive to the surrounding 
environment; thus, Trp fluorescence emission properties of peptides in the presence and 
absence of model membranes can be used to examine whether Trp residues are involved 
in the interaction between the peptide and the lipid membrane. The Trp fluorescence 
emission profile of gHwTx-IV and HwTx-IV was followed upon titration with large unilamellar 
vesicle (LUV) suspensions. Whereas the Trp fluorescence emission profile of HwTx-IV did 
not change upon titration with POPC/POPS (4:1) vesicles, there was a blue shift of 7 nm 
with no considerable change in the quantum yield in the fluorescence emission spectra of 
gHwTx-IV upon titration with lipid vesicles to a concentration of 4 mM (Figure 4A-3C). These 
results show that in the presence of lipid, the Trp residues on gHwTx-IV become less 
exposed to the aqueous environment, and suggest that the residues are involved in the 
binding of the peptide to the lipid bilayer.  
Acrylamide is a water-soluble quencher of fluorescence emission from Trp residues on 
peptides and is unable to partition into lipid bilayers and thus can only efficiently quench 
fluorescence emission of Trp residues that are aqueous exposed. When Trp residues on 
peptides insert into lipid membranes they are protected from acrylamide quenching; 
therefore, the Trp fluorescence quenching efficiency by acrylamide in the presence of lipid 
vesicles was examined to give information on the position of the Trp residues when the 
peptides interact with lipid bilayers. The quenching efficiency of acrylamide was compared 
using the Stern Volmer constant (KSV) (30,31). Acrylamide efficiently quenched the 
fluorescence emission of the Trp residues of HwTx-IV and gHwTx-IV in buffer suggesting 
that the Trp residues of the peptides are solvent exposed and not buried in the core of the 
peptide structures. The acrylamide quenching of the Trp residue on HwTx-IV (KSV = 48.4 ± 
1.2 M-1) was comparable to the negative control (L-Trp) (KSV = 49.1 ± 2.5 M-1) in the presence 
of 1 mM POPC/POPS (4:1) LUVs supporting the observation that HwTx-IV does not insert 
into the membrane. Acrylamide was a less efficient quencher of the Trp fluorescence 
emission of gHwTx-IV in the presence of POPC/POPS (4:1) LUVs (KSV = 37.5 ± 1.5 M-1) 
than in buffer (KSV = 44.1 ± 2.0 M-1) (Figure 4A-3D). The small difference in KSV values 
suggests that the Trp residues in gHwTx-IV have a shallow position when bound to lipid 
membranes such that the residues are still accessible to acrylamide. 
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Figure 4A-3. Interactions of HwTx-IV and its analogues with model membranes. 
Surface plasmon resonance sensorgrams obtained at peptide concentrations of 32 M. Peptides were 
injected for 180 s onto lipid bilayers deposited onto the surface of a L1 chip. (B) Concentration–response 
curves obtained by plotting the amount of peptide bound to lipid (P/L mol/mol) at the end of peptide 
injection (t = 170 s) as a function of the peptide concentration (M) injected over the lipid bilayer. All data 
points represent the mean (± SE) of three replicates. (C) Trp fluorescence emission spectra of 12.5 M 
gHwTx-IV or HwTx-IV upon titration with a suspension of POPC/POPS (4:1) LUVs (0–4 mM). The 
fluorescence emission spectrum of HwTx-IV does not display a shift upon titration with lipid vesicles, 
whereas the fluorescence emission of gHwTx-IV showed a blue shift of 7 nm. (D) Quenching the Trp 
fluorescence emission intensity (excitation at 290 nm and emission at 350 nm) of 12.5 M HwTx-IV, 
gHwTx-IV and L-Trp in the presence of 1 mM POPC/POPS (4:1) LUVs upon titration with acrylamide. 
The acrylamide quenching efficiency was compared by fitting the data to the Stern-Volmer equation (I/I0 
= 1) and calculating the Stern-Volmer constant (KSV) (30). Acrylamide efficiently quenched the 
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fluorescence emission of L-Trp (KSV = 49.1 ± 2.5 M-1) and HwTx-IV (KSV = 48.4 ± 1.2 M-1) in lipid vesicles. 
Fluorescence emission of gHwTx-IV was less efficiently quenched by acrylamide when in the presence 
of LUVs (KSV = 37.5 ± 1.5 M-1) compared to buffer (KSV = 44.2 ± 2.0 M-1); however, the small difference 
between gHwTx-IV KSV values in lipid and buffer indicated a shallow positioning of the peptide in the 
membrane.  
 
Comparison of charge and surface properties of HwTx-IV and gHwTx-IV 
To examine the features that confer gHwTx-IV with the ability to interact with lipid bilayers, 
we compared the net charge, residual dipole moment, solvent accessible surface area 
(SASA), electrostatic surface potentials and chemical surface profiles of gHwTx-IV and 
HwTx-IV. It can be expected that mHwTx-IV would show similar surface properties to HwTx-
IV given the overall similarity in their structures based on secondary H shifts, and the only 
charge difference being the absence of a Glue residue at position 1 (Figure 4A-2A). gHwTx-
IV, on the other hand, has a higher net charge (+6 compared to +4 for HwTx-IV) as well as 
a higher residual dipole moment and more apolar SASA than HwTx-IV (Table 3). A surface 
profile comparison showed that gHwTx-IV had a larger hydrophobic surface area than 
HwTx-IV (Figure 4A-4A). Furthermore, a comparison of the GMT electron density 
distributions showed that the surface of gHwTx-IV possessing the mutations was more 
positive than the same surface on HwTx-IV (Figure 4A-4B). These results are attributable to 
the replacement of the anionic E1, E4, with the apolar G1, and G4 and the replacement of 
F6, Y33 more hydrophobic W6 and W33. 
 
Table 3. Net charge, surface accessible surface area (SASA) and residual dipole moments of 
HwTx-IV and gHwTx-IV 
Peptide Net chargea Total SASAb 
(Å2) 
Polar SASAb 
(% of total 
SASA) 
Apolar SASAb 
(% of total 
SASA) 
Residual dipole 
momenta 
(Debye) 
HwTx-IV +4 3088.98 42.3% 57.7% 70.58 
gHwTx-IV +6 3019.41 37.9% 62.1% 80.76 
a Net charge and residual dipole moment calculated using the g_dipoles tool on GROMACS 
b SASA calculated using GETAREA: http://curie.utmb.edu/getarea.html. 
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Figure 4A-4. Surface profiles and electrostatic surface potential profiles of HwTx-IV and gHwTx-
IV. 
(A) Surface profiles of HwTx-IV (PDB ID: 2M4X) and gHwTx-IV (PDB ID: 5TLR) highlighting the 
positioning of E1, E4, F6 and Y33 on HwTx-IV and the corresponding mutations (G1, G4, W6 and W33) 
on gHwTx-IV. Peptides are colored by residue type including hydrophobic (green), positively charged 
(blue), negatively charged (red) and polar uncharged (white), showing a notable increase in the 
hydrophobic area of gHwTx-IV compared to HwTx-IV. (B) Electron density profiles of HwTx-IV and 
gHwTx-IV oriented to show the face possessing the mutations on gHwTx-IV or corresponding native 
amino acids on HwTx-IV. gHwTx-IV has a more positive surface on the face possessing the four 
mutations compared to the equivalent face on HwTx-IV. Electron density distribution bars show a range 
from −5.0 (red) to +5.0 (blue). 
 
Inhibitory activity of HwTx-IV, mHwTx-IV and gHwTx-IV at hNaV1.7 
To determine whether gHwTx-IV, the analogue that showed increased lipid bilayer 
interactions, would also show increased inhibitory activity at hNaV1.7, the fluorescence 
imaging plate reader (FLIPR) calcium 4 assay was performed using SH-SY5Y 
neuroblastoma cells as previously described (32). The three peptides slowed down the 
activation kinetics of hNaV1.7 (Figure 4A-5A). HwTx-IV (IC50 = 32.4 ± 4.7 nM) and mHwTx-
IV (IC50 = 30.8 ± 5.2 nM) had similar inhibitory activity; whereas gHwTx-IV showed an 
increase in inhibitory potency (IC50 = 7.6 ± 1.5 nM) at hNaV1.7 (Figure 4A-5B). 
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Figure 4A-5. Inhibitory activity of HwTx-IV and its analogues at hNaV1.7 in SH-SY5Y cells. 
Inhibition was monitored by following the fluorescence emission of the FLIPR calcium 4 dye. (A) Activation 
kinetics of HwTx-IV and the two analogues after activation by veratridine is shown at concentrations near 
the respective IC50 values of each peptide and at 1 M. Activation was a measure of calcium influx into 
the cells. HwTx-IV, mHwTx-IV and gHwTx-IV inhibited the activation kinetics of hNaV1.7 as is evidenced 
in their slower slopes of activation (HwTx-IV = 0.0196 ± 0.0006 fluorescence intensity/second; mHwTx-
IV = 0.0143 ± 0.0003 fluorescence intensity/second; gHwTx-IV = 0.0257 ± 0.0009 fluorescence 
intensity/second) compared to veratridine (activation slope = 0.0609 ± 0.0026 fluorescence 
intensity/second). (B) Dose-response curves of HwTx-IV and of the two analogues are shown. 
Fluorescence emission data were normalized to the maximum and minimum signals for each peptide and 
data were fitted as Fmax against concentration using a one-site specific binding curve with Hill slope. Data 
points are the mean ± SE (n = 4). Fitting of the dose–responses shows that gHwTx-IV is the most potent 
inhibitor (IC50 = 7.55 ± 1.54 nM), whereas HwTx-IV (IC50 = 32.4 ± 4.74 nM) and mHwTx-IV (IC50 = 30.8 ± 
5.18 nM) have similar inhibitory potencies. An apparent inhibition of hNaV1.7 at low concentrations is 
evident on the curve and is a false positive effect often seen at low peptide concentrations. 
 
Discussion  
The structures of GMTs isolated from spiders are typically characterized by a conserved 
hydrophobic patch surrounded by a charged ring. This structural feature has been proposed 
to promote not only GMT–voltage-gated ion channel interactions, but also GMT–lipid 
membrane interactions (12,13,17,18,28). Several spider GMTs have been shown to interact 
with model membranes and the unique structures of these peptides have been proposed to 
facilitate a tri-molecular interaction involving the GMTs, the lipid membrane and target 
voltage-gated ion channels (14,27,33-35). HwTx-IV is a potent inhibitor of hNaV1.7; 
however, this GMT has been reported to have a weak affinity for lipid membranes (16,19). 
In this study we confirm that HwTx-IV has weak membrane affinity and we compare the 
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peptide to two analogues, mHwTx-IV and gHwTx-IV. Results from membrane binding 
studies and activity assays show that mHwTx-IV has similar weak membrane binding 
interactions to HwTx-IV and a nearly identical inhibitory potency at hNaV1.7. In contrast, 
gHwTx-IV simultaneously displays increased inhibitory activity at hNaV1.7 and increased 
interactions with lipid membranes.  
Peptide–lipid membrane interactions were studied in fluid and raft-like model membranes of 
both anionic and zwitterionic overall charges. In comparison to HwTx-IV and mHwTx-IV, 
which showed similar weak interactions with the model membranes, gHwTx-IV consistently 
showed the highest affinity to all model membranes tested (Figure 4A-4A, B). Furthermore, 
acrylamide quenching of the fluorescence emission of Trp residues on the peptides 
suggested that gHwTx-IV adopts a superficial position on the membrane (Figure 4A-3D). 
This position on the membrane surface is likely to be facilitated by a combination of 
electrostatic, hydrogen bonding and hydrophobic interactions between the peptide and the 
phospholipid headgroups of the lipid membrane. Several prior GMT–membrane binding 
studies have proposed that the hydrophobic patch present on these spider toxins is 
important for hydrophobic interactions with the membrane and that the charged ring of these 
spider derived peptides participates in electrostatic interactions with the phospholipid 
headgroups (18,36-38). The importance of electrostatic interactions between gHwTx-IV and 
the lipid membrane is supported by the observation that gHwTx-IV has a higher affinity for 
anionic lipid membranes (Figure 4A-3A, B). Furthermore, a global profile of the electrostatic 
surface potential on the surface of gHwTx-IV containing the four mutations (E1G, E4G, F6W 
and Y33W) is more positive than the same surface on HwTx-IV (Figure 4A-4B), and gHwTx-
IV has a higher net charge and residual dipole moment than HwTx-IV (Table 3). Together 
these features can promote GMT electrostatic interactions with the phospholipid 
headgroups of the membrane. The interactions between gHwTx-IV and the lipid membrane 
are likely also facilitated by hydrogen bonding between the indole groups on the side chains 
of W6 and W33, and the phospholipid headgroups of the membrane. Additionally, 
hydrophobic interactions could also play a role in the gHwTx-IV–lipid membrane interaction 
as is evidenced from the findings that gHwTx-IV has a larger hydrophobic patch (Figure 4A-
4A) and apolar SASA (Table 3) than HwTx-IV.  
In addition to increased membrane interactions, gHwTx-IV showed a 4-fold increase in 
inhibition of hNaV1.7 compared to both HwTx-IV and mHwTx-IV, which had similar inhibitory 
potencies. In a previous structure-activity relationship (SAR) study with an alanine scan of 
HwTx-IV, a region at the surface of the molecule was proposed to be responsible for the 
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interaction with hNaV1.7 (12). Specifically, it was suggested that the amino acid residues 
R26, K27 and K32 on HwTx-IV interact with D816, E818 and E811 on the extracellular loop 
of voltage sensor domain II of hNaV1.7 (Figure 4A-6) (12). Our studies with gHwTx-IV 
suggest that the combination of the mutations E1G, E4G, F6W and Y33W result in both 
increased membrane binding and increased inhibition of hNaV1.7. These four mutations are 
part of a hydrophobic patch located at the surface of the molecule distinct from the surface 
formed by the channel binding residues R26, K27 and K32 (Figure 4A-6A).  
We propose that the increased potency observed with gHwTx-IV, compared to HwTX-IV, is 
facilitated by membrane-binding interactions. Briefly, electrostatic interactions between 
gHwTx-IV and the membrane would attract the peptide to the membrane surface and 
additional hydrogen bonding and hydrophobic interactions would orient the peptide such 
that the face containing R26, K27 and K32 is available for interactions with hNaV1.7 (Figure 
4A-6). In addition, the overall decrease in anionic charge and increase in hydrophobicity of 
gHwTx-IV may further augment interactions between the peptide and hNaV1.7 This 
hypothesis was previously proposed by Revell and colleagues [13], when the authors 
observed an increase in the inhibitory potency of the analogue [E1G,E4G,Y33W]HwTx-IV 
(21). In silico docking studies suggested that the residues F6 and Y33 form hydrophobic 
interactions with M750 on hNaV1.7; thus, a supporting explanation for the increased activity 
observed with gHwTx-IV is that the mutations F6W and Y33W would improve the 
hydrophobic interaction with M750 (12,39). Although we cannot exclude the possibility that 
an increased inhibitory potency on hNaV1.7 and increased membrane binding are 
independent, we propose a model where gHwTx-IV acts by binding both to the membrane 
and to the target channel (Figure 4A-6B). A similar mechanism has been suggested for 
ProTx-I and ProTx-II, two GMTs that also seem to possess distinct surface regions 
responsible for membrane interaction and for channel interaction (18,28). Furthermore, the 
fact the amino acid residues that seem to be involved in membrane binding are distinct from 
those involved in channel binding lead us to postulate that gHwTx-IV will show a similar 
selectivity profile to HwTx-IV, particularly against NaV1.5 which is involved in cardiac muscle 
conduction (16). This hypothesis is further supported by [E1G,E4G,Y33W]HwTx-IV, an 
analogue similar to gHwTx-IV, which was found to be inactive at NaV1.5 (21). 
We conclude that by engineering HwTx-IV to increase membrane interactions, we have 
simultaneously designed a peptide with higher activity at hNaV1.7. Overall charge and 
hydrophobicity play important roles both in interactions of gHwTx-IV with hNaV1.7 and with 
lipid membranes. Two predominant theories for GMT–membrane interactions are that the 
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lipid bilayer acts to concentrate the peptide at the active site for the purpose of increasing 
peptide availability at the channel active site and secondly that GMT–membrane interactions 
facilitate access to the voltage sensor domain, which rests at a superficial position in the 
bilayer (40,41). The way forward is therefore to study GMTs, model membranes and 
channels in concert to better understanding of the mechanism of action of this tri-molecular 
complex, with the aim of developing peptides with higher inhibitory potency at hNaV1.7. 
 
Figure 4A-6. Lipid interaction surface and channel binding region of gHwTx-IV. 
Surface profiles of gHwTx-IV oriented to show that the hydrophobic patch possessing the four mutations 
(E1G, E4G, F6W and Y33W (green)) on gHwTx-IV is on a distinct face from the surface possessing the 
residues forming the channel binding region (K27, R26, and K32 (purple)) (12). (B) An illustration of the 
voltage sensor domain II and pore of hNaV1.7 channel is shown highlighting gHwTx-IV, the voltage sensor 
domain II, and the key residues identified as important for the activity of HwTx-IV (E811, D816 and E818 
) are underlined (12). 
 
Materials and methods 
Peptide synthesis and folding 
HwTx-IV, mHwTx-IV and gHwTx-IV (Figure 4A-1C), were synthesized on a rink-amide resin 
at a scale of 0.25mmol to produce C-terminal amidated peptides employing standard 
automated 9-fluorenylmethoxycarbonyl (Fmoc) solid phase peptide synthesis (SPPS) using 
a Symphony peptide synthesizer (Protein Technologies Inc). The peptides were cleaved 
from the resin with simultaneous removal of side chain protecting groups by incubation with 
trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/water (48:1:1) (v/v/v) for 2.5 h. The resin 
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was filtered and TFA was evaporated under vacuum prior to precipitation with ice-cold 
diethyl ether. The peptides were then extracted in 45% acetonitrile (ACN) (v/v) containing 
0.05% TFA (v/v) and lyophilized. The reduced peptides were purified by reversed phase 
high-performance liquid chromatography (RP-HPLC) on a linear gradient of 5–55% solvent 
B (90% (v/v) ACN; 0.05% (v/v) TFA) over 50 min at 50 mL/min. Fractions were collected 
and analyzed using ESI-MS and fractions of interest were pooled, lyophilized and stored at 
–20 °C. 
HwTx-IV and mHwTx-IV were oxidized overnight at room temperature at a concentration of 
0.1 mg/mL in 0.1 M Tris-HCl (pH 8), 0.1 M NaCl, 5 mM reduced glutathione and 0.5 mM 
oxidized glutathione (42).Oxidation reactions were monitored using LC/MS and quenched 
with solvent A (0.05% (v/v) TFA) to 1:2 (v/v). gHwTx-IV was dissolved in 50% (v/v) ACN 
prior to drop-wise addition to a buffer consisting of 0.1 M Tris-HCl, 10% (v/v) filtered 
isopropanol (pH 8), 5 mM reduced glutathione and 1 mM oxidized glutathione bringing the 
final peptide concentration to 0.05 mg/mL. The reaction was quenched by lowering the pH 
to pH 2 using ACN/TFA/water (1:1:1) (v/v/v) (21).  
Oxidized peptides were purified using a linear gradient of 10–70% solvent B over 60 min at 
8 mL/min and further separated at 3 mL/min on a gradient of 20–50% solvent B over 60 min. 
Fractions were collected and analyzed by ESI-MS. Fractions containing the molecular mass 
corresponding to the oxidized peptide were pooled, lyophilized and stored at –20 °C.  
Peptide samples were quantified by absorbance at 280 nm using Nanodrop. Extinction 
coefficients (280) of each peptide were calculated from the contribution of aromatic residues 
and disulfide bonds of the GMTs as follows: HwTx-IV 280 = 7365 M-1cm-1, mHwTx-IV 280 = 
7330 M-1cm-1 and gHwTx-IV 280 = 17430 M-1cm-1. 
 
NMR spectroscopy 
HwTx-IV, mHwTx-IV and gHwTx-IV were dissolved in 90% (v/v) H2O and 10% (v/v) D2O to 
a concentration of ~1mg/mL at pH ~4. Experiments, including 1D 1H spectra and 2D TOCSY 
(80 ms mixing time) and NOESY (200 ms mixing time) were acquired on a Bruker Avance 
600 MHz NMR spectrometer equipped with a cryoprobe at 298 K to confirm correct folding 
of the peptides. Spectra were processed using TopSpin (Bruker), referenced to water at 
4.76 ppm, and the peptide sequences were sequentially assigned using CCPNMR Analysis 
2.4.1 (22,43). 
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Additional NMR data were collected for the solution structure determination of gHwTx-IV, 
including 1H-13C HSQC and 1H-15N HSQC spectra in 90% (v/v) H2O and 10% (v/v) D2O in 
addition to TOCSY, NOESY and exclusive correlation spectra (E.COSY) spectra in 100% 
D2O. Amine proton temperature coefficients were derived from a series of TOCSY 
experiments run on a Bruker 500 MHz NMR spectrometer in 5 K increments (283–308 K). 
Manually assigned intra-residue and sequential NOEs for gHwTx-IV were used to generate 
a list of inter-proton distances using the AUTO function in CYANA 3.97 (44). Several rounds 
of AUTO calculations were used to refine peak assignments. Constraints for  and  
backbone dihedral angles were generated with TALOS-N using H, C, C, HN chemical 
shifts derived from NOESY, 1H-13C HSQC and 1H-15N HSQC spectra (45). H-bond restraints 
derived from temperature coefficient experiments and D2O exchange experiments and 1 
side chain dihedral angle restraints derived from E.COSY in combination with NOE 
intensities were included in structure calculations using the ANNEAL function in CYANA. 
Protocols in the RECOORD database were used in CNS to calculate 50 structures, which 
were further refined in a water shell (46,47). A final set of 20 structures was then chosen 
based on the lowest energy, fewest violations, and the best MolProbity scores and submitted 
to the Protein Data Bank (PDB ID: 5TLR) and the Biomagnetic Resonance Data Bank 
(BMRB: 30190) (Table 1) (48). 
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Table 1. Energies and structural statistics for the family of 20 gHwTx-
IV (PDB ID: 5TLR) structuresa. 
Energies (kcal/mol)  
Overall -990.61 ± 59.80 
Bonds 25.80 ± 1.58 
Angles 52.39 ± 4.77 
Improper 17.46 ± 2.71 
Dihedral 166.04 ± 2.33 
Van der Waals -150.46 ± 4.73 
Electrostatic -1102.63 ± 61.84 
NOE 0.38 ± 0.03 
Constrained dihedral (cDih) 0.39 ± 0.37 
Mol Probity statistics  
Clash score (>0.4 Å / 1000 atoms) 14.05 ± 3.44 
Poor rotamers 0.78 ± 1.39 
Ramachandran outliers (%) 0.76 ± 1.34 
Ramachandran favored (%) 85.17 ± 2.84  
MolProbity score 2.38 ± 0.28  
MolProbity percentile 53.90 ± 15.03c 
Atomic RMSD (Å)  
Mean global backbone (2–31)d 0.59 ± 0.13 
Mean global heavy (2–31) 1.34 ± 0.17 
Mean global backbone (1–35) 0.99 ± 0.34 
Mean global heavy (1–35) 1.72 ± 0.38 
Distance restraints  
Intraresidue (i – j = 0) 130 
Sequential (|i –j| = 1) 134 
Medium range (|i –j| < 5) 36 
Long range (|i –j| > 5) 90 
Hydrogen bondse 10 
Total 395 
Dihedral angle restraints  
 18 
 19 
 1 5 
Total 42 
Violations from experimental restraints  
Total NOE violations exceeding 0.2 Å 1 
Total dihedral violations exceeding 2.0° 2 
a Based on structures with highest overall MolProbity score (48). 
b ± St Dev 
c100th percentile is the best among structures of comparable 
resolution; 0th percentile is the worst. 
d RMSD calculated in MOLMOL (49). 
e Two restraints were used per hydrogen bond. 
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Molecular modelling of HwTx-IV and gHwTx-IV 
SASA, residual dipole moments and electrostatic surface potentials of HwTx-IV and gHwTx-
IV were calculated and analyzed using the following molecular modelling tools. Polar and 
apolar SASA of the GMTs was calculated on GetArea using the default 1.4 Å water probe 
(50). As HwTx-IV and gHwTx-IV are charged molecules, the dipole of these molecules is 
not formally defined and any calculated dipole is dependent on the translation or rotation of 
the peptides with respect to the origin. To facilitate a qualitative comparison between HwTx-
IV and gHwTx-IV, the residual dipole moment, which is independent of position or rotation 
in space (51), was used. The residual dipole moment of HwTx-IV and gHwTx-IV was 
calculated using the g_dipoles tool on GROMACS version 5.1.12 in which the net charge is 
subtracted at the center of mass of the peptides (52). Electrostatic surface potentials were 
calculated by solving the linearized Poisson-Boltzmann equation using the APBS software 
(53). The PDB files of HwTx-IV (PDB ID: 2M4X) and gHwTx-IV (PDB ID: 5TLR) were 
processed using the PDB2PQR online server with the AMBER force field (54), and ProPka 
was used to assign protonation states of the side chains at a pH of 7.4 (47). The electrostatic 
surface potential was visualized using the APBS plugin on PyMOL (55,56). 
 
Preparation of lipid vesicles 
Synthetic POPC, POPS, C1P and SM were obtained from Avanti Polar Lipids. Synthetic 
CHOL was obtained from Sigma Aldrich. Lipids were dissolved in spectroscopic grade 
chloroform and the required amounts combined to obtain mixtures of POPC, POPC/POPS 
(4:1 molar ratio) POPC/SM/CHOL (2.7:4:3.3 molar ratio), or POPC/C1P/CHOL (2.7:4:3.3 
molar ratio). Lipid films were dried under a stream of N2 and left in vacuo overnight to 
remove any remaining solvent. The lipid films were re-suspended in HEPES buffered saline 
(HBS) (10 mM HEPES, 150 mM NaCl, pH 7.4), submitted to eight freeze-thaw cycles and 
extruded through 50 nm or 100 nm pore sized polycarbonate filters to obtain small 
unilamellar vesicles (SUVs) or LUVs respectively. SUVs were used for the SPR studies as 
their small radii facilitate the formation of lipid bilayers when deposited onto the L1 SPR 
sensor chip. LUVs were used for fluorescence experiments as their large radii create a more 
planar surface to mimic the physiological lipid bilayers (31,57). 
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Peptide–membrane kinetic and affinity studies using SPR 
SPR was used to examine peptide–membrane binding kinetics and affinity. Experiments 
were conducted at 25 °C using a Biacore 3000 instrument and an L1 sensor chip. HBS was 
used to prepare the peptide and lipid samples and as running buffer. Lipid bilayers were 
deposited onto the surface of the L1 sensor chip for 2600 s at a flow rate of 2 L/min as 
previously described (18). Peptide samples (concentrations ranging from 0–64 M) were 
injected over the lipid surface for 180 s at a flow rate of 5 μL/min for the association phase. 
The dissociation phase lasted 600 s per injection cycle. Data were corrected for buffer 
contribution and normalized by assuming that 1 response unit (RU) = 1 pg/mm2 of lipid 
deposited, and subsequent peptide binding as previously described (58). Peptide–lipid 
membrane binding was analyzed using non-linear regression one-site specific binding 
curves on Prism 7. Binding kinetics were studied by fitting the data of peptides at 32 M to 
association then dissociation curves based on the 1:1 Langmuir model (59). 
 
Peptide–membrane binding followed by Trp fluorescence 
The peptides used in this study are intrinsically fluorescent due to the presence of Trp 
residue(s) in their sequences. Trp fluorescence emission spectra were therefore used to 
examine whether the Trp residue(s) of the peptides insert into the lipid bilayers (30). 
Peptides and L-Trp (12.5 M in HBS) were titrated with POPC/POPS (4:1) LUV suspensions 
to attain final lipid concentrations ranging from 0–4 mM. Fluorescence emission spectra 
were obtained upon excitation at 280 nm using a Perkin Elmer luminescence LS 
spectrometer with slits set to 3/3 nm. Peptide spectra were corrected for dilution due to 
titration with LUV suspensions and blanks were subtracted to examine changes in Trp 
fluorescence quantum yield. Spectra were normalized to the maximum fluorescence 
emission intensity to delineate a potential blue shift in fluorescence emission. 
To examine whether the peptide Trp residues are solvent exposed when the peptides are in 
the presence or absence of LUVs, samples of GMTs or L-Trp (12.5 M in HBS) with or 
without 1 mM POPC/POPS (4:1) LUVs were titrated with acrylamide, an aqueous quencher, 
in concentrations ranging from 0–100 mM. Fluorescence emission intensity, upon excitation 
at 290 nm and emission at the wavelength at which the sample showed maximum emission 
(around 350 nm), was followed upon titration with acrylamide (30). Data were corrected for 
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dilution by titration with acrylamide and for dispersion from the lipid analyzed using the Stern-
Volmer equation (30). 
 
Inhibition of hNaV1.7 induced by HwTx-IV and its analogues 
The inhibitory potency of HwTx-IV and two analogues on hNaV1.7 was assessed using a 
calcium assay on a FLIPRTETRA assay as previously described (32). SH-SY5Y cells 
expressing hNaV1.7 were maintained in RPMI medium supplemented with 15% (v/v) fetal 
bovine serum (FBS), 100 units/mL penicillin, 100 units/mL streptomycin and 2 mM L-
glutamine, with subculturing every 72 h (70–80% confluence).  
SH-SY5Y cells were plated onto 96 well black-walled Corning™ imaging plates at a density 
of 65,000 cells/well 72 h prior to FLIPRTETRA assays. Immediately prior to assays, media was 
removed and cells were washed in physiological salt solution (PSS: 140 mM NaCl, 11.5 mM 
glucose, 5.9 mM KCl, 1.4 mM MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 1.8 mM CaCl2 and 
10 mM HEPES, pH 7.4). The SH-SY5Y cells were then incubated for 30 min at 37 °C with 
FLIPR calcium 4 dye, 30 nM of OD1 (a selective modulator of hNaV1.7 inactivation), and 
0.1% (w/v) bovine serum albumin (BSA) diluted in PSS buffer as previously described (32). 
Peptides were prepared to achieve final concentrations ranging from 3 M to 1.7  10-5 M 
in PSS with 0.1% (w/v) BSA. The NaV1.7 agonist, veratridine, was prepared to achieve a 
final concentration of 4 M in PSS with 0.1% (w/v) BSA. Test peptides were added to the 
cells and incubated for an additional 15 min using the FLIPRTETRA instrument at 25 °C. 
Fluorescence emission intensity (excitation 470–495 nm; emission 515–575 nm) was 
recorded every second for ten initial baseline reads, followed by the addition of veratridine. 
Fluorescence emission intensity (a measure of calcium influx into the cells following 
veratridine activation of hNaV1.7) was then recorded every second for 300 s and the raw 
data were corrected for the contribution of buffer and transformed to maximal response over 
baseline using Screenworks 3.1.1.4 (Molecular Devices). Data were normalized to the 
maximal change in fluorescence emission for each peptide prior to analysis on Prism 7 using 
one-site specific binding with Hill slope and Bmax = 1.  
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Abstract 
Spider venom contains a cocktail of molecules including disulfide-rich gating modifier toxins 
(GMTs), some of which have proven to be useful pharmacological tools and drug leads for 
voltage-gated ion channels. As some GMTs have affinity for model lipid bilayers, a tri-partite 
relationship between GMTs, the voltage-gated ion channels and the lipid membrane 
surrounding the channels has been proposed. Here we study the relationship between 
HwTx-IV, the voltage-gated sodium channel subtype 1.7 (NaV1.7) (a pain target) and the 
lipid bilayer. We previously showed with gHwTx-IV that increasing lipid bilayer affinity of 
HwTx-IV can correspond with increased in vitro activity at NaV1.7. Here we show that to 
optimize the selectivity of gHwTx-IV, mutations can be made to the positively charged 
residues that contribute to the pharmacophore of the peptide. [R26A]gHwTx-IV, 
[K27A]gHwTx-IV, and [R29A]gHwTx-IV were potent at NaV1.7 and had an overall better 
selectivity when examined against off-target NaVs. The lipid affinity of each of the three 
analogues was lower than gHwTx-IV and higher than HwTx-IV, suggesting that with careful 
optimization of affinity for lipid bilayers and potency at NaV1.7, it is possible to obtain 
selective GMT modulators of NaV1.7 in vitro. The peptides were further tested for on-target 
activity in vivo using a mouse model of NaV1.7 mediated nociception, where [R26A]gHwTx-
IV, but not the remaining peptides, showed efficacy equivalent to HwTx-IV; therefore, further 
optimization is necessary to improve efficacy of the peptides in vivo. 
 
Keywords: Cell membrane, disulfide-rich peptides, NaV1.7, oxidative folding, peptide–lipid 
membrane interactions, drug design, regioselective oxidation, tri-molecular complex, 
voltage-gated ion channels  
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Abbreviations: ACN, acetonitrile; FLIPR, fluorescence imaging plate reader; GMT, gating 
modifier toxin; GSH, reduced glutathione; GSSG, oxidized glutathione; ICK, inhibitor cystine 
knot; LC/MS, liquid chromatography/mass spectrometry; NMR, nuclear magnetic 
resonance; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPS, 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine; SPR, surface plasmon resonance; TFA, 
trifluoroacetic acid; TIPS triisopropylsilane; Tris, tris(hydroxymethyl)aminomethane 
 
Introduction 
Voltage-gated sodium channels (NaVs) are being pursued as targets for pain therapeutics 
because several NaV isoforms have been implicated in pain-related pathologies including 
neuropathic pain (1), mechanical pain associated with inflammatory bowel disease (2,3), 
diabetic neuropathy (4), and inflammation (5-7). NaV architecture is typified by four domains 
(domain I–domain IV), connected via intracellular loops of various lengths, with each domain 
containing six segments (S) such that S1–S4 form the voltage sensor domains, and S5–S6 
form the pore domain (Figure 1A). In the search for novel modulators of these channels, 
gating modifier toxins (GMTs) discovered in spider venom have proven to be useful 
pharmacological probes and drug leads for conditions mediated by NaV function (3,8-11). 
GMTs have also gathered interest because of the presence of a hydrophobic patch and 
charged ring on their surface profiles (Figure 1B), reminiscent of membrane-interacting 
peptides (12-15). 
As some GMTs bind to lipid bilayers (12-14), the concept of a three-way interaction between 
GMTs, voltage-gated ion channels and the lipid membrane has arisen (12,14,16-19). Using 
ProTx-II, a GMT with affinity for lipid membranes (20,21), we recently showed that reducing 
the lipid binding of this particular GMT reduces its potency at NaV1.7 (21). Likewise, HwTx-
IV is a GMT known to have weak affinity for lipid membranes (12,18,22), and we recently 
showed that increasing lipid affinity of HwTx-IV can correspond to an increase in potency at 
NaV1.7 (18). These studies led us to conclude that the lipids surrounding NaVs and other 
voltage-gated ion channels can be exploited to attract, concentrate and manipulate the 
binding of GMTs near their active sites at the channels for improved potency (17,18,21). 
A largely unanswered question is how increased GMT–lipid affinity affects selectivity for 
NaV1.7. GMT selectivity is a highly sought-after feature because of the reported toxicity of 
some of these peptides in vivo (23-25). A difficulty with improving selectivity of HwTx-IV, and 
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similar GMTs, is that these peptides are attracted to a sequence of highly conserved anionic 
amino acid residues (Glu811, Asp816, Glu818 (human NaV1.7 primary accession number: 
Q15858)) located on the extracellular loop between S3–S4 of domain II (Figure 1C) (26,27). 
Previous mutagenesis studies have deduced that the amino acids on loop 4 of HwTx-IV are 
of particular importance for activity (Figure 1C) (11,28,29). Deng and colleagues (29), noted 
that among other residues on loop 4, the R29A mutant lost approximately 260-fold of activity 
at tetrodotoxin-sensitive NaVs which include NaV1.7 (examined on dorsal root ganglion cells) 
(29). The same study also suggested that K27 played an important role in the bioactivity of 
HwTx-IV (29). Additional studies by Minassian and colleagues (28), showed that changes 
to R26 and K27 of HwTx-IV, resulted in some loss of potency at NaV1.7, accompanied by 
larger reductions in potency at NaV1.2. A point mutation at R29, resulted in no change in 
potency at NaV1.7, but a considerable reduction in potency at NaV1.2 (these studies were 
conducted on NaVs expressed in HEK293 cells) (28). The main difference between NaV1.7 
and NaV1.2 at the putative HwTx-IV binding site on S3–S4 of DII, is that NaV1.2 only has 
two anionic residues compared to NaV1.7 in the putative GMT binding site (NaV1.2 contains 
Asn816 in place of Asp816) (Figure 1C), therefore, perhaps the R29 mutation weakened 
electrostatic interactions between HwTx-IV and NaV1.2 (26). Based on these observations 
we hypothesized that manipulation of the basic residues on loop 4 of HwTx-IV may aid in 
improving selectivity by modulating salt-bridge interactions between basic amino acids on 
loop 4 of the GMT and anionic amino acids in the conserved S3–S4 extracellular loop of DII 
on off-target NaVs.  
To include the lipid bilayer in the process of optimization of HwTx-IV’s selectivity, we used 
our recently reported gHwTx-IV ([E1G,E4G,F6W,Y33W]HwTx-IV (11,18), as a starting 
molecule. We previously postulated that the lipid bilayer can attract and concentrate gHwTx-
IV near its binding site at NaV1.7 to increase its apparent potency (18). We were therefore 
interested in establishing whether point mutations to R26, K27 and R29 of gHwTx-IV would 
improve selectivity while compensating for potency at NaV1.7 through interactions with the 
lipid bilayer. To this end, we synthetically produced HwTx-IV, gHwTx-IV, [R26A]gHwTx-IV, 
[K27A]gHwTx-IV and [R29A]gHwTx-IV (Figure 1D). We ensured correct disulfide bond 
formation of the analogues using NMR, examined the lipid binding of the peptides using 
surface plasmon resonance (SPR), and the potency and selectivity of the analogues on a 
suite of NaV channel subtypes expressed in HEK293 cells using a membrane potential assay 
on FLIPRTETRA (30). We further examined the ability of our the analogues to reverse 
nocifensive behavior in an in vivo NaV1.7 mouse model (30). Here, for the first time, we show 
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that it is possible to include the lipid bilayer in the design of potent and selective modulators 
of NaV1.7.  
 
 
Figure 4B-1. Voltage-gated sodium channels and spider gating modifier toxins 
(A) NaV Domains I–IV and transmembrane segments S1–S6 are shown. Extracellular loops between S1–
S2 (green), S3–S4 (red) and S5–S6 (black) are also shown. Figure adapted from Agwa et al. 2017 (17), 
and is based on information from available NaV structures (Including PDB ID: 4EKW and PDB ID: 5X0M). 
(B) gHwTx-IV (PDB ID: 5TLR) is shown as a representative GMT with a surface profile highlighting 
residues forming the hydrophobic patch (green) and positively charged ring (blue). A ribbon 
representation of gHwTx-IV is also shown with cystines forming the ICK motif labelled in roman numerals. 
The loops formed by the disulfide bridges (yellow) are also highlighted: Loop 1, black; Loop 2, purple; 
Loop 3, grey and Loop 4 blue. (C) The positively charged residues (blue) on loop 4, which form part of 
the pharmacophore of gHwTx-IV and HwTx-IV are shown. An alignment of NaV1.1–NaV1.7 at the 
extracellular S3–S4 loop of Domain II is also shown. Red amino acids are the residues where the GMTs 
putatively bind (26,28,29). Black shows equivalent positions on NaVs lacking the conserved anionic 
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residues. (D) Sequences of HwTx-IV, gHwTx-IV, [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-
IV. Mutations that form gHwTx-Iv are shown in green and mutations forming [R26A]gHwTx-IV, 
[K27A]gHwTx-IV and [R29A]gHwTx-IV are shown in red. Peptides are aligned along cysteine residues 
(grey highlight). 
 
Results 
Oxidation and structural analysis of the peptides 
Most spider GMTs are disulfide-rich and fold to adopt a knottin motif consisting of disulfide 
bridges formed between Cys I–IV, Cys II–V and Cys III–VI (31,32). To obtain correctly folded 
peptides, oxidation of HwTx-IV was conducted over 16 h to obtain the oxidized peptide with 
the most thermodynamically favorable fold and a yield of 80% as previously described 
(12,18,26) (Supporting information Figure S1). Thermodynamic oxidation, whereby the 
peptides are incubated in a buffer that enables the peptides to adopt the most 
thermodynamically stable structural confirmation, also facilitated the folding of gHwTx-IV, 
[R26A]gHwTx-IV and [K27A]gHwTx-IV with yields between 10–15% over 48 h (Supporting 
information Figure S1) (11,18). However, repeated misfolding of [R29A]gHwTx-IV using 
thermodynamic approaches prompted the use of orthogonal oxidation (Figure 2, Supporting 
information Figure S1 and S2). 
[R29A]gHwTx-IV was synthesized with s-trityl (Trt) protecting groups on Cys III and Cys VI, 
acetamidomethyl (Acm) protecting groups on Cys II and Cys V and 4-methylbenzyl (4-
MeBzl) protecting groups on Cys I and Cys III. A slow-fast-slow kinetic approach was used 
to oxidize one disulfide bridge at a time (Figure 2). DMSO was chosen for the slow oxidation 
steps (step 1: Cys III–Cys VI (85% yield) and step 3: Cys I–Cys IV, (after cleavage of 4-
MeBzl using hydrogen fluoride (20% yield)) because it offered a low-risk approach with no 
observed side reactions. I2 was used for the removal of ACM protecting groups from Cys II 
and Cys V (step 2) and the subsequent oxidation of the pair. We found that a 10 min reaction 
using 20 molar equivalents of I2 in 15% (v/v) methanol (MeOH), 42.5% (v/v) acetic acid 
(AcOH) and 42.5% (v/v) H2O was optimal to maximize the oxidized product (30% yield) and 
to minimize side reactions between I2 and the indole groups on the Trp residues in the 
peptide. 
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Figure 4B-2. Orthogonal folding of [R29A]gHwTx-IV. 
Free cysteines Cys III and Cys VI were oxidized slowly in DMSO, followed by a fast removal of ACM 
protecting groups with subsequent oxidation of Cys II and Cys V using I2. After HF cleavage of 4-MeBzl, 
Cys III and Cys VI were oxidized slowly in DMSO to give the final product with correct disulfide 
connectivity. MALDI-TOF was used to ascertain that the correct product was formed at each step and 
RP-HPLC analytical traces show a leftward shift in retention time after each oxidation step.  
 
One-dimensional (1D) 1H NMR analysis of the peptides confirmed that they had been folded 
(Supporting information Figure S1). Secondary chemical shift analysis obtained from the 
sequential assignment of two-dimensional (2D) TOCSY and NOESY spectra showed that 
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the overall structure of the peptides was maintained (Figure 4B-3). Expected local 
differences in the backbones of the peptides are observed between gHwTx-IV and HwTx-IV 
at the E1G, E4G, F6W and Y33W mutations as before (18), and between gHwTx-IV and the 
three pharmacophore analogues at R26A, K27A and R29A (Figure 4B-3). 
 
 
Figure 4B-3. Secondary Hα shifts of HwTx-IV and the analogues. 
The secondary Hα shifts of gHwTx-IV overlap well with those of HwTx-IV except near or at positions 
where mutations were made (G1, G4, W6 and W33). [R26A]gHwTx-IV, [K27A]gHwTx-IV and 
[R29A]gHwTx-IV similarly show good alignment with gHwTx-IV except in the region where the mutations 
were made. Sequence alignment of the peptides is shown with cystines highlighted in grey, gHwTx-IV 
mutants in green and mutations forming [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV are 
shown in red.  
 
Affinity of GMTs for lipid bilayers 
Surface plasmon resonance (SPR) was used to examine the affinity of the GMTs for lipid 
bilayers by measuring the amount of peptide bound to lipid (peptide/lipid (P/L mol/mol)) 
using zwitterionic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and anionic 
POPC/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS) (4:1 molar ratio) model 
membranes. The rationale behind choice of lipids for these studies has previously been 
discussed (12,17,18,21,33). Briefly, phospholipids containing phosphatidylcholine-
headgroups are abundant on the outer leaflet of mammalian cells and phospholipids 
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containing phosphatidylserine-headgroups mimic the anionic environment surrounding 
membrane embedded voltage-gated sodium channels (34).  
As before (18), HwTx-IV had weak affinity for model lipid bilayers (all values are P/L mol/mol) 
(POPC = 0.014 ± 0.009; POPC/POPS = negligible), compared to gHwTx-IV (POPC = 0.066 
± 0.018; POPC/POPS = 0.162 ± 0.025) (Figure 4B-4). [R26A]gHwTx-IV (POPC = 0.024 ± 
0.003; POPC/POPS = 0.057 ± 0.006), [K27A]gHwTx-IV (POPC = 0.061 ± 0.008; 
POPC/POPS = 0.120 ± 0.010) and [R29A]gHwTx-IV (POPC = 0.047 ± 0.007; POPC/POPS 
= 0.061 ± 0.005) had intermediate affinities for the lipid bilayers compared to gHwTx-IV and 
HwTx-IV. We previously described the membrane binding face of gHwTx-IV to include G1, 
G4, W6 and W33 amongst other residues on the hydrophobic patch (18). The results herein 
suggest that the positively charged amino acid residues on loop 4 of the GMT also contribute 
to affinity for lipid bilayers. 
 
 
Figure 4B-4. Affinity of peptides for model lipid bilayers. 
SPR was used to examine the affinity of the peptides for model membranes consisting of POPC or 
POPC/POPS (4:1 molar ratio) lipid bilayers. The amount of peptide bound to lipid (peptide/lipid mol/mol) 
is shown and reveals that [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV had weaker affinity 
than gHwTx-IV for the model lipid membranes; however, all the analogues had stronger affinity than 
HwTx-IV for both lipid bilayers. All peptides had stronger affinity for anionic POPC/POPS than zwitterionic 
POPC lipid bilayers. 
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Potency and selectivity of the GMTs 
Potency at NaV1.7 was maintained or improved by each of the mutations compared to HwTx-
IV (Figure 5A). As before (18), gHwTx-IV was approximately three-fold more potent than 
HwTx-IV (HwTx-IV IC50 = 0.24 ± 0.06 M; gHwTx-IV IC50 = 0.07 ± 0.02  M). Potency of 
[K27A]gHwTx-IV was equivalent to HwTx-IV ([K27A]gHwTx-IV IC50 = 0.20 ± 0.05 M), 
whereas [R29A]gHwTx-IV had a potency similar to gHwTx-IV ([R29A]gHwTx-IV IC50 = 0.05 
± 0.01 M). Surprisingly, [R26A]gHwTx-IV was more than twice as potent as gHwTx-IV at 
NaV1.7 ([R26A]gHwTx-IV IC50 = 0.026 ± 0.004 M) (Figure 5A, Table 1).  
As predicted, mutations to positively charged residues on loop 4 improved the selectivity of 
the gHwTx-IV analogues in comparison to HwTx-IV. Whereas HwTx-IV and gHwTx-IV had 
two-fold and three-fold selectivity for NaV1.7 compared to NaV1.1 respectively, these values 
improved for [R26A]gHwTx-IV (eight-fold), [K27A]gHwTx-IV (15-fold) and [R29A]gHwTx-IV 
(72-fold) (Figure 5B, Table1, Supporting information Figure S3). 
Similarly, HwTx-IV and gHwTx-IV showed comparably low selectivity for NaV1.7 compared 
to NaV1.2 (Figure 5B, Table 1); however, [K27A]gHwTx-IV and [R29A]gHwTx-IV both 
showed a 13-fold selectivity for NaV1.7 over NaV1.2, and the selectivity of [R26A]gHwTx-IV 
was 42-fold (Figure 5B, Table 1, Supporting information Figure S3).  
HwTx-IV showed the least selectivity for NaV1.7 when compared to NaV1.3 (approximately 
three-fold). gHwTx-IV had 59-fold selectivity, and in this case [K27A]gHwTx-IV did not 
improve selectivity relative to gHwTx-IV with only 11-fold selectivity for NaV1.7. The 
remaining two analogues showed the best improvements with [R29A]gHwTx-IV having a 
95-fold selectivity and [R26A]gHwTx-IV having a 70-fold selectivity for NaV1.7 compared to 
NaV1.3 (Figure 5B, Table 1, Supporting information Figure S3).  
Upon comparing potency at NaV1.4 relative to NaV1.7, [K27A]gHwTx-IV was 36-fold more 
selective for NaV1.7 over NaV1.4, and this comparable to the 41-fold selectivity of HwTx-IV. 
[R29A]gHwTx-IV had the 59-fold selectivity for NaV1.7 over NaV1.4, gHwTx-IV was 122-fold 
more selective, and [R26A]gHwTx-IV showed the greatest improvement in selectivity for 
NaV1.7 with a 391-fold selectivity for NaV1.7 over NaV1.4 (Figure 5B, Table 1, Supporting 
information Figure S3). 
None of the peptides showed activity at NaV1.5; therefore, if IC50 were set at an arbitrary 
value of 10  M, the selectivity of the peptides relative to NaV1.7 in ascending order is HwTx-
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IV (41-fold), [K27A]gHwTx-IV (51-fold), gHwTx-IV (136-fold), [R29A]gHwTx-IV (186-fold) 
and [R26A]gHwTx-IV (391-fold) (Figure 5B, Table 1, Supporting information Figure S3).  
In comparison to NaV1.6, HwTx-IV and gHwTx-IV had 18-fold and eight-fold selectivity 
respectively for NaV1.7 (Figure 5B, Table 1). However, once again each point mutation 
improved selectivity relative to HwTx-IV and gHwTx-IV with [R26A]gHwTx-IV and 
[R29A]gHwTx-IV being 56- and 57-fold more selective for NaV1.7 and [K27A]gHwTx-IV 
being 23-fold more selective for NaV1.7 over NaV1.6. 
Together, these results show that a combination of HwTx-IV mutations including gHwTx-IV 
(E1G, E4G, F6W and Y33W), and point mutations at the positively charged residues 
contributing to the pharmacophore optimize the potency and selectivity of this GMT at 
NaV1.7. 
Taking these results together with the GMT–lipid affinity studies, removal of positively 
charged residues that contribute to the pharmacophore of gHwTx-IV reduces, but does not 
eliminate affinity for the lipid bilayer, and simultaneously improves the overall selectivity for 
NaV1.7 with respect to off-target NaVs containing a string of anionic residues at HwTx-IV’s 
putative binding site (Figure 1C,D). 
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Figure 4B-5. in vitro and in vivo activity of HwTx-IV and analogues. 
(A, B) A FLIPRTETRA membrane potential assay (30), was used to examine the potency of the peptides at 
(A) NaV1.7 and (B) various off-target NaVs. (A) [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV 
showed maintained or improved potency at NaV1.7 compared to HwTx-IV and/or gHwTx-IV. (B) 
Additionally, the gHwTx-IV analogues showed improved selectivity against off target NaVs. Potency 
relative to HwTx-IV is pIC50 peptide – pIC50 HwTx-IV at NaV1.7. (C, D) Effect of HwTx-IV, gHwTx-IV and 
the analogues in a murine model of NaV1.7 mediated nociception. (C) Time course of OD1 (300 nM/40 
L; control) induced nocifensive behaviors (paw lift, shakes, flinches) shows peak at 10 min post injection 
(109 ± 8.7 behaviors). Spontaneous nociception was reduced by HwTx-IV and [R26A]gHwTx-IV over 30 
min, but not for gHwTx-IV, [K27A]gHwTx-IV or [R29A]gHwTx-IV. (D) Pooled OD1-induced nocifensive 
behaviors between 0–10 min; HwTx-IV and [R26A]gHwTx-IV significantly reduced OD1 induced 
nociception (un-paired t-test, p < 0.01; ** on figure). Though the difference between [K27A]gHwTx-IV is 
significant (un-paired t-test, p < 0.05; * on figure), this is not to the same extent as HwTx-IV and 
[R26A]gHwTx-IV). There was no significant difference in effect for [R29A]gHwTx-IV and gHwTx-IV (un-
paired t-test, p > 0.05; ns on figure). All values expressed as mean ± S.E.M (n ≥ 3). 
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Activity of HwTx-IV, gHwTx-IV and R26A[gHwTx-IV] in murine model of NaV1.7 mediated 
pain 
The effects of the peptides in a mouse model of NaV1.7 mediated nociception were 
examined following intraplantar administration of OD1 (300 nM), an  -scorpion toxin that 
selectively impairs inactivation and enhances current from NaV1.7 (30,35). Time course data 
shows that HwTx-IV and [R26A]gHwTx-IV have the strongest anti-nociceptive effect within 
the first 5 min compared to the control (Figure 5C). gHwTx-IV, [K27A]gHwTx-IV and 
[R29A]gHwTx-IV showed similar behavior to the control; however, gHwTx-IV returned to 
baseline behavior at a faster rate than [K27A]gHwTx-IV and [R29A]gHwTx-IV (Figure 5C). 
There was no significant difference in nocifensive behavior (paw licks, flinches and licks) at 
10 min between gHwTx-IV (214 ± 21), and [R29A]gHwTx-IV (206 ± 16), compared to the 
control (239 ± 21) (un-paired t-test, p > 0.05) (Figure 5D). HwTx-IV (71 ± 16), and 
[R26A]gHwTx-IV (97 ± 7), both caused a significant reduction in nocifensive behavior in the 
mice compared to the control (un-paired t-test, p < 0.01), and although there was a 
significant reduction in nocifensive behavior for [K27A]gHwTx-IV (180 ± 10) (un-paired t-
test, p < 0.05), this effect was less than that of HwTx-IV and [R26A]HwTx-IV (Figure 5D). 
 
Discussion 
NaV1.7 is a promising target for the development of novel therapeutics for the treatment of 
pain (36-38). Spider GMTs, which are potent NaV modulators are being pursued as peptide 
drug leads for NaV1.7. Owing to their proposed affinity for lipid bilayers surrounding NaVs 
(12,17,18,21,33), here we have included the lipid bilayer in the design process of potent and 
selective modulators of NaV1.7. 
Point mutations to the positively charged residues on loop 4 of gHwTx-IV reduce but do not 
eliminate affinity for model lipid bilayers (Figure 4). This places [R26A]gHwTx-IV, 
[K27A]gHwTx-IV and [R29A]gHwTx-IV in between gHwTx-IV and HwTx-IV with respect to 
affinity for neutral POPC and anionic POPC/POPS lipid bilayers. When affinity of HwTx-IV 
for model lipid membranes was first examined, this GMT showed no binding to lipid bilayers 
(18,22). We then engineered gHwTx-IV to increase affinity for model lipid membranes by 
reducing the anionic contribution to the overall surface charge of the peptide, and by 
increasing the size of the hydrophobic patch (18). At the time, we proposed that the peptide 
may bind to the lipid bilayer using a membrane interaction face (Figure 6A), consisting 
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primarily of hydrophobic residues in a manner similar to ProTx-I and ProTx-II (18,21,33). 
The results obtained herein suggest that R26, K27 and R29 also contribute to the membrane 
binding face residues important for affinity for the lipid bilayers, most probably through 
electrostatic interactions with anionic moieties on the lipid bilayer (Figure 6A).  
Point mutations to the basic residues on loop 4 of gHwTx-IV did not adversely influence 
activity for NaV1.7 compared to activity of HwTx-IV. As before (18), gHwTx-IV was three-fold 
more potent than HwTx-IV, [R29A]gHwTx-IV had similar potency to gHwTx-IV, 
[R26A]gHwTx-IV was nine-fold more potent than HwTx-IV and [K27A]gHwTx-IV was as 
potent as HwTx-IV at NaV1.7 (Figure 5A and Table1). As mentioned, the basic residues on 
loop 4 of HwTx-IV have been proposed to form important interactions with anionic amino 
acids on the S3–S4 loop of domain II on NaVs (26,28). In the mutagenesis study by 
Minassian and colleagues (28), reductions in potency at NaV1.7 and NaV1.2 were observed 
for [R26A]HwTx-IV and [K27A]HwTx-IV (28). In the same study, [R29A]HwTx-IV maintained 
potency equivalent to HwTx-IV but lost potency at NaV1.2 (28). Revell and colleagues (11), 
drew similar conclusions from their alanine scan but went further to optimize HwTx-IV 
potency at NaV1.7 by generating a [E1G, E4G, Y33W]HwTx-IV triple mutant (11). Here we 
have shown that the same point mutations, when made to gHwTx-IV (a membrane binding 
analogue of HwTx-IV), do not negatively affect potency at NaV1.7. We propose that this 
maintenance of potency is possible because an affinity for the lipid bilayer compensates for 
potential losses in interactions with NaV1.7. 
gHwTx-IV did not show improved selectivity profile in comparison to HwTx-IV with equivalent 
lack of selectivity against NaV1.2 and NaV1.1, and a reduction of selectivity against NaV1.6 
when compared to NaV1.7 (with respect to the selectivity of HwTx-IV at the same channel) 
(Figure 5B, Table1). We previously proposed that the lipids surrounding NaV1.7 can act to 
anchor and concentrate gHwTx-IV near its channel active site (18). The cell membrane 
environment surrounding the NaVs in vitro (using HEK293 cells) is likely to be similar across 
the different channel types, and therefore, the poor selectivity profile observed for gHwTx-
IV is probably because this peptide is anchored within the cell membrane near the channels 
in a similar manner for all channels.  
Here we have shown that, in general, using the already potent gHwTx-IV, point mutations 
at R26, K27 and R29 improve selectivity for NaV1.7. [R26A]gHwTx-IV and [R29A]gHwTx-IV 
showed the greatest improvements in selectivity with high potencies at NaV1.7. Notably, 
[K27A]gHwTx-IV lost selectivity compared to HwTx-IV and gHwTx-IV at NaV1.4 but was still 
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approximately 40-fold more selective for NaV1.7 compared to NaV1.4. We propose that this 
overall improvement in selectivity, particularly as seen for [R26A]gHwTx-IV and 
[R29A]gHwTx-IV, probably arises from striking a balance between obtaining optimal potency 
through interactions with the channel and with the lipid bilayer. For gHwTx-IV affinity for the 
lipid bilayers does not promote selectivity, but for the loop 4 analogues, we most probably 
weakened interactions with off target NaVs and compensated for potency at NaV1.7 through 
interactions with the model lipid bilayers, which though weaker than gHwTx-IV, are stronger 
than interactions between HwTx-IV and the lipid bilayers studied.  
To examine the effects of the peptides in vivo, we used a NaV1.7 engagement model based 
on intraplantar administration of the NaV1.7 agonist OD1 (30). [R26A]gHwTx-IV, which was 
approximately 10-fold more potent than HwTx-IV in vitro, showed similar in vivo activity 
compared to the native GMT, and the reduction in nocifensive behavior observed for both 
of these peptides is comparable to that observed for other GMTs studied using the same 
model (9,30,39). gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV failed to show 
considerable anti-nociceptive effects even though the peptides had better or comparable 
potency to HwTx-IV at NaV1.7. In vivo effects were poorly correlated to potency or selectivity 
and it is possible that this disparity is caused by species variability (human channels in vitro 
compared to murine channels in vivo). Alternatively, intravascular administration, could have 
been employed for the studies, however, when this method was previously used for ProTx-
II, a non-significant analgesic effect was observed for the peptide (25). A known barrier for 
GMT access to NaV1.7 is the perineurial barrier containing tight junctions that impede 
accessibility of GMTs to their targets (40); however, the issue of the perineurial barrier is 
more relevant for intravascular administration and intraplantar administration of the test 
compounds should have overcome this barrier. The exact distribution of lipids and other 
moieties on the cell surface of DRG neurons is not completely known; however two recent 
reviews from our group and our collaborators respectively (17,19), have outlined membrane 
compositions of mammalian axonal cells and HEK293 cells. In our opinion, the differences 
in lipid compositions in these two cell lines are not large enough to provide a sufficient 
explanation for the absence of a correlation between in vivo and in vitro activity. Optimizing 
GMTs to access their targets in vivo remains an area for future work if these peptides are to 
be converted to efficacious drugs. A second area for future optimization is the toxicity of 
GMTs in vivo. Both HwTx-IV and the most selective analogues of ProTx-II remain toxic in 
animal models, resulting in death and possible histaminergic effects respectively (23,25). 
Gonçalves and colleagues (24), have recently proposed that HwTx-IV’s off target activity at 
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NaV1.6 is responsible for neuromuscular toxicity (24), therefore an area for future 
investigations could be to examine whether the selectivity and efficacy of [R26A]gHwTx-IV 
is accompanied by a loss of neuromuscular toxicity in vivo. 
 
Figure 4B-6. Putative membrane binding and channel interaction of gHwTx-IV 
(A) Surface profile of gHwTx-IV (PDB ID: 5TLR) with hydrophobic patch (green) and positively charged 
ring (blue). The previously proposed membrane binding face (left) (18), and an updated membrane 
binding face (right) is proposed with residues that probably contribute to interactions with lipid bilayers 
shown. (B) We propose that with a membrane binding face that includes some of the pharmacophore 
residues, gHwTx-IV probably interacts with the phospholipid heads found between extracellular loops 
formed by S1–S2 and S3–S4. Figure adapted from Agwa et. al, 2017 (18). 
 
Conclusion 
Here, we have considered the lipid component of the tri-molecular complex in the design of 
potent and selective modulators of NaV1.7 with [R26A]gHwTx-IV showing efficacy in vivo. 
Notably, the role of the effect of the lipid bilayer on GMT activity appears to be limited to in 
vitro activity. Furthermore, as seen for gHwTx-IV, [R26A]gHwTx-IV and [R29A]gHwTx-IV, 
peptides do not require maximal affinity for the lipid bilayer to display an increase in potency 
at NaV1.7, instead for this suite of peptides, an intermediate affinity between gHwTx-IV and 
HwTx-IV is optimal for potency and selectivity. GMTs are probably adapted more for contact 
with the channel than for contact with the lipid bilayer (12); therefore, we propose that the 
tripartite relationship formed by gHwTx-IV and its analogues occurs such that the peptides 
are nestled between the extracellular loops formed by S3–S4 and S1–S2, and probably 
interact with the phospholipid head groups in this region (Figure 6B). We have previously 
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discussed the possibility of this binding mode (17), and others have used molecular 
dynamics combined with channel mutagenesis studies on similar GMTs to demonstrate the 
same binding mode (28,41,42). An alternative option exists, whereby the GMTs are first 
attracted to the anionic environment surrounding voltage-gated ion channels via 
electrostatic interactions, then concentrated in the lipid bilayer and oriented externally near 
the S3–S4 binding site on domain II of NaV1.7 (17,18,21). In our hands, every spider GMT 
has shown a distinct set of behavioral patterns with respect to the lipid bilayer and voltage-
gated sodium channels (12), therefore we believe it is not possible to make sweeping 
statements about GMT behavior. Nevertheless, as we have shown here with HwTx-IV and 
previously with ProTx-II (21), detailed studies on individual GMTs can produce novel insight 
and approaches to optimizing these peptides for use as potential drugs for pain and other 
NaV-dependent pathologies. 
 
Materials and methods 
Peptide synthesis  
Peptides were assembled using Fmoc chemistry on a Rink amide resin (for C-terminal 
amidation) on a scale of 0.25 mmol/g using an automated Symphony peptide synthesizer 
(Gyros Protein Technologies Inc., Tucson, AZ, USA), as previously described (12,18,43). 
Side chain protecting groups for HwTx-IV, gHwTx-IV, [R26A]gHwTx-IV and [K27A]gHwTx-
IV were Arg(Pbf), Asp(tBu), Asn(Trt), Cys (Trt), Gln(Trt) Glu(tBu), Lys(Boc), Ser(tBu), 
Thr(tBu), Trp(Boc), Tyr(tBu). Additionally, as described, Acm was used for Cys II and Cys V 
and 4-MeBzl for Cys I and Cys IV to facilitate orthogonal oxidation of [R29A]gHwTx-IV. 
Cleavage from resin and removal of side chain protecting groups (except Acm and 4-MeBzl) 
was simultaneously achieved in 96% (v/v) trifluoroacetic acid (TFA), 2% (v/v) 
triisopropylsilane (TIPS) and 2% (v/v) H2O for 2.5 h followed by diethyl ether trituration prior 
to solubilizing of the peptide in 45% (v/v) acetonitrile (ACN)/0.05% (v/v) TFA (Solvent AB) 
prior to lyophilization. Reduced peptides were purified using reverse-phase high-
performance liquid chromatography (RP-HPLC) as before (12,18,43). 
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Oxidative folding of inhibitor cystine knot peptides  
As previously described (11,18,22), oxidation of HwTx-IV was achieved in 16 h using 5 mM 
GSH, 0.5 mM GSSG 10% (v/v) 1 M Tris (pH 8) at room temperature for 16 h (18,22). gHwTx-
IV, [R26A]gHwTx-IV and [K27A]gHwTx-IV were oxidized for 48 h at room temperature using 
5 mM GSH, 1 mM GSSG, 10% (v/v) 1 M Tris, 10% (v/v) isopropanol at pH 8 (11,18). 
For [R29A]gHwTx-IV (Figure 2), the Trt protecting groups on Cys III and Cys VI were 
removed during cleavage and the disulfide bridge between these free cysteines was formed 
by incubating the peptide (0.1 mg/mL) in 30% (v/v) DMSO/H2O for 24 h. The peptide was 
purified using previously described semi-preparatory methods (12), and lyophilized prior to 
removal of Acm protecting groups from Cys II and Cys V with simultaneous oxidation of the 
free cysteines (1 mg/mL) using 20 molar equivalents of I2 in 15% (v/v) MeOH, 42.5% (v/v) 
AcOH and 42.5% (v/v) H2O. 0.1 M ascorbic acid was used to quench the reaction after 10 
min and the peptide was purified (12), and lyophilized. Finally the 4-MeBzl groups were 
removed at 0 C for 1 h using hydrogen fluoride for cleavage and p-cresol as a scavenger. 
The peptide was extracted from the cleavage solution using diethyl ether, extracted from the 
diethyl ether using phase separation in 45% (v/v) ACN, 0.05% (v/v) TFA, in H2O and the 
Cys I–Cys IV pair was oxidized over 24 h by diluting to 0.05 mg/mL peptide, 22.5% (v/v) 
ACN and 33% (v/v) DMSO in H2O. Each step of peptide oxidation was monitored using 
matrix-assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-TOF 
MS) and analytical RP-HPLC as previously described (12). Once oxidation was complete, 
the peptide was purified as before (12), lyophilized and stored at –20C. 
 
Peptide quantification 
HwTx-IV, gHwTx-IV and the three analogues contain aromatic residues allowing for 
Nanodrop quantification using the following extinction co-efficients HwTx-IV 280 = 7365 M-
1cm-1 gHwTx-IV, [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV 280 = 17430 M-
1cm-1. 
 
NMR spectroscopy 
As previously described (12), 1D 1H and 2D 1H–1H TOCSY and NOESY spectra (80 ms and 
200 ms respectively) were used to confirm the structural integrity of the peptides (44,45). 
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Spectra were obtained on a cryoprobe-equipped Bruker Avance III 600 MHz spectrometer 
(Bruker Biospin, Callerica, MA). TopSpin 3.5 (Bruker) was used to process the spectra and 
sequential assignments were completed using CCPNMR analysis 2.4.1 (CCPN, University 
of Cambridge, Cambridge, UK) (46). 
 
Affinity of HwTx-IV and its analogues for model lipid bilayers 
As previously described (12,18,21,33,43), model lipid bilayers were prepared using POPC 
and POPS (Avanti Polar Lipids, Alabaster, AL, USA). SPR (Biacore 3000, GE Healthcare 
Life Sciences, Chicago, IL, USA) was used to examine the amount of peptide bound to 
zwitterionic POPC and anionic POPC/POPS (4:1 molar ratio) deposited on an L1 sensor 
chip. Data were analyzed as previously described (18,47). 
 
Cell culture  
Human embryonic kidney (HEK) 293 cells heterologously expressing human NaV1.1, 
NaV1.2, NaV1.3, NaV1.4, NaV1.5 NaV1.6 and NaV1.7 (SB Drug Discovery, Glasgow, UK) 
were maintained at 37 °C in a 5% CO2 humidified incubator within T75 flasks containing 
minimal essential medium eagle, supplemented with 10% (v/v) heat inactivated fetal bovine 
serum, 1% (v/v) glutamax, and varying concentrations of manufacturer recommended 
selection antibiotics. Replicating cells were subcultured at 70–80% confluence using 0.1% 
(v/v) trypLE express reagent (Thermo Fisher Scientific, Waltham, MA, USA). 
 
Examination of sub-type selectivity using FLIPR  
A FLIPR membrane potential assay was performed on the FLIPRTETRA plate reader 
(Molecular Devices, Sunnyvale, CA, USA) and used to examine activity of the peptides at 
NaV channels as previously described (30) .In brief, freshly dissociated cells were plated into 
384-well clear-bottom black-walled imaging plates (Corning, NY, USA) at a density of 
10,000–15,000 cells per well. After 48 h, the growth media was removed from the wells and 
the cells loaded with 20  l per well red membrane potential dye (Molecular Devices) diluted 
in physiological salt solution (PSS; composition in mM: NaCl 140, glucose 11.5, KCl 5.9, 
MgCl2 1.4, Na2H2PO4 1.2, NaHCO3 5, CaCl2 1.8, HEPES 10; pH 7.4) according to the 
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manufacturer's instructions for 30 min at 37 °C, 5% CO2. Peptides were diluted in PSS/0.1% 
(w/v) bovine serum albumin (BSA) and added to the cells to achieve concentrations ranging 
from 10 M to 0.3 nM and incubated for 5 min. NaV channel expressing cells were stimulated 
using 60 M veratridine and changes to membrane potential were measured with a cooled 
CCD camera (excitation 515–545 nm, emission 565–625 nm) with reads taken every 1 s for 
10 s before (baseline values) and for 300s after addition of veratridine. PSS/0.1% (w/v) BSA 
was used as a negative control. ScreenWorks 3.2.0.14 (Molecular Devices) was used to 
compute the area under the curve (AUC) over 300 s and the data were plotted and analyzed 
using GraphPad Prism 7 to quantify inhibitory effects of the peptides. To calculate 
concentration-response curves, a four-parameter Hill equation with variable Hill slope was 
fitted to the data. All data are expressed as the mean ± standard error of the mean (SEM) 
and are representative of at least three independent experiments. Potency of each peptide 
at off targets is compared to potency of HwTx-IV at NaV1.7 (Figure 5B) and to the potency 
of the specific peptide at NaV1.7 (Table 1). 
 
In vivo NaV1.7 target engagement 
Animal ethics approval was obtained from The University of Queensland Animal ethics 
committee. All experiments were conducted in accordance with local and national 
regulations and the International Associations for the Study of Pain Guidelines for the Use 
of Animals in Research. Male C57BL/6J mice aged 6–8 weeks (20–25 g) were housed in 12 
h light-dark cycle with access to food and water ad libitum. To assess the in vivo effect of 
peptide analogs, an OD1 induced model of NaV1.7 target engagement was used as 
previously described (30). 
Briefly, the NaV1.7 selective   scorpion toxin OD1 (300 nM) was diluted in phosphate-
buffered solution and 0.1% (w/v) BSA. Under brief and light (3% (v/v) isoflurane) anesthesia 
mice were administered OD1 (40  L of 300 nM) via shallow intraplantar injection into the 
dorsal hind paw. Animals received OD1 alone (control, n ≥ 3) or were co-administered OD1 
with HwTx-IV, gHwTx-IV, R26A[gHwTx-IV], K27A[gHwTx-IV] or R29A[gHwTx-IV] (100 nM, 
n = 3). Following injection, mice were allowed to recover in polyvinyl boxes and were video 
recorded for 30 min post-injection. Spontaneous nocifensive behaviors (paw lifts, licks, 
shakes and flinches) were counted by a blinded observer.  
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Supporting information 
Figure S1.  
Analytical HPLC traces obtained on a C18 column with a flow rate of 0.3 mL/min (Grace Vydac, 150 x 
2.1 mm, 5 m; Thermo Fisher Scientific, Waltham, MA). HwTx-IV and gHwTx-IV gradient is 1%/min 0–
60% solvent B. [R26A]gHwTx-IV, [K27A]gHwTx-IV and [R29A]gHwTx-IV gradient is 2%/min 0–60% 
solvent B. Observed ESI-MS spectra are shown HwTx-IV calculated mass = 4106.8; gHwTx-IV calculated 
mass = 4024.7; [R26A]gHwTx-IV calculated mass = 3939.6; [K27A]gHwTx-IV calculated mass = 3967.8; 
[R29A]gHwTx-IV calculated mass = 3939.6. Amide region of 1D 1H NMR spectra are also shown. 
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Figure S2. 
Thermodynamic folding of R29A[gHwTx-IV]. All cysteines were simultaneously deprotected during 
release from the resin using 96 % (v/v) TFA 2% (v/v) TIPS 2% (v/v) water. Thermodynamic oxidative 
folding was used to oxidize the peptide and correct mass was obtained using ESI-MS. Analytical HPLC 
on a C18 column with a flow rate of 0.3 mL/min (Grace Vydac, 150 x 2.1 mm, 5 m (2%/min 0–60% 
solvent B), confirmed purity, but 1D-1H NMR showed a misfolded peptide. 
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Figure S3. A FLIPRTETRA membrane potential assay was used to examine the potency of the peptides 
at various off-target NaVs. Traces show concentration–response curves following activation of 
HEK293 cells expressing each channel using veratridine.  
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Table 1. Potencya,b and selectivityc of HwTx-IV, gHwTx-IV and analogues 
Peptide NaV1.1 NaV1.2 NaV1.3 NaV1.4 NaV1.5 NaV1.6 NaV1.7 
HwTx-IV 0.43 ± 0.27a 0.26 ± 0.12a 0.78 ±0.63a >10a,b >10a,b 4.31 ± 0.88a 0.24 ± 0.06a 
 (2c) (1c) (3c) (60c) (42c) (18c) – 
gHwTx-IV 0.21 ± 0.06a 0.11 ± 0.03a 4.35 ± 1.54 a 9.01 ± 6.70 a >10a,b 0.59 ± 0.06a 0.07 ± 0.02a 
 (3c) (1c) (59c) (122c) (143c) (8c) – 
[R26A]gHwTx-IV 0.22 ± 0.05a 1.04 ± 0.40a 1.79 ± 1.03a >10a,b >10a,b 1.44 ± 0.11a 0.03 ± 0.003a 
 (8c) (41c) (70c) (564c) (333c) (56c) – 
[K27A]gHwTx-IV 2.90 ± 0.21a 2.44 ± 0.81a 2.13± 1.53a 7.03 ± 1.97 a >10a,b 4.54 ± 0.55a 0.20 ± 0.05a 
 (15c) (13c) (11c) (36c) (50c) (23c) – 
[R29A]gHwTx-IV 3.86 ± 1.06a 0.70 ± 0.27a 5.04 ± 3.99a 3.13 ± 1.52 a >10a,b 3.05 ± 0.16a 0.05 ± 0.005a 
 (72c) (13c) (95c) (59c) (200c) (57c) – 
a Potency at voltage-gated sodium channels measured using FLIPRTETRA membrane potential assay on HEK293 cells expressing 
each respective channel and IC50 values are in M, ± SEM where n ≥ 3 
b An arbitrary IC50 of > 10 M is assigned where peptides do not show inhibitory activity 
c Fold NaV1.7 selectivity is IC50 NaV1.x/ IC50 NaV1.7 and is shown in brackets below each entry) 
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Chapter 5 
 
Examining the structural stability of gating modifier toxins 
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Overview 
This work, and others in the field (1-4), has successfully demonstrated an ability to procure 
potent, selectivity modulators of NaV1.7 and other voltage-gated ion channels using GMTs. 
However, up to this point, the field lacked a systematic study on the stability of GMTs in 
physiologically relevant and extreme environments. Chapter 5 examines GpTx-I, HnTx-IV, 
HwTx-IV, PaurTx-III and SgTx-I and establishes that these peptides have excellent stability, 
affirming that GMTs provide excellent drug leads. 
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Abstract 
Spider gating modifier toxins (GMTs) are potent modulators of voltage-gated ion channels 
and have thus attracted attention as drug leads for several pathophysiological conditions. 
GMTs contain three disulfide bonds organized in an inhibitor cystine knot, which putatively 
confers them with high stability; however, thus far, there has not been a focused study to 
establish the stability of GMTs in physiological conditions. We examined the resistance of 
five GMTs including GpTx-I, HnTx-IV, HwTx-IV, PaurTx-III and SgTx-I, to pH, thermal and 
proteolytic degradation. The peptides were stable under physiological conditions, except 
SgTx-I, which was susceptible to proteolysis, probably due to a longer C-terminus compared 
to the other peptides. In non-physiological conditions, the five peptides withstood chaotropic 
degradation, and all but SgTx-I remained intact after prolonged exposure to high 
temperature; however, the peptides were degraded in strongly alkaline solutions. GpTx-I 
and PaurTx-III were more resistant to basic hydrolysis than HnTx-IV, HwTx-IV and SgTx-I, 
probably because a shorter interconnecting loop 3 on GpTx-I and PaurTx-III may stabilize 
interactions between the C-terminus and the hydrophobic patch. Here, we establish that 
most GMTs are exceptionally stable, and propose that, in the design of GMT-based 
therapeutics, stability can be enhanced by optimizing the C-terminus in terms of length, and 
increased interactions with the hydrophobic patch. 
 
Keywords: NaV1.7; nuclear magnetic resonance; pain; drug design; serum stability; spider 
venom 
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Introduction 
Gating modifier toxins (GMTs), a class of disulfide-rich peptides expressed in the venom of 
spiders, modulate the gating mechanism (opening and closing of an ion conduction pore), 
of voltage-gated ion channels (5-7). Human voltage-gated ion channels are involved in 
several pathophysiological conditions, including chronic pain, epilepsy, and cardiovascular 
conditions, and, accordingly, GMTs have potential as drug leads (4,8-14). 
Spider GMTs are classified within the inhibitor cystine knot (ICK) family of peptides because 
of the presence of a conserved disulfide bridge connectivity consisting of Cys I–Cys IV, Cys 
II–Cys V and Cys III–Cys VI (15-19). Furthermore, some ICK GMTs including GpTx-I, HnTx-
IV, PaurTx-III and SgTx-I contain two to three antiparallel β-strands as is expected for ICK 
peptides (Figure 1A) (16-22). However, this is not a conserved structural feature, as some 
GMTs, including HwTx-IV, do not display β-sheets, exemplifying the diversity in structures 
of peptides containing the ICK motif (Figure 1A) (15,23,24). In addition to the ICK motif, a 
second conserved feature of the structures of GMTs is a hydrophobic patch surrounded by 
a charged ring of amino acids (Figure 1B) (1,20,22,24-26). This amphipathic characteristic, 
similar to that of membrane active antimicrobial peptides (27), is thought to facilitate GMT 
interactions with both the voltage-gated ion channels and the lipid membrane in which the 
channels are embedded (15,23,28-33).  
It is generally assumed that GMTs have high stability; however, the ability of these ICK 
peptides to maintain their structural integrity in physiologically relevant conditions has not 
been studied in a systematic manner, though a recent study looked at the stability of Hv1a 
in the context of the development of insecticides (34). The current study was designed to 
determine whether the ICK motif engenders GMTs with stability against thermal 
degradation, pH dependent hydrolysis, proteolysis and chemical degradation using GpTx-I, 
HnTx-IV, HwTx-IV, PaurTx-III and SgTx-I as model GMTs (see Figure 1C for sequences). 
GpTx-I, HnTx-IV and HwTx-IV are potent inhibitors of the voltage-gated sodium type 1.7 
channel (NaV1.7), a channel that has been implicated in chronic pain and PaurTx-III and 
SgTx-I are modulators of NaV1.2 (35,36), a sodium channel associated with epilepsy and 
ataxia (5). 
Here we show that GpTx-I, HnTx-IV, HwTx-IV, and PaurTx-III are indeed stable in 
physiologically relevant conditions; however, SgTx-I is susceptible to proteolysis. Our results 
show that, although a majority of GMTs provide excellent scaffolds for drug development, 
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the length of the C-terminus may affect stability and needs to be considered if GMTs are to 
be used as templates in drug design.  
 
 
Figure 1. Conserved structural features of spider-derived GMTs. 
(A) ribbon representations of GpTx-I (20), HnTx-IV (PDB ID: 1NIY) (22), HwTx-IV (PDB ID: 2M4X) (24), 
PaurTx-III (PDB ID: 5WE3, this study) and SgTx-I (PDB ID: 1LA4) (21). The backbones of the GMTs are 
shown in white and the disulfide bridges forming the inhibitor cystine knot are shown in brown. GpTx-I, 
HnTx-IV and PaurTx-III each have two anti-parallel β-strands, SgTx-I has three, and HwTx-IV has no 
anti-parallel β-strands. Locations of N- and C-termini and of Cys I–VI (highlighted in yellow) are identified 
on HwTx-IV for clarity; (B) surface representations of the GMTs showing the conserved hydrophobic 
patch and charged ring of spider toxins, where hydrophobic residues are green, positively charged 
residues are blue and negatively charged residues are red. The disulfide bridges are buried within the 
hydrophobic patch; (C) sequences of the peptides are shown (aligned to cysteine residues of HwTx-IV 
and HnTx-IV) with cysteines highlighted in yellow, residues making up interconnecting loops are identified 
with arrows, N- and C-termini are shown and * denotes amidated C-terminal. 
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Results 
Solution NMR Structure of PaurTx-III 
Three-dimensional structures of the peptides were used to evaluate the relationship 
between peptide structure and stability. The structures of HnTx-IV (PDB ID: 1NIY) (22), 
HwTx-IV (PDB ID: 2M4X) (24) and SgTx-I (PDB ID: 1LA4) (21) were available from the 
protein data bank (PDB), and PDB coordinates for GpTx-I were made available to us as a 
gift (20). The three-dimensional solution structure of PaurTx3 was not available from the 
PDB website and therefore calculated using nuclear magnetic resonance (NMR) 
spectroscopy (Figure 2) including 350 distance restraints, comprising 134 intraresidue (i − j 
= 0), 120 sequential (i − j = 1), 42 medium range (i − j < 5), 40 long range (i − j > 5) and 14 
hydrogen bond restraints and 41 dihedral restraints including 18 ф, 18 ψ and 5 χ1 angle 
restraints. Root Mean Square Deviation (RMSD) values for the 20 lowest energy structures 
superimposed where global backbone = 0.88 ± 0.23 Å; global heavy = 1.67 ± 0.20 Å 
(residues 1–34) and global backbone = 0.71 ± 0.21 Å; global heavy = 1.51 ± 0.21 Å (residues 
2–31, excluding flexible termini) (Table 1). 
 
Figure 2. Solution NMR structure of PaurTx-III (PDB ID: 5WE3, this study).  
The 20 best conformers selected from lowest energy and best MolProbity scores are shown (37). (A) 
backbone of the structures is red and disulfide bridges are yellow with N- and C-termini and cysteines I-
VI labelled; (B) antiparallel β-sheets are shown in red, the residues forming the hydrophobic patch are 
shown in green and the turns on the structures are shown in blue with proline residues in position 11 and 
18. 
 
The structure comprises the expected ICK disulfide bond connectivity of Cys I–Cys IV, 
CysII–Cys V and Cys III–Cys VI (Figure 2A) and two antiparallel β-strands between Val 22–
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Ser 24 and Lys 28–Lys 31 (Figure 2B). The structure also includes a high density of solvent 
exposed hydrophobic residues flanked by a series of loops and turns (Figure 2B). Two of 
the turns are stabilized by proline residues, whereas the third loop lacks a proline residue, 
probably facilitating flexibility for interactions with target voltage-gated ion channels (Figure 
2B).  
Table 1. Energies and structural statistics 1 for the final 20 2 structures of 
PaurTx-III. 
Energies (kcal/mol) 
Overall −1232.31 ± 50.68 
Bonds 23.83 ± 2.03 
Angles 64.83 ± 6.52 
Improper 19.89 ± 2.47 
Dihedral 164.27 ± 1.66 
Van der Waals −131.51 ± 7.15 
Electrostatic −1374.68 ± 52.43 
NOE 0.38 ± 0.04 
Constrained dihedral (cDih) 0.66 ± 0.40 
MolProbity Statistics 
Clash score (>0.4 Å/1000 atoms) 11.10 ± 3.94 
Poor rotamers (%) 2.88 ± 2.30 
Ramachandran outliers (%) 0.47 ± 1.14 
Ramachandran favored (%) 87.50 ± 3.36 
MolProbity score 2.45 ± 0.26 
MolProbity percentile 3 50.40 ± 14.91 
Atomic RMSD (Å) 
Mean global backbone (2–31) 4 0.71 ± 0.21 
Mean global heavy (2–31) 1.51 ± 0.21 
Mean global backbone (1–34) 0.88 ± 0.23 
Mean global heavy (1–34) 1.67 ± 0.20 
Distance Restraints 
Intraresidue (i − j = 0) 134 
Sequential (|i − j| = 1) 120 
Medium range (|i − j| < 5) 42 
Long range (|i − j| > 5) 40 
Hydrogen bonds 5 14 
Total 350 
Dihedral Angle Restraints 
ф 18 
ψ 18 
χ1 5 
Total 41 
Violations from Experimental Restraints 
Total NOE violations exceeding 0.2 Å 1 
Total dihedral violations exceeding 
2.0° 
2 
1 ± St Dev. 2 Based on structures with highest overall MolProbity score 
(37). 3 100th percentile is the best among structures of comparable 
resolution; 0th percentile is the worst. 4 RMSD calculated in MOLMOL 
(Version 2k.2, Institute of Molecular Biology and Biophysics, ETH, Zürich, 
Switzerland) (38). 5 Two restraints were used per hydrogen bond 
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Thermal Stability 
Effects of varying temperature on peptide structure were examined using one-dimensional 
(1D) NMR spectra at temperatures ranging from 20 to 80 °C. The spectra (Figure 3) show 
peaks with narrow line widths and minimal loss in signal intensity up to 80 °C, at which 
temperature HnTx-IV and SgTx-I showed peak broadening and loss of intensity. GpTx-I, 
HwTx-IV and PaurTx-III maintained narrow peaks but also showed some loss in intensity at 
80 °C. Changes in the chemical shifts for all the peptides were reversible, as cooling back 
to 20 °C resulted in spectra identical to the initial ones, at 20 °C, with narrow peaks and no 
loss of signal (Figure 3). Notably, for PaurTx-III, the ε1 proton shifts on the two indole side 
chains of Trp 7 and Trp 29 begin to split with increasing temperature (Figure 3 inset). 
Therefore, nuclear Overhauser effect (NOE) correlation peaks of PaurTx-III were compared 
at 20 °C and 50 °C to confirm that the appearance of a second peak was due to a separation 
of Trp 7 and Trp 29 and not a result of cis-trans proline isomerization of the peptide (Figure 
3 inset). In summary, the reversibility of the chemical shift changes and the well-dispersed 
peaks in the amide regions of the spectra of all five GMTs at each temperature level indicate 
that the peptides remain structured and have good thermal stability. 
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Figure 3. Reversible thermal denaturation of GMTs. 
1D 1H solution NMR was used to monitor the structural changes to the five peptides at temperatures 
ranging from 20 to 80 °C. GpTx-I, HwTx-IV and PaurTx-III maintained narrow peaks up to 80 °C, although 
there was some loss in peak intensity in the amide region of the spectra. SgTx-I and HnTx-IV showed 
both a loss in intensity and broadening of peaks at 80 °C. NOE correlations confirm that the appearance 
of two peaks in the 10 ppm region of the 1D 1H spectra of PaurTx-III are a result of the separation of the 
ε1 proton on the indole rings of Trp 29 and Trp 7.  
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The peptides were also subjected to more extreme temperature by boiling (100 °C) for 30 
min and their stability was examined using analytical reverse-phase high performance liquid 
chromatography (RP-HPLC). GpTx-I, HnTx-IV, HwTx-IV and PaurTx-III could withstand the 
high temperatures, as was demonstrated by identical analytical traces with and without heat 
treatment (Figure 4), whereas analytical traces of SgTx-I showed a minor degradation 
product (Figure 5A). The degradation product from SgTx-I had an 18 Da loss from the 
molecular weight of native SgTx-I (3776.7 Da) as determined by matrix-assisted laser 
desorption/ionization mass spectrometry (MALDI-MS) (Figure 5A). This was most probably 
a thermally induced hydrolyisis and we suspected that the longer C-terminal chain (six amino 
acids from the last cysteine in the sequence) of SgTx-I made this GMT susceptible to 
degradation; therefore, ProTx-I, a GMT that is one amino acid residue longer than SgTx-I 
was similarly subjected to 100 °C for 30 min resulting in two prominent degradation product 
masses, one of which was equivalent to the loss of 390.2 Da from the molecular weight of 
native ProTx-I (3987.6 Da) (Figure 5C). This most likely involved the hydrolytic cleavage of 
three ProTx-I C-terminal residues, Thr 33, Phe 34 and Ser 35 (combined Mw = 389.4 Da) 
(see Figure 5C for sequence). 
 
Figure 4. Analytical RP-HPLC traces of the GMTs following heating to 100 °C. 
All of the peptides except SgTx-I and ProTx-I showed remarkable stability after the thermal assault 
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Figure 5. Irreversible thermal degradation of SgTx-I and ProTx-I.  
Analytical RP-HPLC was used to examine the peptides after heating to 100 °C and subsequent cooling 
to room temperature. Degradation products were further characterized using MALDI-MS (A) SgTx-I lost 
18 Da from the parent peptide; (B) ProTx-I underwent more extensive degradation, showing a 389.4 Da 
loss; (C) sequences of SgTx-I and ProTx-I are shown with cysteines highlighted in yellow and C-terminal 
residues shown in green. 
 
 pH Dependent Hydrolysis 
All five peptides in the current study were stable when incubated at 37 °C in phosphate 
buffer adjusted to pH 2, 4, 7.4 and 9, with more than 75% peptide remaining after the 24 h 
incubation (reduced PaurTx-III was used as a control) (Figure 6A). At pH 12, all of the 
peptides were partially or fully degraded, as shown in the analytical RP-HPLC traces of the 
peptides at pH 12 compared to pH 4 (Figure 6B). GpTx-I and PaurTx-III had a larger 
proportion of the folded peptide remaining in strong alkaline conditions compared to the 
HnTx-IV, HwTx-IV and SgTx-I (Figure 6B). Analysis of the degradation products of SgTx-I, 
HwTx-IV and PaurTx-III are shown as examples (Figure 6C), and reveal that the masses of 
the native for SgTx-I (3776.7 Da) and HwTx-IV (4106.6 Da) were absent, whereas the mass 
of parent PaurTx-III (4059.5 Da) was still observable. Analysis of the degradation products 
for PaurTx-III shows a mass loss of 112.9 Da corresponding to the loss of Ile 34, and HwTx-
IV shows a loss of 461 Da, within a range corresponding to the sequential hydrolytic 
cleavage of Ile 35, Gln 34 and Tyr 33 (458.5 Da).  
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Figure 6. pH dependent hydrolysis of GMTs 
(A) pH dependent hydrolysis of the peptides was monitored at pH 2, 4, 7.4, 9 and 12 using analytical RP-
HPLC following a 24 h incubation at 37 °C. Reduced PaurTx-III was used as a control. Data points are 
relative to amount of peptide at pH 4 and error bars are ± SE for n = 3; (B) comparisons of the analytical 
RP-HPLC traces of the peptides at pH 4 and pH 12 are shown and (C) MALDI-MS spectra for HwTx-IV, 
PaurTx-III and SgTx-I at pH 12 are also shown. 
 
Proteolytic Degradation 
Stability of the peptides against proteolytic degradation in human serum was examined at 0 
h, 1 h, 8 h and 24 h upon incubation at 37 °C. R-BP100 (39), a linear peptide rich in positively 
charged residues that does not contain disulfide bonds and is therefore likely to be 
susceptible to proteolytic degradation, underwent rapid proteolytic degradation to less than 
20% peptide remaining after 1 h, and was completely degraded in 8 h (Figure 7). In contrast, 
HwTx-IV, HnTx-IV, GpTx-I and PaurTx-III were resistant to proteolysis with more than 90% 
peptide remaining after a 24 h incubation in human serum (Figure 7). SgTx-I was degraded 
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to approximately 70% peptide remaining in 8 h, and to approximately 50% peptide remaining 
in 24 h. 
 
 
Figure 7. Proteolytic degradation of GMTs. 
The five GMTs were incubated in human serum and degradation was monitored using RP-HPLC at 0 h, 
1 h, 8 h and 24 h. R-BP100 was used as a control. Data points are relative to amount of peptide at 0 h 
and error bars are ± SEM for n = 3 
 
Chaotropic Degradation 
Resistance of the peptides to chemical degradation was examined by incubating the GMTs 
in 6 M guanidine hydrochloride (GdHCl) at 25 °C for 16 h. Each peptide displayed an 
identical analytical trace in the presence or absence of 6 M GdHCl upon monitoring using 
RP-HPLC (Figure 8). 
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Figure 8. GMT stability in 6 M GdHCl. 
Peptides incubated for 16 h incubation at 25 °C, and monitored using RP-HPLC.  
 
Root-Mean-Square Deviation at the C-Termini GMTs 
Global RMSDs of the backbones of the amino acids forming the C-terminus (comprising 
amino acids from the last cysteine to the C-terminal residue) of the GMTs were calculated 
using MOLMOL (38). GpTx-I and PaurTx-III had relatively less disordered C-terminal 
backbones than HwTx-IV, HnTx-IV and SgTx-I (Table 2). This low disorder is believed to 
reflect decreased flexibility in this region of GpTx-I and PaurTx-III, since other factors that 
can contribute to disorder, such as paucity of NOEs, do not apply for these two peptides. 
 
Table 2. GMT C-terminal RMSD 1 values 
Peptide Backbone RMSD (Å) (Pre C-
Term) 2 
Backbone RMSD (Å) (C-Term) 
3 
GpTx-I 0.18 ± 0.09 (Asp 1–Trp 29) 0.17 ± 0.09 (Lys 31–Phe 34) 
HnTx-IV 0.60 ± 0.13 (Glu 1–Trp 30) 0.51 ± 0.22 (Lys 32–Ile 35) 
HwTx-IV 0.34 ± 0.09 (Glu 1–Trp 30) 0.39 ± 0.17 (Lys 32–Ile 35) 
PaurTx-III 0.79 ± 0.22 (Asp 1–Trp 29) 0.30 ± 0.14 (Lys 31–Ile 34) 
SgTx-I 0.38 ± 0.11 (Thr 1–Tyr 27) 1.58 ± 0.43 (Asp 29–Phe 34) 
1 Global RMSD calculated using MOLMOL (38). 2 Residues prior to the final 
cysteine in the sequence ± standard deviation (SD) from the mean. 3 Residues 
after the final cysteine in the sequence ± SD from the mean 
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Discussion 
This study set out to examine the stability of spider-derived GMTs under thermal, pH-
dependent, proteolytic and chemical conditions. We focused on GpTx-I, HnTx-IV, HwTx-IV, 
PaurTx-III and SgTx-I, which like other peptides in their class, contain the conserved ICK 
motif that stabilizes a solvent exposed hydrophobic patch surrounded by a charged ring of 
amino acid residues (1,18-20,22,24-26,40). We were primarily interested in examining 
whether GMTs withstand physiologically relevant conditions; however, we also subjected 
the peptides to extreme thermal, pH and chemical assault to gauge the extent of the overall 
stability of spider-derived GMTs. 
The five peptides in the current study display high thermal stability, as is illustrated by the 
reversible changes to their 1D 1H NMR chemical shifts after heating to 80 °C in the 
instrument and subsequent cooling back to 20 °C. Only SgTx-I was degraded when the 
peptides were exposed to prolonged, extreme heating and on comparing the structure of 
this GMT to the remaining four peptides, we hypothesized that the longer, more flexible C-
terminus of SgTx-I (six amino acids for SgTx-I compared to four amino acids for the 
remaining GMTs) may have an impact on the lower stability of the peptide. To further 
examine this hypothesis, ProTx-I, a GMT with one additional amino acid residue at the C-
terminus compared to SgTx-I, was exposed to the same prolonged heat treatment, and we 
observed an even greater extent of degradation for ProTx-I compared to SgTx-I. 
Furthermore, C-terminal NOEs for SgTx-I and ProTx-I are broad and less intense, compared 
to the other peptides included in this study, suggesting a more disordered C-terminal. The 
C-terminal residues in SgTx-I and ProTx-I also and have fewer long-distance interactions to 
hydrophobic residues in other loops compared to GpTx-I, PaurTx-III, HnTx-IV and HwTx-IV 
(as observed by the lack of long-range NOEs), which may explain their susceptibility to 
thermal degradation. Similarly, recent work on Hm3a and PcTx1, two spider ICK peptides 
with high sequence homology, found that Hm3a, which contains four C-terminal amino acid 
residues, has higher thermal stability compared to PcTx1, which has seven C-terminal 
amino acid residues (41). OAIP, another spider ICK peptide containing three C-terminal 
amino acid residues, previously showed thermal stability (42); however, PVIIA, an ICK toxin 
extracted from cone snail venom containing only one C-terminal residue, was irreversibly 
denatured at 56 °C (40); therefore, it appears that a C-terminus of 3–4 amino acids may be 
optimal for the stability of ICK peptides against thermal assault. 
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We examined the stability of the peptides at pH values representing various sites in the body 
including pH 2 (stomach), pH 4 (jejunum), pH 7.4 (plasma) and pH 9 (approximate ileum 
pH). pH 12 was used to represent the peptides in an extreme (non-physiological) 
environment. The results suggest that the peptides can withstand physiological pH ranges, 
with SgTx-I perhaps being the least favorable because of the small loss of peptide at pH 2 
(Figure 6A). The peptides began to show degradation at pH 9, but the most substantial 
degradation occurred at pH 12. Previous studies on spider-derived ICK peptides have 
reported that disulfide bond shuffling occurs in alkaline conditions (34,42). However, the 
degradation products of the GMTs in the present study contained mass losses most 
probably from the C-terminus of the peptides (Figure 6B,C), and disulfide bond shuffling was 
not observed. Assuming that SgTx-I was susceptible to the alkaline hydrolysis because of 
the length of the C-terminal on this GMT, we were curious to find out why the four remaining 
peptides each containing four C-terminal amino acids showed different behavior from each 
other when incubated at pH 12. There are three key structural features on the peptides that 
could withstand the alkaline assault within GpTx-I and PaurTx-III, which are absent on 
HwTx-IV and HnTx-IV (which were completely degraded). First, a shorter loop 3, second, 
the presence of Pro 18 in the turn between loop 2 and loop 3 and, third, less disorder across 
the C-terminal residues (Figure 9, Table 2). It is possible that this combination of structural 
features facilitates a stronger attraction of the hydrophobic C-terminal residues of PaurTx-
III and GpTx-I to the hydrophobic patch of the peptides, providing some protection from 
alkaline hydrolysis (Figure 9), whereas peptides like HwTx-IV and HnTx-IV, lacking this 
additional structural rigidity and subsequent hydrophobic attraction, become more 
susceptible to alkaline hydrolysis.  
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Figure 9. Structural features of the loops, turns and C-termini of GMTs. 
(A) ribbon representations of 20 structures of PaurTx-III (PDB ID: 5W3E, this study), HwTx-IV (PDB ID: 
2M4X) (24), and HnTx-IV (PDB ID: 1NIY) (22), and 10 structures of GpTx-I (20), are shown where loop 
2 is highlighted in red, loop 3 is in blue and the C-terminal is in green (labels on HwTx-IV for clarity). The 
side chain of Pro 18 is shown for GpTx-I and PaurTx-III in blue; (B) sequences of the peptides are also 
shown and the residues forming each loop and the C-terminal are identified by arrows. Sequences of 
hydrophobic amino acid residues and residues forming the hydrophobic patch are colored green and * 
denotes amidated C-terminal; (C) green sticks show the side chains of hydrophobic residues on HwTx-
IV and PaurTx-III. 
 
To consider GMTs as viable drug leads, stability of the peptides in human serum is essential. 
GpTx-I, PaurTx-III, HwTx-IV and HnTx-IV show exceptional serum stability (Figure 8); 
however, SgTx-I is susceptible to proteolytic degradation. This degradation of SgTx-I is most 
likely due to the relatively longer C-terminal, making the peptide more susceptible to 
proteolysis in comparison to the other GMTs in the current study. 
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As a final analysis of the overall stability of disulfide-rich GMTs, we examined the ability of 
the peptides to withstand the chaotropic effects of GdHCl. GdHCl has the potential to 
interfere with the integrity of peptide structures via interactions either with the backbone of 
the peptides or through π-cation interactions with the solvent exposed aromatic side chains 
of the solvent exposed hydrophobic amino acid residues (43,44). The five GMTs in the 
current study were unaffected by the chemical assault, most likely because of the presence 
of the ICK motif. A previous study on AS-48, a globular cyclic peptide also containing a 
hydrophobic surface patch, but lacking disulfide bridges, showed that the peptide was 
degraded by 6.3 M GdHCl at 25 °C (45). Cyclic peptides containing the ICK motif were 
subsequently found to be stable when subjected to GdHCl (40). Therefore, we conclude that 
disulfide bridges confer chemical stability to spider-derived ICK GMTs.  
 
Conclusions 
In conclusion, GpTx-I, HwTx-IV, HnTx-IV and PaurTx-III are stable in physiologically 
relevant environments. SgTx-I underwent partial degradation when subjected to proteolytic, 
acidic (pH 2) and extreme temperatures, probably because of the length of the C-terminal 
of this particular peptide. To avoid similar degradation in the use of GMTs as templates for 
drug design, a three to four residue C-terminal appears to be preferable for stability. 
Hydrophobic interactions between the C-terminal chain and the hydrophobic patch on the 
surface of the peptide may provide additional stability to GMTs against hydrolysis in strongly 
alkaline solutions, and these hydrophobic interactions can be augmented by designing GMT 
analogues with a shorter loop 3 stabilized by a proline on the turn between loop 2 and 3.  
Spider-derived GMTs are undeniably among nature’s more interesting pharmacological 
probes in the study of voltage-gated ion channels (10,15,36). The current work has provided 
additional insight into the potential of these ICK peptides as templates for drugs designed to 
target ailments linked to the voltage-gated ion channels. 
Materials and Meth 
Peptide Synthesis 
Peptides were synthetically assembled using automated solid phase peptide synthesis on a 
Symphony peptide synthesizer (Protein Technologies Inc. Tucson, AZ, USA), as previously 
described (28). Side chain protecting groups were removed and the reduced peptides were 
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released from the resin using 96% (v/v) trifluoroacetic acid (TFA), 2% (v/v) water and 2% 
(v/v) triisopropylsilane (TIPS) as before (28).  
Oxidative folding of PaurTx-III and GpTx-I was achieved in 16 h at room temperature in 7.5% 
(v/v) acetonitrile (ACN), 0.1 M Tris(hydroxymethyl)aminomethane, 0.81 mM reduced 
glutathione (GSH) and 0.81 mM oxidized glutathione (GSSG) at pH 7.7 (20). ProTx-I and 
SgTx-I were oxidized over 72 h at 4 °C in a buffer containing 0.1 M ammonium acetate, 2 M 
urea, 2.5 mM GSH and 0.25 mM GSSG at pH 7.8 (21). HnTx-IV and HwTx-IV were oxidized 
at room temperature for 16 h in a buffer containing 0.1 M Tris, 5 mM GSH, 0.5 mM GSSG 
pH 8, oxidation of HnTx-IV additionally required 0.1 M NaCl in the buffer solution (28,46,47). 
The peptides were purified using RP-HPLC on a C18 column using preparatory (8 mL/min) 
and semi-preparatory (3 mL/min) flow rates on gradients obtained using solvent A (0.05% 
TFA in water) and solvent B (0.05% TFA in 90% ACN) as previously described (28). 
 
NMR Structure Calculation for PaurTx-III 
Data used for PaurTx-III structure calculations was acquired on a Bruker Avance 600 MHz 
NMR spectrometer (Bruker, Billerica, MA, USA) equipped with a cryoprobe. The solution 
NMR structure for PaurTx-III was calculated using previously described protocols (28), on a 
Bruker Avance 600 MHz NMR spectrometer equipped with a cryoprobe. CCPNMR Analysis 
2.4.1 (CCPN, University of Cambridge, Cambridge, UK) was used for amino acid 
assignment (48,49). The solution NMR structure for PaurTx-III was calculated as previously 
described (28) using the AUTO and ANNEAL functions in CYANA 3.97 (Güntert Group, 
Goethe-University Frankfurt, Frankfurt, Germany)(50) to refine peak assignments. Dihedral 
angle restraints were generated using TALOS-N (Bax Group, NIH, Pike Bethseda, MD, 
USA) (51). After initial structure determination on CYANA, protocols on the RECOORD 
database (52), were used to generate 50 structures which were then refined in a water shell 
(53), and a final set of 20 structures was chosen based on the lowest energy, best MolProbity 
scores (37), and fewest distance and dihedral angle violations (Table 1). PaurTx-III structure 
and restraints have been submitted to the Protein data bank (PDB ID: 5WE3) and the 
Biomagnetic Resonance Data bank (BMRB: 30317). 
 
Peptide Quantification 
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Stock concentrations of peptides were quantified using Nanodrop at 280 nm using extinction 
coefficient (ε280) values as follows: GpTx-I ε280 = 7365 M−1 cm−1; HnTx-IV ε280 = 7365 
M−1•cm−1; HwTx-IV ε280 = 7365 M−1•cm−1; PaurTx-III ε280 = 12,865 M−1•cm−1; SgTx-I ε280 
= 8855 M−1•cm−1. Unless otherwise stated, stock concentrations of the peptides were 300 
μM in water. 
 
Analytical RP-HPLC 
For experiments monitored using RP-HPLC, solvent A (0.05% TFA in water) and solvent B 
(0.05% TFA in 90% ACN) were used on a C18 phenomenex column at a flow rate of 0.3 
mL/min using a 1% gradient of 0–50% solvent B and monitored at 215 nm. 
 
Thermal Stability 
A Bruker 500 MHz Avance nuclear magnetic resonance (NMR) spectrometer was used to 
heat the peptides (1 mg/mL in 9:1 (v/v) H2O/D2O) and to monitor structural changes at 
temperatures ranging from 20 to 80 °C. 1D 1H NMR spectra and 2D nuclear Overhauser 
effect spectroscopy (NOESY) (200 ms mixing time) spectra were acquired and processed 
using TopSpin 3.5 (Bruker, Billerica, MA, USA) and CCPNMR Analysis 2.4.1 was used in 
the assignment of the NOE spectra (48,49). 
Peptides were also subjected to boiling (100 °C) in water for 30 min using a heating block, 
cooled to 25 °C and analyzed using analytical RP-HPLC. The mass of the degradation 
products from SgTx-I and ProTx-I were determined using MALDI-MS. 
 
pH Dependent Hydrolysis 
The ability of the peptides to withstand varying pH conditions was monitored by incubating 
the peptides (30 μM) at 37 °C in phosphate buffer adjusted to pH 2, 4, 7.4, 9 and 12 using 
phosphoric acid and/or sodium hydroxide. After 24 h, each sample was adjusted to pH 2 
using phosphoric acid and analytical RP-HPLC was used to quantify the percentage of 
peptide remaining by examining the height of the peaks at each pH relative to pH 4 (the pH 
where most samples showed highest stability). Reduced PaurTx-III was used as a control.  
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Proteolytic Degradation 
Human serum isolated from male AB plasma was used to examine the stability of the 
peptides to proteolysis. Peptides (30 μM) were incubated with human serum or phosphate 
buffered saline (PBS) at 37 °C and reactions were stopped at 0, 1, 8 or 24 h by placing the 
samples on ice, 6 M urea was used to denature the proteases and 20% trichloroacetic acid 
was used to precipitate the proteases. Peptides were separated from the proteases by 
centrifugation at 17,000 g for 10 min. Effects of proteolysis were examined using RP-HPLC, 
whereby retention times of the peptides were determined using the PBS controls at 0 h and 
percentage of peptide remaining in human serum was obtained from the heights of the 
peaks at each time point relative to 0 h. RBP-100, a linear peptide lacking any disulfide 
bonds, was the control. 
 
Chaotropic Stability 
Chemical stability of the peptides (12 μM) was studied by incubating them in 6 M GdHCl at 
25 °C for 16 h. Analytical RP-HPLC was used to compare the peptides in GdHCl to peptides 
in water. RBP-100 was used as a control. 
 
RMSD Calculation 
MOLMOL (Version 2k.2, Institute of Molecular Biology and Biophysics, ETH, Zürich, 
Switzerland) (38) was used to calculate the global atomic RMSDs of the backbone of the 
GMTs including the amino acid residue following the last cysteine to the C-terminal of each 
sequence. RMSD values of the amino acids prior to the final cysteine were also calculated. 
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Chapter 6 
 
Bimodal modulation of NaV1.7 using double-knottins 
 
  
 165 
Overview 
In addition to being good drug leads as demonstrated by the ability to optimize potency and 
selectivity of GMTs and by the exceptional stability of these ICK (also known as knottin) 
peptides, Chapter 6 explores the application of GMTs as pharmacological tools. Inspired by 
reports on the discovery of bivalent spider toxins that modulate the function of acid sensing 
ion channels and transient receptor potential cation channel subfamily V member 1 (1,2), 
this chapter sought to biosynthetically produce bivalent GMTs known as double-knottins. In 
keeping with the theme of the project, the double-knottins were fashioned to target NaV1.7. 
gHwTx-IV, the potent, membrane binding analogue of HwTx-IV (3), was studied in 
combination with D1Ia, an optimized version of CcoTx-I (4). In addition to successfully 
ligating the peptides, this chapter reveals that GMTs can cooperatively modulate activity of 
NaV1.7, a feature that can be exploited for optimizing inhibition of the channel for drug 
development. 
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Efficient enzymatic ligation of inhibitor cystine knot spider venom peptides: using 
sortase A to form double-knottins to probe voltage-gated sodium channel NaV1.7 
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Abstract 
Gating modifier toxins from spider venom are disulfide-rich peptides that typically comprise 
a stabilizing inhibitor cystine knot (ICK). These knottin peptides are being pursued as 
therapeutic leads for a range of conditions linked to transmembrane proteins. Recently, 
double-knottin peptides discovered in spider venom and produced by recombinant 
expression, have provided insights into the pharmacology of transmembrane channels. 
Here, we use chemoenzymatic ligation to produce double-knottins to probe the effect of 
bivalent modulation on the voltage-gated sodium channel subtype 1.7 (NaV1.7), which is 
implicated in pain signaling. Monovalent knottins were oxidatively folded, then biochemically 
conjugated using sortase A, to form double-knottins. The structural integrity of the peptides 
was confirmed using NMR, and fluorescence-based activity assays provided evidence 
suggesting that co-incubated monovalent and bivalent knottins can co-operatively modulate 
NaV1.7. We anticipate that double-knottins will provide novel tools for enhancing our 
understanding of, and design strategies for, therapeutically relevant voltage-gated ion 
channels. 
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Keywords: Chemoenzymatic ligation, pain, peptide–lipid bilayer interactions, tri-molecular 
complex, voltage-gated ion channels, sortase A  
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ACN, acetonitrile; ESI-MS, electrospray ionization mass spectroscopy; FLIPR, fluorescence 
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reversed-phase high performance liquid chromatography; SPR, surface plasmon 
resonance; SUV, small unilamellar vesicle; TFA, trifluoroacetic acid. 
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Introduction 
Voltage-gated ion channels have an important role in numerous pathophysiological 
processes and are being pursued as therapeutic targets for conditions including epilepsy, 
stroke, irritable bowel syndrome, cardiovascular conditions and pain (1,5-10). This study is 
focused on the voltage-gated sodium channel subtype 1.7 (NaV1.7), which has been 
genetically validated as a key modulator in pain pathways (8,9,11-13). The functional  -
subunits of voltage-gated sodium channels, which comprise four homologous domains (I-
IV; Figure 1A), are the primary targets for peptide modulators. Activation of the voltage 
sensors in domains I–III turns on Na+ conduction in the adjacent pore region, whereas the 
voltage sensor in domain IV is linked to inactivation of the channels (14). Spider-venom 
peptides known as gating modifier toxins (GMTs) influence the function of voltage-gated ion 
channels by binding to one or more of the voltage sensor domains and thereby allosterically 
modulating activation or inactivation of the channel (15).  
Spider GMTs typically comprise 30–40 amino acid residues, and usually possess excellent 
chemical, thermal and biological stability due to the three conserved disulfide bonds that 
form an inhibitor cystine knot (ICK) motif (16-19). Spider GMTs (henceforth referred to as 
knottins) have been used to probe the pharmacology of several voltage-gated ion channels, 
and some are being pursued as drug leads (15,20-22). Recently, bivalent spider knottins, 
also known as “double-knottins” have been identified in spider venom (1,2,23). The double-
knottins, DkTx and Hi1a, have proven to be useful pharmacological probes for TRPV1 and 
ASIC1a, respectively (1,2,24-26); whereas CpTx-I was proposed to elicit activity primarily 
via interactions with the cell membrane (23), but so far there are no reports of naturally 
occurring double-knottins that target voltage-gated ion channels. However, conversion of a 
spider-derived knottin, GpTx-I, to a bivalent knottin using polyethylene glycol (PEG) linkers, 
increased the peptide residence time on NaV1.7 compared to monovalent GpTx-I (27). In 
the current study, we used amino acid linkers to develop hetero- and homo-bivalent knottins 
that are designed to target NaV1.7. 
We used a panel of four monovalent knottins: CcoTx-I and CcoTx-II (28), D1Ia (4), and 
gHwTx-IV (3), to examine the effects of co-incubation of unlinked knottins at NaV1.7 (see 
Figure 1B for sequences). All the monovalent knottins in the current study modulate the 
activation of voltage-gated sodium channels (3,4,28), and by consensus, are believed to 
bind to the domain II voltage sensor of NaV1.7 (29-33). CcoTx-I and CcoTx-II differ by a 
single amino acid (Asp32 on CcoTx-I and Tyr32 on CcoTx-II) (28), and were used to 
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examine the effect of co-incubating two homologous peptides at NaV1.7. D1Ia and gHwTx-
IV are optimized analogues of CcoTx-I and HwTx-IV respectively (3,4), and were included 
to examine the effect of co-incubation of heterologous knottins at NaV1.7 (Figure 1B). 
Bivalent knottins were assembled from fragments of gHwTx-IV and D1Ia to form DK02 
(gHwTx-IV + D1Ia), DK03 (gHwTx-IV + gHwTx-IV), DK04 (D1Ia + D1Ia) and DK05 (D1Ia + 
gHwTx-IV) (Figure 1B). So far, double-knottins have been produced using bacterial 
expression (1,25), or copper catalyzed 1,3-dipolar cycloaddition in the case of GpTx1 (27). 
Here, for the first time, we utilized an enzymatic approach, to obtain double-knottins. 
Chemically synthesized single-knottins were oxidized, then sortase A was used to ligate the 
C- and N-termini of the folded peptides to form double-knottins (Figure 1C). 
 
 
Figure 1. Architecture of voltage-gated sodium channels 
(A) Left: Cartoon representation of a NaV channel. The channel comprises four homologous domains (I–
IV), each with six transmembrane helices. Helices 1–4 in each domain (shown in blue) form the voltage 
sensors, while helices 5–6 from each domain (shown in grey) come together to form the pore domain. 
The schematic is derived using information from available NaV structures (Including PDB ID: 4EKW and 
PDB ID: 5X0M). Right: Ribbon representation showing a view of the channel from the extracellular side 
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of the membrane, with the four homologous voltage-sensor domains and the Na+ conducting pore. Figure 
adapted from (34). (B) Sequences of the peptides used in this study are aligned along the cysteine 
residues (yellow highlight) that form the knottin motif. Fragments used for ligation are highlighted in blue 
(N-terminal knottin (fragment 1), containing the C-terminal sortase A recognition motif (GLPATGG), or 
red (C-terminal knottin (fragment 2), containing the N-terminal polylgycine nucleophile). The resulting 
double-knottins and their linker regions are highlighted in green. An asterisk indicates C-terminal 
amidation. (C) The process of sortase A mediated bioconjugation whereby the enzyme cleaves between 
T and G in the recognition motif, leading to formation of an amide bond between the C-terminus and a 
nucleophilic polyglycine. 
 
Sortase is an enzyme employed by many Gram-positive bacteria to covalently link surface 
proteins to the cell membrane. We used an optimized pentamutant of Staphylococcus 
aureus sortase A (abbreviated SrtA5) because of its highly efficient catalytic activity (35), 
and its success in intramolecularly ligating disulfide-rich peptides for the purpose of 
cyclization (36,37). Sortase A-mediated ligation involves recognition of a C-terminal 
LPXTGXn sequence (where X can be any amino acid), followed by hydrolytic cleavage 
between T and G to form an intermediate thioacyl by a cysteine on the sortase active site 
and the threonyl C-terminus. A nucleophilic N-terminal polyglycine resolves the intermediate 
to form an amide bond (Figure 1C) (38). We used nuclear magnetic resonance (NMR) to 
confirm correct folding of the peptides, surface plasmon resonance (SPR) to assess binding 
of the peptides to model membranes, and whole-cell patch clamp electrophysiology and the 
fluorescence imaging plate reader (FLIPRTETRA) platform to assess their potency at NaV1.7 
compared to monovalent knottins. We then used the monovalent and bivalent knottin 
peptides to draw insights about the accessibility of NaV1.7 binding sites.  
 
Results and Discussion 
Synthesis, oxidative folding and biochemical ligation 
Our strategy to obtain double-knottins involved chemical synthesis and oxidative folding of 
monovalent knottin fragments, followed by enzymatic ligation of the fragments using SrtA5. 
Reduced linear precursors containing a C-terminal glycine plus the sortase A recognition 
sequence (GLPATGG) (D1Ia_GLPATGG and gHwTx-IV_GLPATGG), or an N-terminal 
nucleophilic polyglycine sequence (GGGG_D1IA, and GGGG_gHwTx-IV) were successfully 
produced (see Figure 1B for sequences and Supporting information Figures S1–S3). D1Ia, 
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gHwTx-IV, CcoTx-I, and CcoTx-II were also synthesized as monovalent knottin controls for 
pharmacological experiments (see Figure 1B for sequences and Supporting information 
Figures S1–S3). The monovalent knottins for ligation were oxidized and purified giving yields 
of 15–25%, except for GGGG_gHwTx-IV, which contained several isomers, allowing a yield 
of only ~ 4% of the correctly folded peptide (Table 1). Most reported protocols using wild-
type SrtA or SrtA5 for bioconjugation allowed reactions to proceed for up to over 2 h 
(36,39,40); however, we found that ligation using SrtA5 for 15 min at 37 ºC with shaking, 
was optimal to minimize loss of double-knottin products to hydrolysis. Yields were calculated 
from the starting quantity of the fragment containing the GLPATGG motif, and were between 
40–50% except for DK03 with a yield of 10% (Table 1, Figure 2A, B). The low DK03 yield 
was a result of the formation of a SrtA5 hydrolysis product eluting with the same retention 
time as the ligated product, making it challenging to obtain a pure final product. 
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Table 1. Masses and yields for peptides examined in this study. 
Peptide Theoretical ion 
massa (m/z) 
Experimental ion 
massa (m/z) 
% Yieldb, c 
CcoTx-I 4044.6 4042.5 25 
CcoTx-II 4092.7 4092.5 20 
gHwTx-IV 4024.7 4024.6 15 
gHwTx-IV_GLPATGG 4579.3 4578.9 20 
GGGG_gHwTx-IV 4253.0 4252.9 4 
D1Ia 3967.8 3967.5 20 
D1Ia_GLPATGG 4522.3 4522.0 25 
GGGG_D1Ia 4196.0 4195.8 17 
DK02 8643.2 8643.0 50 
DK03 8700.0 8699.6 10 
DK04 8586.2 8586.0 44 
DK05 8643.2 8643.0 67 
aTheoretical ion mass (m/z) was calculated from the peptide sequence. 
Experimental ion mass (m/z) is that observed by ESI-MS. 
b % Yield for monovalent peptides was calculated from crude, reduced 
starting material and final oxidation product.  
c % Yield for bivalent peptides was calculated from oxidized, pure monovalent 
knottin starting material and final ligation product. 
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Figure 2. Biochemical ligation of four double-knottins. 
(A) Analytical RP-HPLC traces showing the ligation process from 0 min to 15 min. Peaks of fragment 1, 
fragment 2, SrtA5 hydrolysis products and the resulting double-knottin are shown. (B) Analytical RP-
HPLC traces of the pure double-knottins and individual gradients used to analyze the purity of the 
peptides. (C) Comparison of the 1H NMR spectra of double-knottins and individual fragments, which 
indicates that the double-knottins are correctly folded. 
 
The use of SrtA5 for ligation of already folded knottin fragments ensured that various 
combinations of monovalent knottins could be used and that only correctly folded double-
knottins were obtained. Previous reports affirm that initially oxidizing disulfide-rich peptides 
prior to C–N ligation using SrtA minimizes misfolded product (40). Native chemical ligation 
has been used as a strategy to make large disulfide rich peptides (41-43), but it requires the 
presence of reducing agents (44), and therefore oxidative folding is necessary after the 
ligation, which presents a risk of producing non-native disulfide isomers. A copper catalyzed 
1,3-dipolar cycloaddition reaction was used in the production of a bivalent GpTx-I (27); 
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however, click chemistry leaves an 1,2,3-triazole moiety as a permanent footprint on the 
final product, whereas SrtA5 allows for the use of proteogenic amino acids. Peptiligases 
(and optimized versions like omniligase), which support an increased product–to–hydrolysis 
ratio and a broader range of substrates leading towards footprint-free ligated products are 
limited in their use because these enzymes require the presence of a C-terminal 
carboxamidomethyl-ester (45-48). In contrast, SrtA5 offers a straightforward approach 
applicable to precursor peptides produced by chemical synthesis or recombinant methods. 
Two drawbacks that we experienced in the use of SrtA5 for production of double-knottin 
were: (1) the requirement of up to four glycines as the nucleophilic element to minimize steric 
hindrance (trials using shorter sequences (DK01) were unsuccessful) and (2) the potential 
difficulty of separating hydrolysis products from the final product as was the case for DK03. 
Generally, however, SrtA5 proved to be an efficient method, not only with respect to high 
yields and rapid reaction times, but also because of the ability to reclaim unligated products 
as well as the enzyme itself for future ligations. 
 
NMR analysis of double-knottins 
One-dimensional 1H spectra of the double-knottins were compared to the monovalent 
peptide fragments to confirm that the bivalent peptides were correctly folded. For all 
peptides, there was good dispersion of peaks in the amide region (6.5–10 ppm) of the NMR 
spectra, and the double-knottin spectra overlapped well with the monovalent knottins (Figure 
2C). Additional NMR experiments were conducted on DK02, gHwTx-IV_GLPATGG and 
GGGG_D1IA to further confirm that the double-knottin had adopted the correct secondary 
structure with native disulfide-bond connectivity. H chemical shifts obtained from TOCSY 
and NOESY spectra of DK02 were in good agreement with shifts from gHwTx-IV_GLPATGG 
and GGGG_D1Ia, although we observed a downfield shift for Trp33 and Pro38 in DK02 
compared to gHwTx-IV_GLPATGG, possibly arising from constraints introduced by linking 
the monovalent fragments (Figure 3A). Furthermore, all Xaa-Pro (where Xaa is the amino 
acid preceding the proline) peptide bonds adopted a trans configuration as evidenced by 
the presence of NOEs between the H protons of prolines and the H of the preceding 
residue; no cis-trans isomerization was observed. Most spider GMT knottins contain a 
conserved hydrophobic patch and charged ring (18,49,50), with the aromatic residues of the 
hydrophobic patch often being involved in – interactions. Expected – interactions 
between aromatic rings of Trp6–Trp30 and Phe50–Trp72 were evident due to the upfield 
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shifted Ile5 H, Arg29 H, Met49 H and Arg71 H, preceding each aromatic amino acid 
involved in the – interactions (Figure 3B). The DK02 linker was flexible as expected, with 
very few NOEs from residues in the GLPATGGGG linker; assignment of most of these 
residues was only possible in the H–H and side-chain region of the 2D spectra. 
 
Figure 3. Analysis of peptide integrity using NMR. 
(A) Secondary H chemical shifts of gHwTx-IV_GLPATGG, GGGG_D1Ia and the resultant DK02 were 
obtained from sequential assignment of the amino acids using 2D TOCSY and NOESY spectra. The 
secondary H shifts of DK02 aligned well with each fragment. Sequences of the peptides are shown 
beneath the graph. Asterisks indicate indicates C-terminal amidation. (B) Trp6/Trp30 and Phe50/Trp72 
are involved in – interactions, as evidenced by upfield shifted H residues preceding each of the 
aforementioned aromatic amino acids. 
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Pharmacology of double-knottins and co-incubated monovalent knottins at NaV1.7 
We used patch-clamp electrophysiology to quantify the ability of each double-knottin to 
inhibit currents from human NaV1.7 stably expressed in human embryonic kidney cells 
(HEK) 293 cells. All four double-knottins blocked >80% of NaV1.7 currents (Figure 4). To 
further explore the pharmacology of the monovalent and bivalent knottin peptides, 
FLIPRTETRA assays were used to examine the ability of the peptides to inhibit NaV1.7 
expressed in SH-SY5Y neuroblastoma cells (51). The SH-SY5Y neuroblastoma cells were 
chosen for this assay because this neuronal cell line offers an environment that is similar to 
that which NaVs may be found in vivo. Co-incubation of CcoTx-I with CcoTx-II, peptides with 
high sequence similarity, resulted in a potency and Hill slope nearly equivalent to that of 
individually incubated CcoTx-I and CcoTx-II (CcoTx-I co-incubated with CcoTx-II IC50 = 5 ± 
1 nM, Hill slope = –1.2 ± 0.3; CcoTx-I IC50 = 15 ± 1 nM, Hill slope = –1.2 ± 0.1; CcoTx-II IC50 
= 8 ± 1 nM, Hill slope = –1.1 ± 0.1) (Figure 5A, Table 2). Conversely, co-incubation of gHwTx-
IV with D1Ia (peptides with high sequence diversity) resulted in an intermediate potency, 
accompanied by a much steeper Hill slope (gHwTx-IV co-incubated with D1Ia IC50 = 53 ± 
10 nM, Hill slope = –6.0 ± 0.3) compared to individually incubated gHwTx-IV and D1Ia 
(gHwTx-IV IC50 = 28 ± 2 nM, Hill slope = –1.8 ± 0.2; D1Ia IC50 = 328 ± 38 nM, Hill slope = –
1.3 ± 0.2); this is suggestive of cooperative binding of gHwTx-IV and D1Ia (Figure 5B, Table 
2). As mentioned in the introduction, because consensus predicts that gHwTx-IV and D1IA 
both bind to domain II of NaVs (3,4,28-33,52), the evidence for cooperativity seen here 
suggests that there is more than one possible binding site within domain II that is accessible 
to gHwTx-IV and D1Ia.  
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Figure 4. Efficacy of monovalent and bivalent knottins.  
Peak currents (pA) from NaV1.7 stably expressed in HEK 293 cells measured using whole-cell patch 
clamp electrophysiology. Each data point represents 1 min. White circles are baseline current, while 
purple, grey, green and blue circles represent 0.1, 1, 10 and 100 nM peptide respectively. The red circles 
represent the nonspecific NaV channel blocker tetrodotoxin (TTX, 1 M). At the highest concentration 
used (100 nM), each of the monovalent and bivalent knottins inhibited 80–100% of NaV1.7 currents. 
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To explore the possibility that multiple NaV1.7 binding sites are simultaneously accessible 
to spider knottins, we measured the activity of the double-knottins at NaV1.7 channels 
expressed in SH-SY5Y neuroblastoma cells. DK03 (gHwTx-IV_GLPATGGGG_gHWTx-IV) 
showed comparable potency and Hill slope to gHwTx-IV (15 min incubation DK03 IC50 = 65 
± 9 nM, Hill slope = –1.4 ± 0.2; gHwTx-IV IC50 = 28 ± 2 nM, Hill slope = –1.8 ± 0.2) (Figure 
5C, Table 2), in a manner similar to co-incubated CcoTx-I and CcoTx-II (Figure 5A). This is 
probably because CcoTx-I, CcoTx-II and gHwTx-IV are examples of monovalent knottins 
that occupy a single binding site each on NaV1.7, and slow dissociation from this binding 
site allows observation of potency equivalent only to a single peptide at a time, both for co-
incubated monovalent knottins and for the DK03 double-knottin. To examine whether the 
peptides had achieved binding equilibrium, we compared the Hill slopes of the peptides 
following 15 min and 30 min incubation at 37 °C, such that a change in Hill slope indicated 
that the peptide had not achieved binding equilibrium, but a constant Hill slope indicated that 
the peptide had reached binding equilibrium. Increasing the incubation time for DK03 from 
15 min to 30 min, resulted in similar potency to the 15 min incubation time; however, a 
steeper Hill slope at 30 min indicated that binding equilibrium of this double-knottin had not 
been achieved (30 min incubation DK03 IC50 = 94 ± 9 nM, Hill slope = –3.5 ± 1.5) (Table 2). 
DK04 (D1IA_GLPATGGGG_D1IA) failed to achieve a binding equilibrium with NaV1.7 as 
evidenced by the lack of an observable effect upon incubation for 15 min and a steep Hill 
slope with large standard error of the mean upon incubation for 30 min (15 min incubation 
DK04 IC50 > 3000 nM; 30 min incubation IC50 > 1000 nM, Hill slope = –6.9 ± 18) (Figure 5D, 
Table 2); this is probably the result of slow association because of the bulk of the peptide 
combined with intramolecular forces present unique to DK04 that are absent from the other 
double-knottins.  
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Table 2. Peptide inhibition of NaV1.7 
 15 min a 30 min a Block of 
peak 
current b 
Peptide IC50 (nM) Hill slope IC50 (nM) Hill slope (% ) 
CcoTx-I 15 ± 1 –1.2 ± 0.1  – c – – 
CcoTx-II 8 ± 1 –1.1 ± 0.1 – – – 
CcoTx-I + CcoTx-II 5 ± 1 –1.2 ± 0.3 – – – 
gHwTx-IV 28 ± 2 –1.8 ± 0.2 – – 97 
D1Ia 328 ± 38 –1.3 ± 0.2 – – 96 
gHwTx-IV + D1Ia 53 ± 10 –6.0 ± 0.3 – – – 
DK02  756 ± 69 –1.8 ± 0.3 683 ± 78 –3.6 ± 1.0 94 
DK03 65 ± 9 –1.4 ± 0.2 94 ± 9 –3.5 ± 1.5 83 
DK04  > 3000 – > 1000 –5.9 ± 18 82 
DK05 657 ± 60 –2.8 ± 0.5 508 ± 43 –2.9 ± 0.5 95 
a Inhibition of NaV1.7 measured using Ca2+ dependent FLIPRTETRA assay on SH-SY5Y 
neuroblastoma cells, values are ± SEM n ≥ 3 repeats with peptide incubation times of 15 
min or 30 min 
b Peptide block of NaV1.7 peak current measured using patch-clamp electrophysiology on 
HEK 293 cells 
c Not tested 
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Figure 5. Inhibition of NaV1.7. 
(A–F) Concentration-response curves obtained for inhibition of Nav1.7 endogenously expressed in SH-
SY5Y cells by the monovalent and bivalent knottins. Data were obtained from a FLIPRTETRA-based 
calcium entry assay in which fluorescence intensity is directly proportional to NaV1.7 activation (51). Data 
are mean ± SEM, from n ≥ 3 experiments.  
 
Both DK02 (gHwTx-IV_GLPATGGGG_D1IA) and DK05 (D1Ia_GLPATGGGG_gHwTx-IV) 
had potencies similar to D1IA (15 min incubation D1Ia IC50 = 328 ± 38 nM, Hill slope = –1.3 
± 0.2; DK02 IC50 = 756 ± 69 nM, Hill slope = –1.8 ± 0.3; DK05 IC50 = 657 ± 60 nM, Hill slope 
= –2.8 ± 0.5) (Figure 5 E, F), suggesting that the D1IA binding site may be more readily 
accessible to these two double-knottins compared to the gHwTx-IV binding site. Following 
a 15 min incubation, DK05 had a steeper Hill slope than DK02 (15 min incubation DK02 Hill 
slope = –1.8 ± 0.3; DK05 Hill slope = –2.8 ± 0.5) (Figure 5E, F; Table 2), and whereas the 
Hill slope for DK02 was steeper at 30 min, indicating disturbance of equilibrium, DK05 had 
the same potency and Hill slope at 30 min compared to 15 min, indicating maintenance of 
equilibrium (30 min incubation DK02 IC50 = 683 ± 78 nM; Hill slope = –3.6 ± 1.0; DK05 IC50 
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508 ± 43 nM; Hill slope = –2.9 ± 0.5) (Table 2), once again suggesting probable cooperative 
binding of heterogeneous double-knottins at NaV1.7. The differences in activities and Hill 
slopes observed for DK02 and DK05, are evidence that the relative orientation of the 
individual knottins making up the double-knottins influences activity and accessibility to 
NaV1.7 binding sites. 
The probable cooperative binding at NaV1.7 provides the possibility for a novel approach to 
the modulation of voltage-gated sodium channels. Most approaches to modulate NaV1.7 
and similar channels have used small molecules, including XEN401 (now known as 
Funapide) (53), and PF-089771 (54), or monovalent knottins including analogues of GpTx-
1 (55), ProTx-II (56), and CcoTx-I (4). As seen previously for the non-native bivalent knottin 
produced from GpTx-I, the potential benefits of modulating NaV channels with bivalent 
knottins are prolonged peptide residence time on the channel, leading to a sustained 
inhibitory effect, and an ability to modulate inhibitory potency with varied PEG linkers (27). 
Bivalent modulation of NaV channels further offers the possibility to combine two optimized 
modalities that may facilitate improved selectivity, for example by combining a knottin that 
binds to a voltage-sensor domain with one that binds to the pore domain. Similar 
cooperativity could also be potentially obtained by linking knottins that bind to adjacent 
voltage-sensor domains. 
 
Peptide–lipid bilayer affinity using SPR 
The lipid bilayer is an additional component to consider when studying spider GMT knottin–
voltage-gated sodium channel interactions, with some monovalent knottins reportedly 
showing affinity for model lipid membranes (3,34,57,58). It has therefore been proposed that 
the lipid membrane can act to attract and concentrate spider GMT knottins near their binding 
sites on voltage-gated ion channels (59,60). Furthermore, CpTx-I, a naturally occurring 
double-knottin was proposed to elicit activity primarily via cell-membrane mechanism of 
action (23). Thus, we used SPR to compare the affinity of double-knottins and monovalent 
knottins to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/ 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-L-serine (POPS) (4:1 molar ratio) model membranes (Figure 5A, B). 
gHwTx-IV and D1IA showed similar binding maxima, but D1Ia dissociated from the model 
membrane at a faster rate than gHwTx-IV (Figure 5A). We have previously proposed that 
the increased potency of gHwTx-IV, compared to that of HwTx-IV, is associated to the ability 
of gHwTx-IV to be concentrated in the lipids near its active site of NaV1.7 (3). Similarly, DK03 
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and gHwTx-IV had slow dissociation rates from the lipid bilayer and DK03 had the highest 
overall potency amongst the bivalent peptides; therefore, it is possible that DK03 interacts 
with the channel and lipid membrane in a similar manner to gHwTx-IV. Conversely, DK04 
rapidly dissociated from the lipid bilayer at the same rate as D1Ia and therefore interaction 
with, and concentration within, the lipid bilayer is probably not an important component of 
their mechanism of interaction with NaV1.7. DK02 and DK05, the heterogenous double-
knottins, both washed off the channel rapidly in comparison to gHwTx-IV and DK03, 
suggesting that even though the overall structures of the double-knottins are conserved, 
additional intramolecular forces may reduce peptide affinities for the lipid bilayer. Overall, 
these results suggest that for some peptides, such as DK03 and gHwTx-IV, the peptide–
membrane interactions can be exploited to concentrate and optimize the potency of spider 
knottins. 
 
 
Figure 6. Affinity of peptides for POPC/POPS (4:1) model membranes. 
(A) SPR sensorgrams obtained for binding of peptides (64  M) to POPC/POPS lipid bilayers. (B) 
Concentration–response curves (0–64 M) were used to determine the affinity of the peptides for anionic 
model membranes. Response units are shown as the fraction of peptide bound to lipid (peptide/lipid 
mol/mol). 
 
Conclusion 
Here we employed SrtA5 in the first reported enzymatic conjugation of double-knottin 
peptides. Using SrtA5, we were able to achieve ligation of two monovalent knottins 
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incorporating only natural amino acids. SrtA5 proved to be an efficient method of ligation 
with an ability to obtain optimal yields of double-knottin peptides within 15 min. By using 
previously oxidized monovalent knottins, we were ensured of correctly folded double-
knottins. Furthermore, the modular approach meant that combinations of different knottins 
could be ligated with ease and any un-ligated starting material could be re-purified and 
repurposed for future reactions.  
By comparing the activity of monovalent and bivalent knottins, we revealed the possibility of 
cooperative binding at NaV1.7, a pharmacological behavior that has the potential to be 
exploited for optimizing the potency and selectivity of analgesics targeting NaV1.7. Future 
work will be directed towards fine-tuning the size of the pharmacophores and linkers of 
double-knottins with a view to engineer enhanced knottin peptides that modulate the activity 
of NaV channels with greater potency, selectivity and prolonged residence time on the 
channel. 
 
Materials and methods 
Peptide synthesis  
Peptides were assembled on a 2-chlorotrityl chloride resin or rink amide resin for C-terminal 
amidation, using Fmoc chemistry on a Symphony peptide synthesizer (Gyros Protein 
Technologies Inc., Tuscon, AZ, USA). D1Ia, gHwTx-IV, CcoTx-I and CcoTx-II (see Figure 
1B for sequences) were synthesized on a scale of 0.25 mmole and the individual fragments 
of the double-knottins were synthesized on a 0.5 mmole scale as described previously (58). 
 
Oxidative folding of monovalent knottins  
D1Ia, GGGG_D1Ia and D1Ia_GLPATGG were oxidized at 4 °C for 16 h in 100 mM 
tris(hydroxymethyl)aminomethane (Tris), 150 mM NaCl, 2 mM reduced glutathione (GSH) 
and 2 mM oxidized glutathione (GSSG) pH 8. gHwTx-IV, GGGG_gHwTx-IV and gHwTx-
IV_GLPATGG were oxidized at room temperature for 48 h in 100 mM Tris, 10% (v/v) 
isopropanol, 5 mM GSH and 1 mM GSSG pH 8. CcoTx-I and CcoTx-II were oxidized in 7.5% 
(v/v) acetonitrile (ACN), 100 mM Tris, 0.81 mM GSH and 0.81 mM GSSG pH 7.7 for 16 h 
(58). The final peptide concentration in all oxidation reactions was 0.1 mg/mL. After 
quenching the reaction mixtures by acidification to pH 3–4, they were diluted to less than 
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5% organic solvent (isopropanol or ACN) in solvent A (0.05% v/v TFA), filtered, and purified 
using preparatory and semi-preparatory reversed-phase (RP) HPLC as described 
previously (58). Electrospray ionization mass spectroscopy (ESI-MS) was used to identify 
fractions containing the correct mass, which were then pooled and lyophilized prior to 
ligation or use in experiments (Supporting information Figures S1–S3). 
 
Ligation to form double-knottins 
Double-knottin peptides were formed by incubating 90 M of fragment 1 (D1Ia_GLPATGG 
or gHwTx-IV_GLPATGG) with an excess of at least 1.5-fold of fragment 2 (GGGG_D1Ia or 
GGGG_gHwTx-IV) in a reaction buffer consisting of 50 mM Tris pH 7.5, 150 mM NaCl, 10 
mM CaCl2 and 30 M SrtA5. The reactions were conducted for 15 min at 37°C with shaking. 
Ligation was monitored via analytical RP-HPLC using a gradient of 0–60% solvent B (0.05% 
v/v TFA, 90% v/v ACN) over 60 min at a flow rate of 1 mL/min on a C18 column (Grace 
Vydac 150 mm x 2.1 mm, 5 m; Thermo Fisher Scientific, MA, USA). Ligation was slowed 
down by placing the reaction vessels on ice, then terminated by acidification with 1% v/v 
TFA to pH ~ 2. SrtA5 was separated from the ligation products by adding nickel-
nitrilotriacetic acid agarose sludge and centrifuging (Sigma 4K10 centrifuge, B. Braun, 
Melsungen, Germany) at 5500 rpm for 15 min (twice). The supernatant was then filtered and 
the ligation products were separated using semi-preparatory RP-HPLC on a C18 column 
(Grace Vydac 150 mm x 2.1 mm, 5 m) using a gradient of 0–60% solvent B over 60 min 
with flow rate of 3 mL/min. Ligation products were identified using ESI-MS prior to further 
purification using semi-preparatory and analytical methods. Bivalent knottins were 
lyophilized and stored at –20 °C. Reaction remnants of individual fragments were re-purified 
and stored for future ligations. 
 
Peptide quantification 
All peptides examined here contain several aromatic residues, including Trp and Tyr. Thus, 
peptide concentrations were determined from their absorbance at 280 nm, measured on a 
Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific, MA, USA), using the 
following extinction coefficients: D1Ia, GGGG_D1Ia and D1Ia_GLPATGG 280 = 11740 M-
1cm-1; gHwTx-IV, GGGG_gHwTx-IV and gHwTx-IV_GLPATGG 280 = 17430 M-1cm-1; 
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DK02 280 = 29170 M-1cm-1; DK03 280 = 34860M-1cm-1; DK04 280 = 23480M-1cm-1 and 
DK05 280 = 29170 M-1cm-1. 
 
NMR spectroscopy 
Structural integrity and correct folding (i.e. native disulfide bond arrangement) of the 
peptides was examined using NMR. Spectra were acquired on a Bruker 600 MHz Avance 
spectrometer equipped with a cryoprobe (Bruker, Callerica, MA, USA) as previously 
described (3,16,58). Spectra collected included one-dimensional 1H, and two-dimensional 
1H-1H TOCSY and NOESY (80 and 200 ms mixing times, respectively) and natural 
abundance 1H-15N HSQC and 1H-13C HSQC (61,62). Spectra were processed using 
TopSpin 3.5 (Bruker), then CCPNMR Analysis 2.4.1 (CCPN, University of Cambridge, 
Cambridge, UK) was used for resonance assignment (63,64). 
 
HEK 293 cell culture and inhibition of NaV1.7 assay using patch-clamp electrophysiology 
We used automated whole-cell patch-clamp electrophysiology (QPatch-16X instrument; 
Sophion A/S, Ballerup, Denmark) to examine the ability of each peptide to inhibit currents 
from NaV1.7 heterologously expressed in HEK 293 cells stably expressing human NaV1.7 
(α + β1 subunits) (SB Drug Discovery, Glasgow, UK). Cells were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) heat inactivated fetal bovine 
serum (HI-FBS), 1% (v/v) GlutaMAX, 1% (v/v) MEM non-essential amino acids, 0.004 
mg/mL blasticidin and 0.6 mg/mL geneticin. The intracellular solution contained (in mM) 140 
CsF, 1 EGTA, 5 CsOH, 10 HEPES, and 10 NaCl pH 7.2 and adjusted to 325 mOsm with 
sucrose. Extracellular solution comprised (in mM), 2 CaCl2, 1 MgCl2, 10 HEPES, 4 KCl, 145 
NaCl, pH 7.4 and 315 mOsm. Voltage-clamp experiments were performed in single hole 
configuration mode. Na+ currents were sampled at 25 kHz and filtered at 4 kHz. Na+ current 
was elicited by hyperpolarizing from a holding potential of -90 mV to -120 mV for 200 ms 
followed by a depolarizing step to 0 mV for 20 ms and returning to holding potential. The 
protocol was applied every minute. The peak current (negative value) for each protocol 
application was extracted using the Qpatch software and graphs were further generated by 
plotting the peak current value on the y-axis over the time of the experiment on the x-axis 
using PRISM 7™. 
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SH-SY5Y cell culture and activity assay on FLIPRTETRA 
Human neuroblastoma (SH-SY5Y) cells that endogenously express NaV1.7 (51), were 
maintained in Roswell Park Memorial Institute (RPMI) medium supplemented with 15% v/v 
HI-FBS, 2 mM L-glutamine, 100 units/mL penicillin and 100 units/mL streptomycin. Cells 
were incubated at 37 °C in 5% CO2, split at 70–80% confluence using 0.25% v/v 
trypsin/EDTA, then aliquoted into 96-well plates at a density of 40,000–50,000 cells per well 
72 h prior to FLIPRTETRA calcium 4 assays being performed (51). In preparation for the 
assays, the cells were washed in physiological saline solution: (in mM) 40 NaCl, 11.5 
glucose, 5.9 KCl, 1.4 MgCl2, 1.2 NaH2PO4, 5 NaHCO3, 1.8 CaCl2 and 10 HEPES, pH 7.4, 
containing 0.1 % w/v bovine serum albumin, then incubated for 30 min (37 °C, 5% CO2), 
with the calcium-sensitive Fluo-4 dye (Molecular Devices, Sunnyvale, CA, USA) 
reconstituted in PSS/BSA and 30 nM of OD1, a scorpion toxin that delays inactivation of, 
and selects for NaV1.7 within this assay (51). Peptides, prepared to achieve final 
concentrations starting at 3 M in PSS/BSA, were added to and incubated with the cells for 
15 min (37 °C, 5% CO2). For experiments examining the possibility of a delayed association 
rate to NaV1.7, the peptides were incubated with the cells for 30 min prior to commencing 
assays. The inhibitory potency of the peptides was then assessed by examining the ability 
of veratridine to activate NaV1.7. This was measured by following the fluorescence emission 
(excitation 470–495 nm and emission 515–575 nm) of the dye for 5 min, which is an indicator 
of Ca2+ influx into cells. Tetrodotoxin was used as a positive control. Data were normalized 
to the difference between maximum and minimum fluorescence intensity after subtraction 
of buffer contribution as previously reported (3). Sample raw data is provided (Supporting 
information Figure S4). Differences in potency observed between the FLIPRTETRA assay 
compared to the Q-patch electrophysiology platform are due to several reasons (1) the 
difference in cell lines (SH-SY5Y neuroblastoma cells for FLIPRTETRA compared to HEK 293 
for electrophysiology), (2) the mechanism of activation (veratridine for FLIPRTETRA compared 
to changes to voltage for Q-patch, (3) the method of addition of test compounds to the cells 
(each concentration of a peptide is added to confluent cells on a 96 well plate in the 
FLIPRTETRA assay, whereas concentrations are titrated to give a cumulative effect on the 
whole-cell patch clamp platform. 
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Binding of peptides to model lipid membranes 
Small unilamellar vesicles comprised of POPC and POPS (4:1 molar ratio) (Avanti Polar 
Lipids, Alabaster, AL, USA) and were prepared as previously reported (3). The binding of 
the peptides to lipid bilayers was monitored using SPR using a Biacore 3000 instrument (GE 
Healthcare Life Sciences, Chicago, IL, USA) as previously described (3,65). 
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Supporting information 
Figure S1. 
Analytical HPLC traces obtained using 2%/min gradient 0–60% solvent B, with a flow rate of 0.3 mL/min 
for D1IA and gHwTx-IV, and 1%/min 0–60% solvent B, flow rate of 0.3mL/min for CcoTx-I and CcoTx-II 
(first 40 min of traces shown). Column is C18 analytical column (Grace Vydac, 150 x 2.1 mm, 5 m; 
Thermo Fisher Scientific, Waltham, MA). Observed ESI-MS spectra and amide region of 1D 1H NMR 
spectra are also shown. D1Ia calculated mass = 3967.8; gHwTx-IV calculated mass = 4024.7; CcoTx-I 
calculated mass = 4044.6; CcoTx-II calculated mass = 4092.7. 
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Figure S2.  
Analytical HPLC traces of oxidized monovalent peptides prior to ligation, obtained using 2%/min gradient 
0–60% solvent B, with a flow rate of 0.3 mL/min for gHwTx-IV_GLPATGG, GGGG_gwTx-IV and 
D1Ia_GLPTGG, and a 1%/min gradient 0–60% solvent B, first 40 min shown for GGGG_D1Ia. Column 
is C18 analytical column (Grace Vydac, 150 x 2.1 mm, 5 m; Thermo Fisher Scientific, Waltham, MA). 
Observed ESI-MS spectra and amide region of 1D 1H NMR spectra are also shown. gHwTx-
IV_GLPATGG calculated mass = 4579.3; GGGG_gHwTx-IV calculated mass = 4253.0 D1Ia_GLPATGG 
calculated mass = 4522.3; GGGG_D1Ia calculated mass = 4196.0. 
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Figure S3. 
Analytical HPLC traces of ligated double-knottins obtained using 2%/min gradient 0–60% solvent B with 
a flow rate of 1 mL/min of DK02 and DK04, and a 1%/min gradient 0–60% solvent B for DK03 and DK05 
(first 40 min shown). Column is C18 analytical column (Grace Vydac, 150 x 2.1 mm, 5 m; Thermo Fisher 
Scientific, Waltham, MA). Observed ESI-MS spectra and amide region of 1D 1H NMR spectra are also 
shown. DK02 calculated mass = 8643.2; DK03 calculated mass = 8700.0; DK04 calculated mass = 
8586.2; DK05 calculated mass = 8643.2. 
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Figure S4. 
Example of raw data from a FLIPRTETRA assay. SH-SY5Y cells were incubated with scorpion toxin OD1 
in PSS/BSA buffer and calcium-4 dye for 30 min prior to incubation of knottins for 15 min (51). Veratridine 
was added to the cells and activity measured as the ability of a knottin to prevent veratridine activation. 
Influx of Ca2+ into the cells is followed by fluorescence emission of the dye (excitation 470–495 nm and 
emission 515–575 nm) for 5 min. Tetrodotoxin (TTx) was used as a positive control (3,51). 
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Chapter 7 
 
Conclusion 
 
Solution NMR structures.  
Some of the GMT structures solved during the candidature: CcoTx-I PDB ID: 6BR0, CcoTx-II PDB ID: 
6BTV, gHwTx-IV PDB ID: 5TLR, PaurTx-III PDB ID: 5WE3 
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Overview 
GMTs can be extracted from the cocktail of molecules produced by some spiders. 
Throughout this candidature, these peptides have proven to be fascinating pharmacological 
probes and possible drug leads for voltage-gated ion channels. The work presented in this 
thesis has focused on the amphipathic nature of GMTs and how a conserved hydrophobic 
patch and charged ring may influence interactions with lipid bilayers and with voltage-gated 
sodium channels. This chapter is a summary of the major findings and suggestions for future 
directions. 
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Why study the tri-molecular complex? 
The conserved hydrophobic patch and charged ring on the surface profiles of GMTs 
resembles many peptides that interact with the cell membrane (1,2). Prior to the start of this 
project, studies had shown that GsMTx-IV was capable of modulating mechano-selective 
channels solely via interactions with the cell membrane (3). Furthermore, affinity of VsTx-I 
and HaTx-I for voltage-gated potassium channels had been associated to an affinity for the 
cell membrane surrounding the channels (4,5). Several additional GMTs including ProTx-II, 
ProTx-I and SgTx-I (6-9), amongst others (10), had shown affinity for model membranes, 
with proposals that the pharmacology of some of these peptides was dependent not only on 
interactions with their target transmembrane channels, but also with the lipid membrane 
(11,12). The term tri-molecular complex was thus coined to describe the three-way 
interaction between GMTs the channels that they modulate and the lipid bilayer (8,12). 
In Chapter 2, a critical review of the literature led to questions about the validity of the 
existence of the tri-molecular complex. Of particular concern with early GMT–lipid bilayer 
studies was the use of high concentrations of anionic phosphatidylglycerol phospholipids 
which are not expected to be found on the outer leaflet of mammalian cells and especially 
not on human axonal membranes (13). A second concern was that initial studies had 
reported the possibility that GMTs could insert up to 9 Å into the lipid bilayer, but these 
studies had used model membranes prepared in unbuffered solutions lacking NaCl (5,9), 
therefore the integrity of these model membranes was questionable. Despite these 
concerns, there was evidence that the pharmacology of ProTx-I was dependent on the lipids 
surrounding voltage-gated ion channels (11), and that a reduction in the lipid affinity of 
ProTx-II could be accompanied by a reduction in potency at NaV1.7 (14). 
A motivating conclusion from Chapter 2 was that there was a possibility to use GMT 
lipid affinity to manipulate GMT activity at voltage-gated ion channels, therefore in 
Chapter 3 the objective was to establish the extent to which unmodified GMTs interact with 
lipid bilayers and whether these interactions are related to GMT amphipathicity and to GMT 
interactions with voltage-gated ion channels (Chapter 3). A second objective with respect to 
the tri-molecular complex, was to include the lipid bilayer in the design process of potent 
and selective modulators of NaV1.7 (Chapter 4). 
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How does GMT amphipathicity influence interactions with the lipid bilayer and with 
voltage-gated ion channels? 
For the first time, a panel of nine native (unmodified) GMTs was examined for their affinity 
for rationally chosen model lipid bilayers, and how this affinity relates to activity at a panel 
of NaVs (Chapter 3) (15). Model lipid bilayers formed using phosphatidylcholine (PC) 
phospholipid headgroups were chosen for their abundance in healthy cell membranes (16), 
phosphatidylserine and phosphatidylinositol phospholipid headgroups were chosen to study 
the effects of anionic charge and sugar moieties on GMT affinity for lipid bilayers, and 
mixtures of PC, sphingomyelin and cholesterol (CHOL) or PC, ceramide-1-phosphate and 
CHOL were used to mimic raft-like lipid domains that may surround voltage-gated sodium 
channels (14,17). Furthermore, particular attention was applied to optimizing the oxidative 
folding of these disulfide-rich peptides (Chapter 3, Supporting information Table S1), and 
NMR studies confirmed that the folded peptides were structured (Chapter 3, Figure 2 and 
Supporting information Figure S3). New solution NMR structures of CcoTx-I PDB ID: 6BR0, 
CcoTx-II PDB ID: 6BTV and PaurTx-III PDB ID: were completed and submitted to the PDB. 
The survey revealed that the panel of nine GMTs all showed preferential affinity for model 
membranes prepared with anionic lipids and this was attributed to electrostatic attractive 
forces between the positively charged residues on GMTs and the model membranes. The 
panel of GMTs showed promiscuity for the NaVs studied, and this was also associated to 
the residues of the positively charged ring interacting with a conserved sequence of anionic 
residues on the voltage-gated sodium channels studied. 
Notably, there was no direct correlation between the physicochemical properties of GMTs 
and affinity for model membranes. This led to the hypothesis that perhaps the 
conserved hydrophobic patch and charged ring on the GMT surface profile is an 
adaptation that spiders use to simultaneously target as many voltage-gated ion 
channels on their prey (or predators) as possible. Affinity for lipid membranes is 
probably an additional, but not essential, feature that increases the potency of some 
GMTs.  
A limitation of this work, and a suggested area of focus for future work, is that the three 
components of the tri-molecular concept were not studied in concert. A recent cryo-electron 
microscopy study has shown bivalent GMTs interacting with phospholipid head groups while 
bound to the target channel embedded in a nanodisc (18). As described in Chapter 2, 
nanodiscs provide the opportunity to stabilize large transmembrane proteins in stabilized 
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model membranes. Future endeavors could immobilize nanodiscs containing voltage-gated 
ion channels onto SPR chips or use NMR chemical shift mapping to better delineate the 
interactions occurring between GMTs, voltage-gated ion channels and the surrounding lipid 
membrane.  
 
Can the lipid bilayer be included in the design of potent and selective modulators of 
NaV1.7? 
With the knowledge that electrostatic interactions are important both for interactions with 
NaVs and with anionic lipid bilayers, the focus of Chapter 4 was to examine how an increase 
in affinity for lipid bilayers influences the potency and selectivity of HwTx-IV at NaV1.7. 
Previously, optimizing GMT activity at NaVs was focused on mutagenesis studies (19-21), 
multi-attribute positional scans (22), and combinations of directed evolution and saturation 
mutagenesis (where each non-cysteine residue is replaced by each of the remaining 18 
possible proteogenic amino acids) (23). Building on these fundamental studies, for the first 
time, Chapter 4 shows how the lipid bilayer can be included in the design of potent and 
selective GMTs. [E1G, E4G, F6W, Y33W]HwTx-IV, an analogue of HwTx-IV referred to as 
gHwTx-IV, was designed to increase the overall electropositive potential of the peptide by 
reducing anionic charge, and to increase hydrophobicity, by introducing Trp amino acid 
residues. Ultimately, gHwTx-IV showed both increased affinity for the lipid bilayer, and 
increased potency at NaV1.7. This observation most probably resulted from 
electrostatic attraction of gHwTx-IV to the lipid membrane where the peptide was 
anchored, concentrated and oriented to face its active site at NaV1.7, to give the 
apparent increase in potency (Chapter 4A).  
Chapter 4B examined the selectivity profile of gHwTx-IV, which was similar to that of HwTx-
IV, but not optimal, with low selectivity for NaV1.7 when compared to NaV1.1 and NaV1.2. It 
is uncommon to remove useful pharmacophore residues with the intention to improve 
pharmacology of GMTs. However, three analogues [R26A]gHwTx-IV, [K27A]gHwTx-IV and 
[R29A]gHwTx-IV were synthesized with the rationale that if the membrane can contribute to 
potency of gHwTx-IV, then changes to the pharmacophore may help to improve selectivity. 
All three analogues showed acceptable (or improved) potency coupled with better selectivity 
in favor of NaV1.7. The removal of positively charged residues most probably reduced 
electrostatic attraction to the cell membrane and this resulted in slightly lower affinity for the 
model membranes compared to gHwTx-IV, but this loss in lipid bilayer affinity did not 
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negatively impact potency at NaV1.7. For the first time, the lipid bilayer had been 
included in the design of potent, selective GMT modulators of NaV1.7. 
Notably, oxidative folding of [R29A]gHwTx-IV proved difficult, but this is not unusual for 
modified disulfide-rich GMTs. To obtain the correctly folded peptide, regio-selective folding 
of the peptide employed DMSO for Cys III-Cys VI (step 1) and for Cys I-Cys IV (step 3). This 
slow 24 h reaction was chosen because DMSO would not aversely interact with non-Cys 
residues, particularly Trp residues which are sensitive to oxidation in the presence of I2 which 
is frequently used in regio-selective folding. A fast (10 min) reaction in I2 was used for Cys 
II–Cys V (step 2) because trials revealed that this was the most efficient way to oxidize the 
pair. This stepwise oxidation method can be applied for similar disulfide- and Trp-rich 
peptides.  
The design strategy used here, though it includes the lipid bilayer in the design of potent 
and selective modulators of NaV1.7, cannot be referred to as rational drug design because 
the in vitro success in obtaining selective analogues of HwTx-IV are at present, only 
applicable to this GMT. It is not known whether the same strategy is transferable to similar 
spider ICKs. Furthermore, as mentioned in Chapter 3 and 4B, during the course of the 
project it was noted that each GMT displays a unique set of lipid binding that cannot be 
broadly applied to all GMTs. It is possible that with detailed studies on the specific 
components of the lipid distribution around NaVs and with enhanced techniques studying 
the three components of the trimolecular complex in concert, the field will move closer 
towards incorporating the lipid bilayer in rational drug design.  
At the same time, obtaining selectivity of GMTs is particularly important in the translation of 
GMTs to peptide therapeutics. HwTx-IV and ProTx-II have shown analgesic activity in vivo 
(24,25); however, promiscuity of HwTx-IV has been associated to muscle tonia in 
mammalian models (26), and for ProTx-II, an already selective GMT relative to other similar 
NaV1.7 inhibitors, improvement of selectivity still left mammalian models with off target 
effects including itching and scabbing, a possible histaminergic effect (27). Therefore, 
obtaining improved selectivity of gHwTx-IV was a step in the right direction. A major 
challenge with converting GMTs to therapeutics will be to fashion or deliver the peptides in 
such a way as to enable them to cross the blood–nerve barrier, specifically the perineurium 
(28), to access their target channels, while maintaining efficacy. A second consideration is 
that in vivo, efficacy at NaV1.7 may not be optimal without co-administration with additional 
analgesics including opioids (29). The drawback to coadministration with opioids, is that 
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opioids are well known to cause several severe unwanted effects and to create an economic 
burden world-wide because of the propensity for their misuse. It is possible that 
coadministration of opioids with GMTs may reduce off-target effects because of lower 
dosing; however, a lot remains to be done to optimize in vivo behavior before GMTs will 
become therapeutic analgesics. 
 
The versatility of GMTs as stable drug leads and double-knottins 
There remain several benefits, to the continued use of GMTs as drug leads, and one such 
advantage is the stability of these peptides. Prior to this work, most references to the stability 
of GMTs were based on similarities between these peptides and other known, stable 
disulfide-rich peptides. Chapter 5 was a study focused on the stability of ICK GMTs. Though 
these peptides are not cyclic (the peptides possess free N- and C-termini), Chapter 5 shows 
that these peptides are stable in physiologically relevant environments; therefore, there is 
little need to expend efforts towards increasing the stability of these peptides for their 
use as drug leads. However, as progress is made towards obtaining therapeutics from 
GMTs, a lot remains to be learnt about the pharmacology of NaVs and other voltage-gated 
ion channels. GMTs have already contributed a wealth of knowledge to our understanding 
of the pharmacology of voltage-gated ion channels (30-33), for example, VsTx-I contributed 
to an understanding of the opening and closing of the pore-domain of voltage-gated 
potassium channels (34). Chapter 6 provides a novel approach to understanding the 
pharmacology of NaVs using bivalent GMTs known as double-knottins. 
In Chapter 6, sortase A was used in the chemoenzymatic production of DK02, DK03, DK04 
and DK05, four chemoenzymatically produced double-knottins formed by ligating gHwTx-IV 
and D1Ia, an optimized version of CcoTx-I. Additional pharmacological studies which 
included the double-knottins and co-incubation of monovalent knottins, provided data that 
suggests the possibility of cooperative binding to NaV1.7, a feature that provides a 
novel approach to designing NaV1.7 modulators. Future studies in this regard can 
therefore focus on bivalent knottins possessing linkers of varying lengths designed to access 
either adjacent channel voltage sensor domains or a voltage sensor domain and the pore 
domain. 
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Finally, Appendix 1 is an applicable tool, in the form of a detailed protocol, on the use of 
sortase A for C–N terminal ligation of disulfide-rich peptides. Though the protocol is written 
for cyclic peptides, the technique is translatable to production of double-knottins.  
 
Concluding remarks and advances to the field 
This was a multidisciplinary project that used chemical approaches to obtain correctly folded 
GMTs, biochemical conjugation of some of the ICKs to form double-knottins, biological 
assays to examine the activity of the peptides, and biophysical methodologies to elucidate 
structural information and insight on peptide–lipid bilayer interactions. The project was 
mainly focused on characterizing the interaction of GMTs with lipid membranes, and to use 
this information to guide the design of potent, selective modulators of NaV1.7 whilst 
considering GMT–lipid bilayer interactions.  
Insights from a panel of nine unmodified GMTs suggested that electrostatic interactions 
were important for interactions between GMTs and model lipid bilayers. These insights 
guided the development of gHwTx-IV, a peptide analogue of HwTx-IV with increased affinity 
for lipid bilayers accompanied by an increase in potency. R26A[gHwTx-IV], K27A[gHwTx-
IV] and R29A[gHwTx-IV], were then designed to optimize the selectivity of gHwTx-IV and 
through this series of analogues, it was shown that the lipid bilayer can be included in the 
design of potent, selective analogues of NaV1.7. 
A secondary aim of this thesis was to explore applicability of GMTs as stable drug leads and 
as flexible probes for NaV1.7. Exposing the disulfide-rich peptides to extreme thermal, pH, 
enzymatic and chemical degradation consistently left >75% of the peptides intact promoting 
their use as stable drug leads. Double-knottins were successfully and efficiently produced 
using sortase to show the applicability of GMTs not just as cooperative modulators of NaVs 
but also as novel tools for understanding the mechanism of NaV pharmacology.  
Specific advances to the field arising from this work include: 
1. Successfully incorporated the lipid bilayer in the design of potent and selective 
modulators of NaV1.7 with in vivo efficacy 
2. Demonstrated that GMT amphipathicity is most probably an adaptation that facilitates 
their promiscuity, and this is beneficial to spiders for prey/predator immobilization 
3. Provided rational lipid choices for studying GMT–membrane interactions 
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4. Provided several methods for the thermodynamic oxidative folding of GMTs, and 
using regio-selective oxidation, provided an alternative folding method with low risk 
of side reactions  
5. Validated GMTs as physiologically stable drug leads 
6. Used chemoenzymatic ligation for the efficient production of double-knottins and 
provided a protocol enabling others in the field to use the same methods 
7. Used double-knottins to demonstrate that more than one binding site can be 
simultaneously targeted for modulation of NaV1.7 
These advances contribute to the ground-work for the future use of GMTs as 
pharmacological probes and drug leads targeting voltage-gated ion channels. 
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Overview 
As discussed in Chapter 6, sortase A is a beneficial tool for the chemoenzymatic ligation of 
disulfide-rich (and other) peptides and proteins. Appendix 1 is a protocol that was submitted 
to in Methods in Molecular biology of a special issue titled “Enzyme mediate ligation 
methods”. The protocol details the methods used in synthesis, oxidation and ligation of 
disulfide-rich peptides. 
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Abstract 
Sortase A (SrtA) is an enzyme obtained from Staphylococcus aureus that catalyzes site-
specific transpeptidation of surface proteins to the bacterial cell membrane. SrtA recognizes 
an LPXTG amino acid motif and cleaves between the Thr and Gly to form a thioester linked 
acyl–enzyme intermediate. The intermediate is resolved in the presence of a nucleophilic 
N-terminal polyglycine resulting in ligation of the acyl donor to the polyglycine acceptor. Here 
we describe the application of SrtA as a tool for the cyclization of disulfide-rich peptides. 
Reactions are typically tailored to each disulfide-rich peptide with optimal conditions 
producing yields of 40–50% cyclized peptide. 
 
Keywords: Cyclotide, cyclization, kalata B1, macrocycle, peptide ligation, semi-enzymatic 
 
Running head: Sortase A in the production of disulfide-rich macrocycles 
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1. Introduction 
Disulfide-rich peptides are obtainable from a wide variety of plant and animal species and 
typically adopt well defined and stable three-dimensional structures. Cyclotides are an 
example of disulfide-rich macrocycles that are distinguished by their knotted core enclosed 
within a head-to-tail cyclized backbone. These ultra-stable peptides are being pursued as 
pharmaceutical tools and drug leads, particularly as scaffolds onto which bioactive epitopes 
can be grafted (1,2). Cyclotides are also being employed in the agricultural industry as 
natural pesticides, with Sero-X, a cyclotide-based pesticide, recently receiving regulatory 
approval and becoming commercially available in Australia (3). Thus, in general, there is a 
requirement for the efficient, cost-effective synthesis of cyclotides and other disulfide-rich 
macrocyclic peptides compatible with both synthetic and recombinant expression routes. 
Chemical approaches to the head-to-tail cyclization of disulfide-rich peptides have proven 
valuable for a wide range of research studies, but are nevertheless limited by their 
requirement for toxic, corrosive, or specialized reagents that are associated with low-yielding 
and/or expensive production processes (4-6). The use of sortase A for the chemo-enzymatic 
ligation of disulfide-rich peptides offers an affordable and efficient approach to peptide 
cyclization. 
Sortase A (SrtA) is a bacterial enzyme, originally isolated from Staphyloccocus aureus, that 
is now applied as a biochemical tool. It contains a cysteine in the active site, recognizes 
substrates containing an LPXTG motif (where X can be any proteogenic amino acid) and 
hydrolytically cleaves between the threonine and glycine, forming a threonyl-SrtA 
intermediate that is resolved in the presence of a polyglycine nucleophile to ligate the 
substrate to the polyglycine containing moiety (Figure 1A). The ability of SrtA to form amide 
bonds has been utilized for a wide range of protein and peptide engineering applications, 
including N- and C-terminal labelling (7-10), peptide PEGylation (11), and the production of 
macrocycles, where peptides are strategically designed to contain the polyglycine 
nucleophile at the N-terminus, and the LPXTG ‘sortagging’ motif at the C-terminus (12,13).  
The protocol we present here describes the use of sortase A in the cyclization of disulfide 
rich peptides, using an optimized SrtA pentamutant (P94R/D160N/D165A/K190E/K196T) 
(abbreviated henceforth as SrtA5), which has a reported increase in enzymatic efficiency 
of approximately 120-fold compared to wild type (wt) SrtA (14). As described in the protocol, 
wt SrtA may be used if slower reactions are deemed to be optimal for specific cyclization 
reactions. For illustration, we use the prototypic cyclotide kalata B1 as an example of a 
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disulfide-rich cyclic peptide, but the protocol is also applicable to the intermolecular ligation 
of non-cyclic disulfide-rich peptides (15). The protocol involves an approach where the 
disulfide-rich peptides are oxidized prior to cyclization to facilitate obtaining the final product 
with minimal amounts of misfolded isomers; however, the option to cyclize the peptides first, 
followed by the formation of the disulfide bridges is also possible, and can be achieved by 
adding a reducing agent like tris(2-carboxyehyl)phosphine hydrochloride (TCEP) or 1,4-
dithiothreitol (DTT) to maintain the peptides in a reduced state during cyclization (13). 
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Figure 1. Schematic for sortase A mediated cyclization of disulfide-rich peptides 
(A) Cartoon showing a linear disulfide-rich peptide (sequence of kalata B1) with an N-terminal polyglycine 
and the C-terminal containing the native residues LPV and additional TGG to form the LPXTGG sortase 
recognition motif. The process of sortase A cyclization is also shown including recognition of the 
sortagging sequence and cleavage between T/G to form an intermediate that is resolved by the N-
terminal polyglycine to form the final cyclized. (B) Representation of the cyclization trials that facilitate 
tailoring the sortase A ligation to specific peptides by varying ratio of peptide:sortase and temperature. 
Samples at fixed time-points should be collected and monitored using RP-HPLC and MS. (C) Once 
peptide-specific concentrations and temperatures have been determined scale-up the cyclization 
reaction, remove His-tagged sortase A by centrifuging with Ni2+-NTA, filter, purify and lyophilize final 
product. 
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2. Materials  
2.1 Fmoc solid phase peptide synthesis 
Perform synthesis in a glass column containing a stopcock and a fritted filter attached to a 
vacuumed flask for waste collection. Carefully and responsibly dispose all waste according 
to site-specific regulations. 
1. Glass column containing a stopcock and fritted glass filter for solid phase peptide 
synthesis. 
2. 2-chlorotitryl resin (0.8 mmol/g substitution value, 0.1 mmol scale). 
3. Fmoc-protected amino acids. 
4. Activating agent: 0.5 M O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) in dimethylformamide (DMF). 
5. Base: N,N,-diisopropylethylamine (DIPEA). 
6. Capping solution: methanol (MeOH)/DIPEA/DCM (2:1:17 v/v/v) for first coupling 
reaction 
7. Resin wash solvents: DMF and dichloromethane (DCM). 
8. Fmoc deprotection solution: piperidine in DMF (1:2 v/v). 
9. Cleavage solution: 95% (v/v) trifluoroacetic acid (TFA), 2.5% (v/v) water, 2.5% 
(v/v) triisopropylsilane. 
10. Peptide extraction solutions: diethyl ether and 45% (v/v) acetonitrile (ACN), 0.01% 
(v/v) TFA in water. 
11. Dry ice to flash freeze samples prior to lyophilization. 
2.2 Peptide oxidative folding 
1. Solution to dissolve peptide prior to oxidation: 50% (v/v) isopropanol in water. 
2. Oxidation buffer for kalata B1: 50% (v/v) isopropanol, 0.1 M ammonium 
bicarbonate pH 8.0 and 1 mM reduced glutathione in water. 
3. Reaction quenching solution: 1% (v/v) TFA in water. 
 
2.3 Peptide purification  
Dissolve peptides in high performance liquid chromatography (HPLC) solvents A and/or B 
(see below) and filter using 0.45 m filter before loading onto column for purification. 
1. Reverse phase (RP)-HPLC C18 columns for proteins and peptides. 
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2. HPLC Solvent A: 0.05% (v/v) TFA in ultrapure water, filter through a 0.45 m filter 
and store at room temperature. 
3. HPLC Solvent B: 0.05% (v/v) TFA and 90% (v/v) acetonitrile (ACN) in ultrapure 
water, filter through a 0.45 m filter and store at room temperature. 
4. HPLC Solvent A/B: 0.05% (v/v) TFA and 45% (v/v) ACN in ultrapure water, filter 
through a 0.45 m filter and store at room temperature. 
5. LC/MS Solvent A: 0.05% (v/v) formic acid in ultrapure water, filter through a 0.45 
m filter and store at room temperature 
6. LC/MS Solvent B: 0.05% (v/v) formic acid and 90% (v/v) ACN in ultrapure water, 
filter through a 0.45 m filter and store at room temperature. 
2.4 Sortase A expression and ligation material 
1. SrtA and SrtA5 are commercially available (see Note 1) or can be produced by 
recombinant expression. Removal of the 59-amino acid transmembrane domain 
from the N-terminal of SrtA (SrtA 59), leaves the soluble catalytic domain of SrtA 
which is ideal for the transpeptidation reaction (16). Additional materials are listed 
below: 
2. SrtA5 expression plasmid (pET29) (see Note 1), or 
3. SrtA 59 expression plasmid SrtA (pET28a+) (see Note 1). 
4. E. coli BL21(DE3) cells.  
5. Luria-Bertani (LB) medium agar plates: 10 g/L peptone, 5g/L yeast extract, 5g/L 
sodium chloride, 12 g/L agar and 50  g/mL kanamycin. 
6. LB broth medium: 20 g/L peptone, 5 g/L yeast extract, 5 g/L sodium chloride and 
50 g/mL kanamycin. 
7. Isopropyl--D-1thiogalactopyranoside (IPTG) 1 M stock solution in water (sterile 
filtered). 
8. Lysis buffer: 50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM imidazole, 10% (v/v) 
glycerol and 20 g/L DNase I. 
9. Elution buffer: 50 mM Tris, pH 7.5, 150 mM NaCl, 500 mM imidazole, 10% (v/v) 
glycerol. 
10. Sortagging buffer stock solution: 0.5 M Tris, 1.5 M NaCl, 0.1 M CaCl2. Adjust to 
pH 8 using 0.5 M HCl or 0.5 M NaOH. Store at 4 C for up to 3 months (see Note 
2). 
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11. Working sortagging buffer (x10 of working concentrations): 0.05 M Tris, 0.15 M 
NaCl, 0.01 M CaCl2. Adjust to pH 8 using 0.5 M HCl or 0.5 M NaOH. Make fresh 
on day of experiment. 
12. Sortagging quenching solution: 1% (v/v) TFA in water. 
13. Nickel-nitriloacetic acid (Ni2+-NTA) agarose sludge is available commercially. To 
prepare the agarose sludge prior to separation of x6 His-tagged SrtA see 
methods section 3.6. 
2.5 Additional equipment 
1. Round bottom flasks. 
2. Magnetic stirrer and stirrer bars. 
3. Vacuum rotary evaporator. 
4. Lyophilizer. 
5. Nanodrop UV/Vis spectrophotometer. 
6. Eppendorf tubes (1.5 mL and 2 mL capacity). 
7. Centrifuges: table top microcentrifuge and large capacity centrifuge.  
8. Reverse phase RP-HPLC instrument. 
9. LC/ Electrospray-Mass spectroscopy (ESI-MS) instrument. 
10. Incubator with shaker. 
11. Cell disruptor. 
12. UV/Vis spectrophotometer. 
13. 5 mL HisTrap™ Ni2+-NTA FF column (available from GE Healthcare). 
14. 10 kDa centrifugal ultrafiltration unit. 
3. Methods 
3.1 Peptide assembly using Fmoc solid phase peptide synthesis 
Synthesize the desired peptide to contain an N-terminal polyglycine (at least two glycine 
residues) and the LPXTGG sortase A recognition motif at the C-terminus (see Note 3 and 
Figure 1A for sequence of kalata B1). 
1. Add 0.125 g of 2-chlorotitryl resin (0.8 mmol/g substitution value, 0.1 mmol scale) to 
a glass column containing a stopcock and a fritted glass filter (see Note 4). Soak in 
5 mL DCM for 20 min then drain the DCM by vacuum filtration. 
 219 
2. Prepare the first amino acid (Fmoc-Gly-OH) for coupling by completely dissolving the 
amino acid (2 equiv.) in 5 mL DCM and DIPEA (8 eq). Add the coupling solution to 
the resin and allow the coupling reaction to proceed for 1 h. 
3. Open the stopcock on the column filter and drain coupling solution into a waste flask 
under vacuum, wash with 5 mL DCM/MeOH/DIPEA resin capping solution x3 (see 
Note 5), then with 5 mL DCM x3 and finally with 5 mL DMF x3 (see Note 6). 
4. Remove the Fmoc protecting group using 5 mL DMF/piperidine deprotecting solution 
for two times 5 min. Wash with 5 mL DCM x3 and finally with 5 mL DMF x3. 
5. Prepare subsequent amino acids for coupling using amino acid (4 equiv.), HCTU (4 
equiv.) and DIPEA (8 equiv.) in 5 mL DMF, add the coupling solution to the resin and 
couple for 10 min. Repeat the coupling step. Wash with 5 mL DCM x3, followed by 5 
mL DMF x3. 
6. Repeat steps 4 and 5 until all amino acids are coupled. 
7. Remove final Fmoc group as in step 4, wash resin (5 mL DCM x1, then 5 mL DMF 
x1) x3 and finally with 5 mL DCM x3. Subsequently, dry the resin completely under a 
flow of N2. 
8. Release peptide from resin and simultaneously cleave amino acid side-chain 
protecting groups by incubating for 2 h in the TFA/triisopropylsilane/water peptide 
cleavage solution using a volume of 20 mL/g dry resin. Concentrate the peptide using 
a vacuum rotary evaporator. 
9. Add chilled diethyl ether (50 mL/g dry resin) to precipitate the peptide and separate 
the cleavage material (in solution) from the desired peptide using a column filter. 
10. Dissolve the peptide in solvent A/B, collect the solution in a round bottom flask via 
filtration using a fritted column filter and remove the excess of organic solvent on a 
vacuum rotary evaporator. Flash-freeze the solution using dry ice and lyophilize the 
peptide. Confirm the correct product using ESI- LC/MS (see Note 7), purify crude 
peptide using RP-HPLC, lyophilize and store at -20 C prior to oxidation. 
3.2 Peptide oxidative folding 
Oxidation is peptide specific (see Note 8). The following is a description of the oxidation of 
kalata B1. 
1. Dissolve peptide in 50% (v/v) isopropanol/water to a tenth of the final oxidation buffer 
volume (see Note 9), and leave stirring at 200 rpm using stirrer bar and magnetic 
stirrer while preparing oxidation buffer. 
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2. Prepare oxidation buffer (see Note 9), then add peptide dropwise to oxidation buffer. 
Leave stirring using magnetic stirrer and stirrer bar and monitor reaction at fixed time 
points (e.g. (T1 h, T8 h, T16 h, T24 h) by diluting 10 L samples in 10 L solvent A and 
examining mass and LC trace (0–70% solvent B gradient) using LC/MS (see Note 
10). 
3. Quench the complete reaction by acidification (pH 4) using 1% (v/v) TFA in water, 
dilute to less than 10 % (v/v) isopropanol using solvent A, filter (0.45 m) and purify 
using RP-HPLC. Analyze fractions using ESI-MS to obtain folded peptide (see Note 
10), pool relevant fractions, flash-freeze using dry ice lyophilize and store at -20 C 
prior to ligation. 
 
3.3 Expression of SrtA and SrtA5 
These methods have been adapted from references (9,17,18). 
1. Put 50 L of competent E. coli BL21(DE3) cells into a 1.5 mL Eppendorf tube, 
keep on ice and add 100 ng SrtA or SrtA5 plasmid (pET28a+ or pET29a, 
respectively), tap gently and incubate on ice for 10–15 min. 
2. Incubate the cells at 42 C for 30 sec, then put on ice for 1 min before adding 500 
L LB medium prewarmed to 42 C. Incubate for 1 h at 37 C while shaking at 
200 rpm. 
3. Centrifuge the cell containing medium at 7000 x g, discard supernatant and 
resuspend in 20 L LB medium. 
4. Streak the cells onto a LB medium agar plate and incubate upside down overnight 
at 37 C. 
5. Inoculate one colony in 100 mL LB medium and incubate overnight at 25 C while 
shaking at 200 rpm. 
6. Dilute culture to 1 L and incubate overnight in LB medium at 25 C while shaking 
at 200 rpm. Regularly measure the OD600 using a UV/Vis spectrophotometer to 
obtain an OD600 ~ 0.7. 
7. At OD600 ~ 0.7 induce protein expression by adding 0.5 mL of 1 M IPTG (to 1 L of 
medium) to make a final concentration of 0.5 mM IPTG and incubate for 3 h at 37 
C.  
8. Centrifuge at 7000 x g at 4 C for 10 min to harvest cells. 
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9. Resuspend cell pellet in ice cold lysis buffer and lyse by passing through a cell 
disrupter at 26000 psi. 
10. Separate protein from cell debris by centrifuging at 12000 x g at 4 C for 30 min, 
collect supernatant and keep on ice prior to purification. 
11. To purify the protein, wash the 5 mL HisTrap™ Ni2+-NTA FF column with lysis 
buffer (5 mL x10 washes; gravity flow). Load the protein (supernatant from step 
10) to the column using gravity flow and wash with lysis buffer (5 mL x20 washes; 
gravity flow). 
12. Elute the protein using elution buffer (5 mL x5; gravity flow), collect fractions 
containing SrtA (or SrtA5) and concentrate the protein using the 10 kDa 
centrifugal filter at 14000 x g for 30 min, to a tenth of the volume. 
13.  Aliquot into 500 L portions and quantify using UV/Vis spectrophotometry (see 
Note 11), flash freeze, and store at -80 C. 
3.4 Small-scale reactions to tailor ratio of linear peptide:SrtA5 and temperature to 
specific disulfide-rich peptides  
1. Prepare working buffer in ultrapure water and vary peptide:SrtA5 in molar ratios of 
1:1, 2:1 and 3:1 using 10–150 M peptide and SrtA5 (see Note 11, Note 12, Note 
13 and Note 14) (Figure 1B). Confirm that pH = 8 and adjust if necessary using 0.5 
M HCl or 0.5 M NaOH to final trial reaction volumes of 250 L in 1.5 mL Eppendorf 
tubes (see Note 15). Perform reactions at 25 C and use a magnetic stirrer and stir 
bar to mix at 200 rpm. 
2. Collect 10 L samples from reaction at T0 min, T5 min, T15 min, T30 min, T1 h, T2 h and T24 h 
and add 10 L of 1% (v/v) TFA to quench the reaction.  
3. Load time-point samples onto a RP-HPLC C18 column, monitor at 215 nm and/or at 
280 nm (for peptides containing aromatic residues). Collect eluent from each peak 
and analyze masses from each peak using ESI-MS to identify products (see Notes 
16, and 17). 
4. Once ideal ratio of peptide:SrtA5 has been achieved (see Note 18), optimize 
reaction speed by varying temperature while keeping SrtA5 and buffer concentration 
and ratio of peptide:SrtA5 constant. Monitor reactions at 4 C, 25 C and 37 C with 
and without stirring (see Note 19). Collect and prepare time point samples (as done 
for 2. above) (see Note 19), Monitor and analyze the samples using analytical RP-
HPLC and ESI-MS (as done for 3. above).  
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3.5 Scaling up of the enzymatic cyclization reaction 
Final volumes for larger scale reactions will be dependent on desired final amount of peptide 
(see Note 20 and 21) (Figure 1C). 
1. Prepare working sortagging buffer in ultrapure water and use optimized specific ratio 
of peptide:SrtA5, optimal temperature and duration as determined during prior trials 
(see 3.1 above). 
2. At the pre-determined optimal end-point (see 3.1 above) slow down the reaction by 
placing reaction vessel on ice and lowering the pH to < 6 using reaction quenching 
solution (1% (v/v) TFA in water).  
3.6 Purification 
His-tagged SrtA5 may be separated from the final products (cyclized variant of kalata B1) 
using Ni2+-NTA agarose sludge (see Note 1). 
1. Prepare the Ni2+-NTA agarose sludge obtaining a volume equivalent to the final 
sortagging reaction volume. Centrifuge (5000 x g for 15 min at 4 C) and discard 
supernatant. Re-suspend in a volume of solvent A equivalent to the final reaction 
volume (enzymatic cyclization) to equilibrate the resin, centrifuge (5000 x g for 15 min 
at 4 C) and discard the supernatant (see Note 22). 
2. Re-suspend the Ni2+-NTA agarose sludge with the quenched reaction solution, 
centrifuge (5000 x g for 20 min at 4 C), collect and keep the supernatant. Re-suspend 
Ni2+-NTA agarose sludge in a volume of solvent A equivalent to the final reaction 
volume (enzymatic cyclization), centrifuge (5000 x g for 20 min at 4 C), collect and 
keep the supernatant.  
3. Filter the collected supernatant through a 45 m filter to separate any remaining Ni2+-
NTA, load on to a semi-preparatory C18 RP-HPLC column and purify the peptide 
using a suitable gradient (e.g. gradient of 0–70% solvent B for kalata B1). Monitor at 
214 and/or 280 nm (for peptides containing aromatic amino acid residues). Collect 
each peak and analyze products using ESI-MS (see Note 16).  
4. Flash-freeze and lyophilize product containing fractions. Purify further as necessary 
(see Note 23). 
4. Notes 
1. Wt SrtA and SrtA5 may be obtained commercially or made by recombinant 
expression. We obtained pET29, for expression of SrtA5, as a kind gift from Prof 
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David Liu (14). The present protocol describes the use of wt SrtA and SrtA5 
containing a C-terminal x6 His-tag for separation of the enzyme from cyclization buffer 
and final product. However, the enzyme may also be separated from the reaction 
solution using a 10 kDa centrifugal concentrator or by preparing covalently 
immobilized SrtA5 on a sepharose or PEG bead as described previously (19,20).  
2. SrtA and SrtA5 use the same sortagging buffer. 
3. Add an additional amino acid to the C-terminal LPXTG motif (e.g. LPXTGG) to 
facilitate SrtA5 binding to the peptide. Glycine is used in the present example; 
however, any amino acid will suffice. 
4. The synthesis scale is dependent on desired amount of product and the substitution 
of the resin.  
5. MeOH caps unreacted functional groups of the CTC-resin. 
6. A ninhydrin test (Kaiser test) can be employed to confirm coupling efficiency by 
exposing any unreacted NH2 groups (21). 
7. The expected mass for linear reduced [GGG]kalata B1[GG] is 3302.7 Da 
8. Oxidation of disulfide-rich peptides is often peptide-specific. Perform peptide oxidation 
trials using buffers that maintain pH between 7.5 and 8. Ensure proper solubility of the 
linear peptide in oxidation buffer using organic co-solvents such as isopropanol or 
ACN. Catalyze the oxidation reactions using reduced and oxidized glutathione as 
necessary and further control the rate of reaction by conducting the reactions at room 
temperature or at 4 C. The following references contain details on some oxidation 
buffers that have been used for successful oxidation of disulfide-rich peptides: 
(13,17,22,23).  
9. The final peptide concentration should be 0.1 mg/mL. 
10. The expected mass for linear oxidized [GGG]kalata B1[TGG] is 3296.7 Da. The 
oxidized, linear peptide shows a rightward shift on RP-HPLC compared to the 
reduced, linear peptide. 
11. Proteins and peptides containing disulfide bonds and aromatic residues can be 
quantified using a UV/Vis photospectrometer. For accurate quantification extinction 
coefficient values at 280 nm (280) where the peptide 280 is equivalent to the sum of 
contributions from tyrosine residues (280 = 1280 M-1•cm-1), tryptophan residues (280 
= 5690 M-1•cm-1) and disulfide bonds (280 = 120 M-1•cm-1) (24). For [GGG]kalata 
B1[GG] the extinction coefficient is 280 = 6050 M-1•cm-1, for Wt SrtA and SrtA5 280 = 
13370 M-1•cm-1 (calculated from sequence available here (14)). Additional options for 
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quantification of peptides include amino acid analysis, peptide mass and pulse length 
based concentration determination using nuclear magnetic resonance amongst 
others, as discussed here: (25). 
12. Add SrtA5 to reaction vessel last to enable accurate timing when monitoring the 
reaction. 
13. 2% (v/v) dimethyl sulfoxide may be added to the reaction mixture to enhance solubility 
of SrtA5. 
14. If working with reduced disulfide-rich peptide with the intention of oxidizing the peptide 
after cyclization, include reducing agents (0.2 M TCEP or 0.2 M DTT) to sortagging 
buffer, ensuring pH = 8. 
15. In our hands, a lower concentration of SrtA5 with respect to peptide, minimizes 
accumulation of SrtA5 hydrolysis products. Therefore, optimization trials, in which the 
concentration of peptide is kept constant (e.g. 150 M peptide) and concentration of 
SrtA5 is varied may be the best approach for reaction optimization. 
16. Expected mass for cyclized, oxidized [GGG]kalata B1[T] is 3164.5 Da, and the RP-
HPLC trace of cyclized peptide has a rightward shift compared to the linear, oxidized 
peptide. 
17. The optimal reaction will be recognizable from the highest yield of cyclized product 
with minimal accumulation of hydrolysis products and additional oligomers.  
18. For kalata B1, the optimal ratio of peptide:SrtA is 3:1 (molar ratio) (13). 
19. Additional time points for the 4 C reaction including up to 72 h might be necessary 
during ligation optimization. An alternative to long reactions at 4 C is use of wt SrtA 
at room temperature for 24–48 h. Optimal conditions for kalata B1 are, 37 C for 24 h 
(13).  
20. Typically, transpeptidation yields of 40–50% final cyclized product are expected when 
working with oxidized, disulfide-rich peptides. 
21. Reactions are best conducted in glass vessels (e.g. scintillation vial or glass bottle) to 
prevent reactants from adsorbing to walls. 
22. Low temperature is used during centrifugation to ensure that the sortagging reaction 
does not produce unwanted hydrolysis by-products.  
23. Unreacted linear peptide can be collected during purification, re-purified, lyophilized 
and re-used. 
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